IMAX (IMAX) 10-K 24 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Jan. 31, 2022	Jun. 30, 2021
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	0000921582
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 1,069.2
Entity Common Stock, Shares Outstanding		58,575,134
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IMAX
Security Exchange Name	NYSE
Entity File Number	001-35066
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	98-0140269
Entity Address, Address Line One	2525 Speakman Drive
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5K 1B1
City Area Code	(905)
Local Phone Number	403-6500
Document Annual Report	true
Document Transition Report	false
Auditor Firm ID	271
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Toronto, Canada
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement to be filed within 120 days of the close of IMAX Corporation’s fiscal year ended December 31, 2021, with the Securities and Exchange Commission pursuant to Regulation 14A involving the election of directors and the annual meeting of the stockholders of the registrant (the “Proxy Statement”) are incorporated by reference in Part III of this Form 10-K to the extent described therein.
Other Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	902 Broadway, Floor 20
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10010
City Area Code	(212)
Local Phone Number	821-0100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 189,711	$ 317,379
Accounts receivable, net of allowance for credit losses	110,050	56,300
Financing receivables, net of allowance for credit losses	141,049	131,810
Variable consideration receivable, net of allowance for credit losses	44,218	40,526
Inventories	26,924	39,580
Prepaid expenses	11,802	10,420
Film assets, net of accumulated amortization	4,241	5,777
Property, plant and equipment, net of accumulated depreciation	260,353	277,397
Investment in equity securities	1,087	13,633
Other assets	17,799	21,673
Deferred income tax assets, net of valuation allowance	13,906	17,983
Other intangible assets, net of accumulated amortization	23,080	26,245
Goodwill	39,027	39,027
Total assets	883,247	997,750
Liabilities
Accounts payable	15,943	20,837
Accrued and other liabilities	111,896	99,354
Revolving credit facility borrowings, net of unamortized debt issuance costs	2,472	305,676
Convertible notes, net of unamortized discounts and debt issuance costs (see Note 14)	223,641
Deferred revenue	81,281	87,982
Deferred income tax liabilities	17,642	19,134
Total liabilities	452,875	532,983
Commitments and contingencies (see Notes 15 and 16)
Non-controlling interests
Non-controlling interests	758	759
Shareholders' equity
Capital stock common shares no par value. Authorized unlimited number. 58,653,642 issued and 58,921,008 outstanding (December 31, 2020 ? 58,921,731 issued and 58,921,008 outstanding)	409,979	407,031
Less: Treasury stock, nil shares at cost (December 31, 2020 — 723)		(11)
Other equity (see Note 3	174,620	188,845
Statutory surplus reserve	3,932
Accumulated deficit	(234,975)	(202,849)
Accumulated other comprehensive income	2,527	988
Total shareholders' equity attributable to common shareholders	356,083	394,004
Non-controlling interests (see Note 3)	73,531	70,004
Total shareholders' equity	429,614	464,008
Total liabilities and shareholders' equity	$ 883,247	$ 997,750

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021
Shareholders' equity
Common stock, par value
Common stock, shares issued	58,921,731	58,653,642
Common stock, shares outstanding	58,921,008	58,653,642
Number of treasury shares held in trust for future settlement of share based awards	723

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenues, total	$ 254,883	$ 137,003	$ 395,664
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	120,477	115,463	181,492
Gross margin	134,406	21,540	214,172
Selling, general and administrative expenses	117,322	108,485	123,456
Research and development	6,944	5,618	5,203
Amortization of intangibles	4,877	5,394	4,955
Credit loss (reversal) expense, net	(3,951)	18,608	2,430
Asset impairments		1,151
Legal judgment and arbitration awards (see Note 16)	(1,770)	4,105
Exit costs, restructuring charges and associated impairments			850
Income (loss) from operations	10,984	(121,821)	77,278
Realized and unrealized investment gains (losses)	5,340	(2,081)	(517)
Retirement benefits non-service expense	(463)	(600)	(737)
Interest income	2,218	2,388	2,105
Interest expense	(7,092)	(7,010)	(2,793)
Income (loss) before taxes	10,987	(129,124)	75,336
Income tax expense	(20,564)	(26,504)	(16,768)
Equity in (losses) income of investees, net of tax	0	(1,858)	3
Net (loss) income	(9,577)	(157,486)	58,571
Net (income) loss attributable to non-controlling interests	(12,752)	13,711	(11,705)
Net (loss) income attributable to common shareholders	$ (22,329)	$ (143,775)	$ 46,866
Net (loss) income per share attributable to common shareholders - basic and diluted:
Net (loss) income per share — basic and diluted	$ (0.38)	$ (2.43)	$ 0.76
Technology Sales [Member]
Revenues
Revenues, total	$ 66,153	$ 49,728	$ 118,245
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	37,039	33,170	63,627
Image Enhancement and Maintenance Services [Member]
Revenues
Revenues, total	131,148	59,318	188,547
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	58,062	53,598	88,175
Technology Rentals [Member]
Revenues
Revenues, total	46,790	17,841	77,961
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	25,376	28,695	29,690
Finance Income [Member]
Revenues
Revenues, total	$ 10,792	$ 10,116	$ 10,911

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (9,577)	$ (157,486)	$ 58,571
Other comprehensive income, before tax
Unrealized defined benefit plan actuarial gain (loss)	132	(897)	157
Unrealized postretirement benefit plans actuarial gain (loss)	140	(351)	(153)
Prior service cost arising during the period			(456)
Amortization of prior service cost	185	87
Unrealized net gain from cash flow hedging instruments	468	500	552
Realized net (gain) loss from cash flow hedging instruments	(1,707)	604	1,183
Reclassification of unrealized gain from ineffective cash flow hedging instruments	(318)
Foreign currency translation adjustments	3,364	5,992	(729)
Total other comprehensive income, before tax	2,264	5,935	554
Income tax benefit (expense) related to other comprehensive income	286	55	(378)
Other comprehensive income, net of tax	2,550	5,990	176
Comprehensive (loss) income	(7,027)	(151,496)	58,747
Comprehensive (income) loss attributable to non-controlling interests	(13,763)	11,899	(11,483)
Comprehensive (loss) income attributable to common shareholders	$ (20,790)	$ (139,597)	$ 47,264

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Activities
Net (loss) income	$ (9,577)	$ (157,486)	$ 58,571
Adjustments to reconcile net (loss) income to cash provided by (used in) operating activities:
Depreciation and amortization	56,082	52,704	62,978
Amortization of deferred financing costs	2,513	902	509
Credit loss (reversal) expense, net	(3,951)	18,608	2,430
Write-downs	1,764	17,729	4,376
Deferred income tax expense	2,996	23,618	6,762
Share-based and other non-cash compensation	26,079	22,038	23,570
Unrealized foreign currency exchange loss (gain)	256	(1,355)	32
Realized and unrealized investment (gains) losses	(5,340)	2,081	517
Equity in losses (income) of investees	0	1,858	(3)
Changes in assets and liabilities:
Accounts receivable	(52,453)	33,597	(8,621)
Inventories	11,451	1,637	1,942
Film assets	(14,810)	(7,665)	(23,437)
Deferred revenue	(6,591)	(6,637)	(12,242)
Changes in other operating assets and liabilities	(2,354)	(24,640)	(27,008)
Net cash provided by (used in) operating activities	6,065	(23,011)	90,376
Investing Activities
Purchase of property, plant and equipment	(3,590)	(697)	(7,421)
Investment in equipment for joint revenue sharing arrangements	(10,094)	(6,654)	(40,489)
Acquisition of other intangible assets	(4,092)	(1,904)	(2,931)
Proceeds from sale of (investment in) equity securities	17,769		(15,153)
Net cash used in investing activities	(7)	(9,255)	(65,994)
Financing Activities
Proceeds from issuance of convertible notes, net	223,675
Debt issuance costs related to convertible notes	(1,161)
Purchase of capped calls related to convertible notes	(19,067)
Revolving credit facility borrowings	3,600	287,610	35,000
Repayments of revolving credit facility borrowings	(307,609)		(55,000)
Credit facility amendment fees paid	(527)	(1,073)
Repurchase of common shares	(13,905)	(36,624)	(2,659)
Treasury stock purchased for future settlement of restricted share units		(3,086)	(13,833)
Taxes withheld and paid on employee stock awards vested	(3,660)	(512)	(590)
Common shares issued - stock options exercised	883		2,404
Issuance of subsidiary shares to non-controlling interests (net of return on capital)			1,106
Dividends paid to IMAX China non-controlling interests	(4,889)	(4,214)	(4,384)
Net cash (used in) provided by financing activities	(132,720)	240,567	(57,118)
Effects of exchange rate changes on cash	(1,006)	(406)	630
(Decrease) increase in cash and cash equivalents during year	(127,668)	207,895	(32,106)
Cash and cash equivalents, beginning of year	317,379	109,484	141,590
Cash and cash equivalents, end of year	189,711	317,379	109,484
IMAX China
Financing Activities
Repurchase of common shares	$ (10,060)	$ (1,534)	$ (19,162)

Consolidated Statements of Shar

Consolidated Statements of Shareholder's Equity - USD ($) $ in Thousands	Total	Capital Stock [Member]	Other Equity [Member]	Statutory Surplus Reserve [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Non-controlling Interests [Member]	Common Shares Issued and Outstanding [Member]
Balance, beginning of year at Dec. 31, 2018		$ 421,539	$ 179,079		$ (85,385)	$ (3,588)
Movement of Shareholders' Equity
Amortization of share-based payment expense - stock options			8,813
Amortization of share-based payment expense - restricted share units			13,481
Change in shares held in treasury		(3,122)
Restricted share units vested			(10,295)
Employee stock options exercised, net of shares withheld for employee tax obligations		1,752
Grant date fair value of stock options exercised		104	(104)
Cash received from the issuance of common shares in excess of par value			454
Change in ownership interest related to IMAX China common share repurchases			(9,642)				$ (9,520)
Common shares repurchased and retired		(925)			(1,734)
Stock options exercised from treasury shares			(1,561)
Net income (loss) attributable to common shareholders	$ 46,866				46,866
Net income (loss) attributable to non-controlling interests	11,705						13,343
Other comprehensive income net of tax	176					398	(223)
Share-based compensation attributable to non-controlling interests							568
Dividends paid to non-controlling shareholders							(4,384)
Shares held in treasury								(187,020)
Balance, end of year at Dec. 31, 2019		419,348	180,225		(40,253)	(3,190)
Balance, beginning of year at Dec. 31, 2018							81,273
Balance, end of year at Dec. 31, 2019							81,057
Common shares issued and outstanding, Balance, beginning of year at Dec. 31, 2018								61,433,589
Movement of Shareholders' Equity
Employee stock options exercised								19,088
Restricted share units and stock option exercises settled from treasury shares purchased on open market								44,579
Repurchase of common shares								(134,384)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2019								61,175,852
Movement of Shareholders' Equity
Total shareholders' equity	637,187
Amortization of share-based payment expense - stock options			2,426
Amortization of share-based payment expense - restricted share units			13,532
Amortization of share-based payment expense - performance stock units			2,708
Change in shares held in treasury		4,027
Restricted share units vested		1,448	(9,370)
Change in ownership interest related to IMAX China common share repurchases			(676)				(858)
Common shares repurchased and retired		(17,803)			(18,821)
Net income (loss) attributable to common shareholders	(143,775)				(143,775)
Net income (loss) attributable to non-controlling interests	(13,711)						(8,572)
Other comprehensive income net of tax	$ 5,990					4,178	1,812
Share-based compensation attributable to non-controlling interests							779
Dividends paid to non-controlling shareholders							(4,214)
Shares held in treasury	(723)							(723)
Balance, end of year at Dec. 31, 2020	$ 394,004	407,020	188,845		(202,849)	988
Balance, end of year at Dec. 31, 2020	$ 70,004						70,004
Movement of Shareholders' Equity
Restricted share units and stock option exercises settled from treasury shares purchased on open market								187,020
Restricted share units settled with new treasury shares								42,982
Repurchase of common shares								(2,484,123)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2020	58,921,008							58,921,008
Movement of Shareholders' Equity
Total shareholders' equity	$ 464,008
Amortization of share-based payment expense - stock options			1,267
Amortization of share-based payment expense - restricted share units			17,116
Amortization of share-based payment expense - performance stock units			5,733
Change in shares held in treasury		11
Restricted share units vested		9,833	(14,740)
Employee stock options exercised, net of shares withheld for employee tax obligations		883
Grant date fair value of stock options exercised		271	(271)
Change in ownership interest related to IMAX China common share repurchases			(4,263)				(5,797)
Purchase of capped calls related to convertible notes			(19,067)
Common shares repurchased and retired		(8,039)			(5,865)
Net income (loss) attributable to common shareholders	(22,329)				(22,329)
Net income (loss) attributable to non-controlling interests	12,752						12,753
Other comprehensive income net of tax	2,550					1,539	1,011
Share-based compensation attributable to non-controlling interests							449
Establishment of statutory surplus reserve, IMAX China				$ 3,932
Statutory surplus reserve deducted from retained earnings, IMAX China					(3,932)
Dividends paid to non-controlling shareholders							(4,889)
Balance, end of year at Dec. 31, 2021	356,083	$ 409,979	$ 174,620	$ 3,932	$ (234,975)	$ 2,527
Movement of Shareholders' Equity
Establishment of statutory surplus reserve, IMAX China							1,699
Statutory surplus reserve deducted from IMAX China retained earnings							(1,699)
Balance, end of year at Dec. 31, 2021	$ 73,531						$ 73,531
Movement of Shareholders' Equity
Employee stock options exercised								41,613
Restricted share units and stock option exercises settled from treasury shares purchased on open market								723
Restricted share units settled with new treasury shares								531,629
Repurchase of common shares								(841,331)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2021	58,653,642							58,653,642
Movement of Shareholders' Equity
Total shareholders' equity	$ 429,614

Description of the Business

Description of the Business	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Business	1. Description of the Business IMAX Corporation is a Canadian corporation that was formed in March 1994 as a result of an amalgamation between WGIM Acquisition Corp. and the former IMAX Corporation (“Predecessor IMAX”). Predecessor IMAX was incorporated in 1967. As of December 31, 2021, IMAX Corporation indirectly owns 71.11% of IMAX China Holding, Inc. (“IMAX China”), whose shares trade on the Hong Kong Stock Exchange. IMAX China is a consolidated subsidiary of the Company. IMAX Corporation, together with its consolidated subsidiaries (the “Company”), is a premier global technology platform for entertainment and events. Through its proprietary software, theater architecture, patented intellectual property, and specialized equipment, IMAX offers a unique end-to-end solution to create superior, immersive content experiences for which the IMAX ® The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the digital remastering of films and other content into the IMAX format (“IMAX DMR ® IMAX Theater System arrangements also include a requirement for the Company to provide maintenance services over the life of the arrangement in exchange for an extended warranty and annual maintenance fee paid by the theater owner or operator. Under these arrangements, the Company provides preventative and emergency maintenance services to ensure that each presentation is up to the highest IMAX quality standard. The Company’s theater business activities also include the after-market sale of IMAX projection system parts and 3D glasses. As of December 31, 2021, there were 1,683 IMAX Theater Systems operating in 87 countries and territories, including 1,599 commercial multiplexes, 12 commercial destinations and 72 institutional locations. This compares to 1,650 IMAX Theater Systems operating in 84 countries and territories as of December 31, 2020 including 1,562 commercial multiplexes, 12 commercial destinations, and 76 institutional locations. The Company also distributes large-format documentary films, primarily to institutional theaters, and distributes exclusive experiences ranging from live performances to interactive events with leading artists and creators. In addition, the Company provides film post-production and quality control services for large-format films, whether produced by IMAX or third parties, and digital post-production services. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; (vii) Film Post-Production; and (viii) New Business Initiatives, which are described in Note 21.

Impact of COVID-19 Pandemic

Impact of COVID-19 Pandemic	12 Months Ended
	Dec. 31, 2021
Impact Of Coronavirus Nineteen Pandemic [Abstract]
Impact of COVID-19 Pandemic	2. Impact of COVID-19 Pandemic The impact of the COVID-19 pandemic is complex and continuously evolving, resulting in significant disruption to the Company’s business and the global economy. At various points during the pandemic, authorities around the world imposed measures intended to control the spread of COVID-19, including stay-at-home orders and restrictions on large public gatherings, which caused movie theaters in countries around the world to temporarily close, including the IMAX theaters in those countries. As a result of these theater closures, movie studios postponed the theatrical release of most films originally scheduled for release in 2020 and early 2021, including many of the films scheduled to be shown in IMAX theaters, while several other films were released directly or concurrently to streaming platforms. Beginning in the third quarter of 2020, The COVID-19 pandemic resulted in significantly lower levels of revenues, earnings, and operating cash flows for the Company during 2020 and, to a lesser extent, during 2021, when compared to periods prior to the onset of the pandemic, as box office results from the theaters in the IMAX network declined, the installation of certain theater systems was delayed, and maintenance fees were generally not recognized for theaters that were closed or operating with reduced capacities. In addition, as a result of the financial difficulties faced by certain of the Company’s exhibition customers arising out of pandemic-related theater closures, although improving, the Company has experienced and may continue to experience delays in collecting payments due under existing theater sale or lease arrangements. In response, beginning in the second quarter of 2020 through the fourth quarter of 2021, the Company provided temporary relief to certain exhibitor customers by waiving or reducing maintenance fees during periods when theaters were closed or operating with reduced capacities and, in certain situations, by providing extended payment terms on annual minimum payment obligations in exchange for a corresponding or longer extension of the term of the underlying sale or lease arrangement. As a result of the uncertainties associated with the pandemic, the Company took significant steps in 2020 and 2021 to preserve cash by eliminating non-essential costs, temporarily furloughing certain employees, reducing the working hours of other employees, and reducing all non-essential capital expenditures to minimum levels. The Company also implemented an active cash management process, which, among other things, required senior management approval of all outgoing payments. Also, in the first quarter of 2021, the Company issued $ 230.0 223.7 In 2020 and 2021, the Company recognized a total of $10.9 million in wage subsidies, tax credits, and other financial support under COVID-19 relief legislation that has been enacted in the countries in which it operates, primarily under the Canada Emergency Wage Subsidy (“CEWS”) program. For the years ended December 31, 2021 and 2020, these benefits were recognized in the Consolidated Statements of Operations as reductions to Selling, General and Administrative Expenses ($2.9 million and $6.0 million, respectively), Costs and Expenses Applicable to Revenues ($0.9 million and $1.0 million, respectively), and Research and Development ($nil and $0.1 million, respectively). The CEWS program expired in October 2021. The impact of the COVID-19 pandemic on the Company’s business and financial results will continue to depend on numerous evolving factors that cannot be accurately predicted and that will vary by jurisdiction and market, including the duration and scope of the pandemic, the emergence of variants of the virus, the progress made on administering vaccines and developing treatments, the continuing impact of the pandemic on global economic conditions and ongoing government responses to the pandemic, which could lead to further theater closures, theater capacity restrictions and/or delays in the release of films.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The Company prepares its Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (a) Revision of prior year amounts and other reclassifications In the current year’s Consolidated Balance Sheets and Consolidated Statements of Shareholders’ Equity, the Company revised the December 31, 2020 and December 31, 2019 balances of Total Shareholders’ Equity Attributable to Common Shareholders and Non-Controlling Interests. The revisions were principally made to properly reflect changes in the Company’s ownership interest in IMAX China as a result of common share repurchases and the amortization of share-based compensation related to IMAX China. The revisions resulted in a $0.5 million reclassification between the January 1, 2019 balances of Other Equity and Non-Controlling Interests, as well as reclassifications of $8.5 million and $8.4 million, respectively, between the balances of Other Equity and Non-Controlling Interests as of December 31, 2020 and 2019. There is no change in Total Shareholders’ Equity as a result of the revisions. (b) Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has interests in ten film production companies, which have been identified as VIEs The Company is the primary beneficiary of and consolidates of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant relating to these production companies The Company does not consolidate the other film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Consolidated Financial Statements. A loss in value of an equity method investment that is other than temporary is recognized as a charge in the Consolidated Statements of Operations. As of December 31, 2021 and 2020, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Total assets $ 1,576 $ 1,543 Total liabilities $ 259 $ 230 (c) Estimates and Assumptions The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying notes. Management’s judgments, assumptions, and estimates are based on historical experience, future expectations and other factors that are believed to be reasonable as of the date of the Consolidated Financial Statements. Actual results may ultimately differ from management’s original estimates, as future events and circumstances sometimes do not develop as expected, and the differences may be material. Significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX Theater System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Theater Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements theater system equipment supporting joint revenue sharing arrangements The COVID-19 pandemic resulted in significantly lower levels of revenues, earnings, and operating cash flows for the Company during 2020 and, to a lesser extent, during 2021, when compared to periods prior to the onset of the pandemic , as described in Note 2. Although judgments, assumptions, and estimates used by management in preparing the Company’s Consolidated Financial Statements (d) Cash and Cash Equivalents The Company considers all highly liquid investments convertible to a known amount of cash and with an original maturity of three months or less to be cash equivalents. (e) Receivables In 2016, the Financial Accounting Standards Board (“FASB”) issued No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The standard requires financial assets measured on the amortized cost basis to be presented at the net amount expected to be collected. The Company’s accounts receivable, financing receivables and variable consideration receivables are within the scope of ASU No. 2016-13. The Company adopted ASU No. 2016-13 and several associated ASUs on January 1, 2020 with no required cumulative-effect adjustment to accumulated deficit. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. (See Note 5 for more information related to the Company’s receivables and current expected credit losses.) (f) Inventories Inventories are carried at the lower of cost, determined on an average cost basis, and net realizable value except for raw materials, which are carried at the lower of cost and replacement cost. Finished goods and work-in-process includes the cost of raw materials, direct labor, theater design costs, and an applicable share of manufacturing overhead costs. The costs related to IMAX Theater Systems under sales and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues – Technology Sales in the period when the sale is recognized in the Consolidated Statements of Operations. The costs related to IMAX Theater Systems under joint revenue sharing arrangements are transferred from Inventories to assets under construction in Property, Plant and Equipment when allocated to a signed joint revenue sharing arrangement. The Company records write-downs for excess and obsolete inventory based upon management’s judgments regarding future events and business conditions, including the anticipated installation dates for the current backlog of theater system contracts, contracts in negotiation, technological developments, growth prospects within the customers’ ultimate marketplace and anticipated market acceptance of the Company’s current and pending theater systems. Finished goods inventories includes IMAX Theater Systems for which title has passed to the Company’s customer in situations when the theater system has been delivered to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. (g) Film Assets Film Assets consist of: (i) capitalized costs associated with the digital remastering of films where the copyright is owned by a third party, including labor and allocated overhead, and (ii) capitalized costs associated with the production of films, including labor, allocated overhead, and the cost of acquiring film rights. Production financing provided by third parties that acquire substantive rights in the film is recorded as a reduction of the cost of the film. Capitalized film costs are amortized and participation costs are accrued to Costs and Expenses Applicable to Revenues using the individual-film-forecast method, which amortizes such costs in the same ratio as the associated ultimate revenue. Estimates of ultimate revenues are prepared on a title-by-title basis and reviewed regularly by management and revised where necessary to reflect the most current information. Ultimate revenues reflect management’s estimates of future revenue over a period not to exceed ten years following the date of the film’s initial release. The recoverability of the Company’s film assets is dependent upon the commercial acceptance of the underlying films and the resulting level of box office results and, in certain situations, ancillary revenues If management’s projections of future net cash flows resulting from the exploitation of a film indicate that the carrying value of the film asset is not recoverable, the film asset is written down to its fair value. Film exploitation costs, including advertising costs, are expensed as incurred to Costs and Expenses Applicable to Revenues. (h) Property, Plant and Equipment Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life (7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements. The cost of theater system components and related equipment expected to be used in future joint revenue sharing arrangements, including related direct labor costs and an allocation of direct production costs, are recorded within assets under construction until the underlying IMAX Theater System is installed and in working condition. These assets are depreciated to Costs and Expenses Applicable to Revenues on a straight-line basis over the lesser of the term of the joint revenue sharing arrangement and the equipment’s expected useful life. The estimated useful lives of the theater system components and related equipment used in joint revenue sharing arrangements are reviewed periodically to determine if any adjustments are required. Property, Plant and Equipment is grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating such assets for impairment include a current expectation that it is more likely than not that the long-lived asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the long-lived asset, and a significant change in the extent or manner in which the long-lived asset is being used. (i) Investment in Equity Securities Equity securities with readily determinable fair values are reported at fair value with changes in fair value recorded within Gain (Loss) in Fair Value of Investments in the Consolidated Statements of Operations. (j) Other Assets Other Assets principally includes lease incentives provided to certain theater customers under joint revenue sharing arrangements classified as an operating lease, as well as sales commissions and other deferred selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses. To a much lesser extent Other Assets also includes various investments and foreign currency derivatives. Capitalized lease incentives are amortized on a straight-line basis over the term of the lease as a reduction to rental revenue. Sales commissions and other selling expenses paid prior to the recognition of the related revenue are deferred and recognized within Costs and Expenses Applicable to Revenues upon the client acceptance of the IMAX Theater System or the abandonment of the sale arrangement. Foreign currency derivatives are accounted for at fair value using quoted prices in active markets. In periods when there are no outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are recorded within Other Assets and amortized on a straight-line basis over the term of the facility. In periods when there are outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are reclassified to reduce the principal amount of outstanding borrowings and amortized on a straight-line basis over the term of the facility. (See Note 14 for information related to the Company’s revolving credit facilities.) (k) Goodwill Goodwill represents the excess of the purchase price paid over the fair value of net assets acquired in a business combination. Goodwill is not amortized, but is tested annually for impairment at the reporting unit level in the fourth quarter of the year and between annual tests if indicators of potential impairment exist. These indicators could include a decline in the Company’s stock price and market capitalization, a significant change in the outlook for the reporting unit's business, including projections of future box office results and IMAX Theater System installations, lower than expected operating results, increased competition, legal factors, or the sale or disposition of a significant portion of a reporting unit. For reporting units with goodwill, an impairment loss is recognized for the amount by which the reporting unit's carrying value, including goodwill, exceeds its fair value. assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. In the fourth quarter of 2021, the Company performed its annual goodwill impairment test considering the latest available information and determined that its goodwill was not impaired. As of December 31, 2021 , the Company’s total Goodwill was $39.0 million, of which $19.1 million relates to the IMAX Systems reporting unit, $13.5 million relates to the Joint Revenue Sharing Arrangements reporting unit, and $6.4 million relates to the IMAX Maintenance reporting unit. assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. Actual results may materially differ from management’s estimates, especially due to the (l) Other Intangible Assets Patents, trademarks, and other intangible assets are recorded at cost and generally amortized on a straight-line basis over estimated useful lives ranging from 4 to 10 years except for intangible assets that have an identifiable pattern of consumption of the economic benefit of the asset. Such intangible assets are amortized over the consumption pattern. The Company capitalizes costs associated with internally developed and/or purchased software systems for internal use that have reached the application development stage. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages are charged to expense. These capitalized costs are amortized on a straight-line basis over the estimated useful life. Intangible Assets are grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating intangible assets for impairment include a current expectation that it is more likely than not that the intangible asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the intangible asset, and a significant change in the extent or manner in which the intangible asset is being used. (m) Deferred Revenue In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. To a lesser extent, the Deferred Revenue balance also relates to situations when a theater customer (n) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10% of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50% of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may (o) Income Taxes Income taxes are accounted for under the liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the Company’s Consolidated Financial Statements in the period in which the change is enacted. Investment tax credits are recognized as a reduction of income tax expense. The Company assesses the realization of deferred income tax assets and based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. In assessing the need for a valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If management determines that sufficient negative evidence exists (for example, if the Company experiences cumulative three-year losses in a certain jurisdiction), then management will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, management’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove more difficult to support the realization of these deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on the Company’s effective income tax rate and results. Conversely, if, after recording a valuation allowance, management determines that sufficient positive evidence exists in the jurisdiction in which a valuation allowance is recorded (for example, if the Company is no longer in a three-year cumulative loss position in the jurisdiction, and management expects to have future taxable income in that jurisdiction based upon management’s forecasts and the expected timing of deferred tax asset reversals), the Company may reverse all or a portion of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on the Company’s effective income tax rate and results in the period such determination was made. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Tax benefits are recognized only when it is more likely than not, based on the technical merits, that the benefits will be sustained on examination. Tax benefits that meet the more-likely-than-not recognition threshold are measured using a probability weighting of the largest amount of tax benefit that has greater than 50% likelihood of being realized upon settlement. Whether the more-likely-than-not recognition threshold is met for a particular tax benefit is a matter of judgment based on the individual facts and circumstances evaluated in light of all available evidence as of the balance sheet date. Although management believes that the Company has adequately accounted for its uncertain tax positions, tax audits can result in subsequent assessments where the ultimate resolution may result in the Company owing additional taxes above what was originally recognized in its financial statements. Tax reserves for uncertain tax positions are adjusted by the Company to reflect its best estimate of the outcome of examinations and assessments and in light of changing facts and circumstances, such as the completion of a tax audit, expiration of a statute of limitations, the refinement of an estimate, and interest accruals associated with the uncertain tax positions until they are resolved. Some of these adjustments require significant judgment in estimating the timing and amount of the additional tax expense. (p) Revenue Recognition IMAX Theater Systems The Company evaluates each of the performance obligations in an IMAX Theater System arrangement to determine which are considered distinct, either individually or in a group, for accounting purposes and which of the deliverables represent separate performance obligations. The Company’s “System Obligation” consists of the following: (i) an IMAX Theater System, which includes the projector, sound system, screen system and, if applicable, a 3D glasses cleaning machine; (ii) services associated with the IMAX Theater System, including theater design support, the supervision of installation services, and projectionist training; and (iii) a license to use the IMAX brand to market the theater. The System Obligation, as a group, is a distinct performance obligation. The Company is not responsible for the physical installation of the equipment in the customer’s facility; however, it supervises the installation by the customer. The customer has the right to use the IMAX brand from the date the Company and the customer enter into an arrangement. IMAX Theater System arrangements also include a requirement for the Company to provide maintenance services and an extended warranty over the life of the arrangement in exchange for an annual maintenance fee, which is subject to a consumer price index increase on renewal each year. Consideration related to the provision of maintenance services is included in the allocation of the transaction price to the separate performance obligations in the arrangement at contract inception, as discussed in more detail below. The Company’s maintenance services are a stand ready obligation and, as a result, are recognized on a straight-line basis over the contract term. The transaction price in an IMAX Theater System arrangement is allocated to each good or service that is identified as a separate performance obligation based on estimated standalone selling prices. This allocation is based on observable prices when the Company sells the good or service separately. The Company has established standalone prices for the System Obligation and maintenance and extended warranty services, as well as for film license arrangements. The Company uses an adjusted market assessment approach for separate performance obligations that do not have standalone selling prices or third-party evidence of estimated standalone selling prices. The Company considers multiple factors including its historical pricing practices, product class, market competition and geography. IMAX Theater System arrangements involve either the lease or the sale of an IMAX Theater System. The transaction price for the System Obligation, other than for IMAX Theater Systems delivered pursuant to joint revenue sharing arrangements, consist of upfront or initial payments made before and after the final installation of the system and ongoing payments throughout the term of the arrangement. The Company estimates the transaction price, including an estimate of future variable consideration, received in exchange for the goods delivered or services rendered. The arrangement for the sale of an IMAX Theater System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual theater, which are developed using historical data for the theater and, if necessary, comparable theaters and territories IMAX Theater System arrangements are non-cancellable unless the Company fails to perform its obligations. In the absence of a material default by the Company, there is no right to any remedy for the customer under the Company’s arrangements. If a material default by the Company exists, the customer has the right to terminate the arrangement and seek a refund only if the customer provides notice to the Company of a material default and only if the Company does not cure the default within a specified period. Sales Arrangements For IMAX Theater System arrangements that qualify as a sale, the transaction price allocated to the System Obligation is recognized in the Consolidated Statements of Operations upon the transfer of control of the system to the customer, which is when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater. The initial revenue recognized in a sales arrangement consists of payments made before and in connection with the installation of the IMAX Theater System and the present value of any future payments, including ongoing fixed minimum payments, which are subject to indexed increases over the term of the arrangement, and potential additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. Potential payments based on the future box office receipts of the customer are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal (see “Constraints on the Recognition of Variable Consideration” below). The Company has also agreed, on occasion, to sell equipment under lease or at the end of a lease term. The transaction price agreed to for these lease buyouts is reflected in the Company’s Consolidated Statements of Operations within Revenues – Technology Sales. Taxes assessed by governmental authorities that are both imposed on and concurrent with the specific revenue-producing transactions and collected by the Company have been excluded from the measurement of the transaction prices discussed above. Constraints on the Recognition of Variable Consideration The recognition of variable consideration involves a significant amount of judgment. Variable consideration is recognized subject to appropriate constraints to avoid a significant reversal of revenue in future periods. The Company reviews its variable consideration assets on at least a quarterly basis considering recent box office performance and, when applicable, updated box office projections for future periods. The relevant accounting guidance identifies the following examples of situations when constraining the amount of variable consideration is appropriate: • The amount of consideration is highly susceptible to factors outside the entity’s influence; • The uncertainty about the amount of consideration is not expected to be resolved for a long period of time; • The Company’s experience (or other evidence) with similar types of contracts is limited, or that experience has limited predictive value; and • The entity has a practice of either offering a broad range of price concessions or changing the payment terms and conditions of similar contracts in similar circumstances. As discussed above, the Company’s significant streams of variable consideration relate to arrangements for the sale of IMAX Theater Systems which include indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include variable consideration based on a percentage of the customer’s box office receipts over the term of the arrangement. Variable consideration related to indexed minimum payment increases is outside of the Company’s control, but the movement in the rates is historically well documented

Recently Issued Accounting Stan

Recently Issued Accounting Standards Not Yet Adopted	12 Months Ended
	Dec. 31, 2021
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recently Issued Accounting Standards Not Yet Adopted	4. Recently Issued Accounting Standards Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2020-04 is to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of ASU 2020-04. An entity may elect to apply the amendments prospectively through December 31, 2022. The only contract held by the Company that references the London Interbank Offered Rate ( LIBOR) is the Credit Agreement (as defined in Note 14), which utilizes USD LIBOR to determine the interest rate applicable to borrowings. The Credit Agreement matures on June 28, 2023, prior to the date that USD LIBOR rates will cease publication on June 30, 2023. Accordingly, the Company does not expect ASU 2020-04 to have a material effect on its Consolidated Financial Statements. In July 2021, the FASB issued ASU No. 2021-05, “Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments” (“ASU 2021-05”), which requires sales-type or direct financing leases that have variable payments (that do not depend on a rate or an index) and result in a day-one loss to be classified as operating leases. When a lease is classified as operating, the lessor does not recognize a net investment in the lease, does not derecognize the underlying asset, and, therefore, does not recognize a selling profit or loss. The amendments are effective for annual periods beginning after December 15, 2021 including interim periods within those periods. Early adoption is permitted. The Company has not yet adopted ASU 2021-05, but has determined that the impact of adopting this guidance will not have a material impact on its Consolidated Financial Statements. In November 2021, the FASB issued ASU No. 2021-10, “2021-10: Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The amendments are effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company will adopt ASU 2021-10 for the year ending December 31, 2022 and will provide the required disclosures, if material. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standards updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Consolidated Financial Statements for the year ended December 31, 2021.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Receivables	5. Receivables The ability of the Company to collect its receivables is dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties, such as those caused by the COVID-19 pandemic, that could result in their being unable to fulfill their payment obligations to the Company. In order to mitigate the credit risk associated with its receivables, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category , but are not in as good condition as the receivables in the Credit Watch category. In certain situation s , a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of finance income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of finance income for Financing Receivables. During the period when the accretion of Finance Income is suspended for Financing Receivables, any payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of provision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income. When a customer’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectability of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect (see Note 2). Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under theater sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance, and fees for theater maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators principally for digitally remastering films into IMAX formats, as well as for film distribution and post-production services. The following tables summarize the activity in the Allowance for Credit Losses related to Accounts Receivable for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Beginning balance $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period provision (reversal), net 793 (1,913 ) (332 ) (1,452 ) Write-offs (357 ) (551 ) (19 ) (927 ) Foreign exchange 63 (23 ) (10 ) 30 Ending balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Year Ended December 31, 2020 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Beginning balance $ 3,302 $ 893 $ 943 $ 5,138 Current period provision, net 5,793 3,393 522 9,708 Write-offs (975 ) — — (975 ) Foreign exchange 248 195 (19 ) 424 Ending balance $ 8,368 $ 4,481 $ 1,446 $ 14,295 For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to Accounts Receivable decreased by $2.3 million. This decrease is principally due to improved collection experience with respect to foreign studio receivable balances, . For the year ended December 31, 2020, the Company’s allowance for current expected credit losses related to Accounts Receivable increased by $9.2 million, principally reflecting a reduction in the credit quality of and heightened collection risk associated with theater and foreign movie studio accounts receivable primarily due to the COVID-19 pandemic. Financing Receivables Financing receivables are due from theater operators and consist of the Company’s net investment in sales-type leases and receivables associated with financed sales of IMAX Theater Systems. As of December 31, 2021 and 2020, financing receivables consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Net investment in leases Gross minimum payments due under sales-type leases $ 29,953 $ 20,830 Unearned finance income (763 ) (859 ) Present value of minimum payments due under sales-type leases 29,190 19,971 Allowance for credit losses (798 ) (557 ) Net investment in leases 28,392 19,414 Financed sales receivables Gross minimum payments due under financed sales 152,315 150,917 Unearned finance income (34,244 ) (31,247 ) Present value of minimum payments due under financed sales 118,071 119,670 Allowance for credit losses (5,414 ) (7,274 ) Net financed sales receivables 112,657 112,396 Total financing receivables $ 141,049 $ 131,810 Net financed sales receivables due within one year $ 29,115 $ 34,937 Net financed sales receivables due after one year 83,542 77,459 Total financed sales receivables $ 112,657 $ 112,396 As of December 31, 2021 and 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: December 31, December 31, 2021 2020 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.6 8.3 Weighted-average interest rate Sales-type lease arrangements 6.56 % 6.56 % Financed sales receivables 8.79 % 8.92 % The tables below provide information on the Company’s net investment in leases by credit quality indicator as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 1,928 $ 28,319 Credit Watch — — — — — — — Pre-approved transactions — — — — — — — Transactions suspended — — — — — 871 871 Total net investment in leases $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 2,799 $ 29,190 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,143 $ 1,190 $ 2,730 $ — $ — $ 1,826 $ 7,889 Credit Watch 2,005 7,278 — 988 — 1,047 11,318 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 764 764 Total net investment in leases $ 4,148 $ 8,468 $ 2,730 $ 988 $ — $ 3,637 $ 19,971 The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 12,520 $ 8,251 $ 10,593 $ 13,278 $ 12,615 $ 47,950 $ 105,207 Credit Watch — — — — 321 1,292 1,613 Pre-approved transactions — — 743 418 2,098 3,650 6,909 Transactions suspended — — 335 — 680 3,327 4,342 Total financed sales receivables $ 12,520 $ 8,251 $ 11,671 $ 13,696 $ 15,714 $ 56,219 $ 118,071 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,830 $ 5,480 $ 3,547 $ 3,740 $ 5,072 $ 12,660 $ 37,329 Credit Watch 1,986 6,501 11,356 12,520 11,446 34,351 78,160 Pre-approved transactions — — — — 613 755 1,368 Transactions suspended — — — 987 728 1,098 2,813 Total financed sales receivables $ 8,816 $ 11,981 $ 14,903 $ 17,247 $ 17,859 $ 48,864 $ 119,670 The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of December 31, 2021 and 2020: As of December 31, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 225 $ 156 $ 1,267 $ 1,648 $ 27,542 $ 29,190 $ (798 ) $ 28,392 Financed sales receivables 1,750 989 8,378 11,117 106,954 118,071 (5,414 ) 112,657 Total $ 1,975 $ 1,145 $ 9,645 $ 12,765 $ 134,496 $ 147,261 $ (6,212 ) $ 141,049 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 298 $ 180 $ 689 $ 1,167 $ 18,804 $ 19,971 $ (557 ) $ 19,414 Financed sales receivables 3,307 1,943 10,699 15,949 103,721 119,670 (7,274 ) 112,396 Total $ 3,605 $ 2,123 $ 11,388 $ 17,116 $ 122,525 $ 139,641 $ (7,831 ) $ 131,810 The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of December 31, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 143 $ 132 $ 825 $ 1,100 $ 12,619 $ (176 ) $ 13,543 Financed sales receivables 959 729 6,190 7,878 41,439 (1,413 ) 47,904 Total $ 1,102 $ 861 $ 7,015 $ 8,978 $ 54,058 $ (1,589 ) $ 61,447 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 231 $ 162 $ 359 $ 752 $ 13,912 $ (310 ) $ 14,354 Financed sales receivables 2,026 1,551 10,249 13,826 62,602 (4,434 ) 71,994 Total $ 2,257 $ 1,713 $ 10,608 $ 14,578 $ 76,514 $ (4,744 ) $ 86,348 The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of December 31, 2021 and 2020: As of December 31, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 871 $ (309 ) $ 562 $ 764 $ (18 ) $ 746 Net financed sales receivables 8,642 (2,357 ) 6,285 2,813 (1,482 ) 1,331 Total $ 9,513 $ (2,666 ) $ 6,847 $ 3,577 $ (1,500 ) $ 2,077 For the year ended December 31, 2021, the Company recognized $0.1 million (2020 — $0.2 million) in Finance Income related to the net investment in leases with billed amounts past due. For the year ended December 31, 2021, the Company recognized $nil (2020 – less than $0.1 million) in Finance Income related to the net investment in leases in nonaccrual status. For the year ended December 31, 2021, the Company recognized $3.7 million (2020 — $5.7 million) in Finance Income related to the financed sale receivables with billed amounts past due. For the year ended December 31, 2021, the Company recognized $0.2 million (2020 – less than $0.1 million) in Finance Income related to the financed sales receivables in nonaccrual status. The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for years ended December 31, 2021 and 2020: Year Ended December 31, 2021 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 557 $ 7,274 Current period provision (reversal), net 235 (1,947 ) Foreign exchange 6 87 Ending balance $ 798 $ 5,414 Year Ended December 31, 2020 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 155 $ 915 Current period provision, net 451 6,574 Write-offs (69 ) (330 ) Foreign exchange 20 115 Ending balance $ 557 $ 7,274 For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables decreased $1.6 million. This decrease is principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry continues to recover from the COVID-19 pandemic, partially offset by new provisions recorded in the period. For the year ended December 31, 2020, the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables increased by $6.8 million, principally reflecting a reduction in the credit quality of and heightened collection risk associated with these receivables primarily due to the COVID-19 pandemic. Variable Consideration Receivables In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal. The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the years ended December 31, 2021 and 2020: Year Ended December 31, (In thousands of U.S. Dollars) 2021 2020 Beginning balance $ 1,887 $ — Current period (reversal) provision, net (787 ) 1,875 Foreign Exchange (18 ) 12 Ending balance $ 1,082 $ 1,887 For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables decreased by $0.8 million. This decrease is principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry begins to recover from the COVID-19 pandemic, partially offset by new provisions recorded in the period. For the year ended December 31, 2020, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables increased by $1.9 million, principally reflecting a reduction in the credit quality of and heightened collection risk associated with Variable Consideration Receivables primarily due to the COVID-19 pandemic.

Lease Arrangements

Lease Arrangements	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Lease Arrangements	6. Lease Arrangements (a) IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. For the years ended December 31, 2021, 2020, and 2019 the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Operating lease cost (1) $ 713 $ 540 $ 850 Amortization of lease assets 2,791 3,114 2,370 Interest on lease liabilities 937 1,052 1,102 Total lease cost $ 4,441 $ 4,706 $ 4,322 (1) Includes short-term leases and variable lease costs, which are not significant for the years ended December 31, 2021, 2020, and 2019. For the years ended December 31, 2021, 2020 upplemental cash and non-cash information related to leases is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 3,839 $ 3,743 $ 3,607 Right-of-use assets obtained in exchange for lease obligations (1) $ 1,047 $ 563 $ 17,147 (1) For the ASC Topic As of December 31, 2021 , December 31, (In thousands of U.S. Dollars) 2021 2020 Assets Balance Sheet Classification Right-of-Use-Assets Property, plant and equipment $ 12,132 $ 13,911 Liabilities Balance Sheet Classification Operating Leases Accrued and other liabilities $ 14,691 $ 16,634 As of December 31, 2021 and 2020 December 31, 2021 2019 Weighted-average remaining lease term (years) 7.0 7.6 Weighted-average discount rate 5.97 % 5.91 % As of December 31, 2021, the maturities of the Company’s operating lease liabilities are as follows: (In thousands of U.S. Dollars) 2022 $ 3,364 2023 2,449 2024 2,226 2025 2,075 2026 2,051 Thereafter 5,982 Total lease payments $ 18,147 Less: interest expense (3,456 ) Present value of operating lease liabilities $ 14,691 (b) IMAX Corporation as a Lessor The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3(p). Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 to 20 years with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company also provides IMAX Theater Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX Theater System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX Theater System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX Theater System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) Sales-Type Leases Joint Revenue Sharing Arrangements 2022 $ 3,590 $ 190 2023 3,145 128 2024 3,086 — 2025 2,933 — 2026 2,694 — Thereafter 14,505 — Total $ 29,953 $ 318 (See Note 5 for additional information related to the net investment in leases related to the Company’s sales-type lease arrangements.)

Variable Consideration Receivab

Variable Consideration Receivable from Contracts With Customers	12 Months Ended
	Dec. 31, 2021
Change In Contract With Customer Asset [Abstract]
Variable Consideration Receivable from Contracts With Customers	7. Variable Consideration from Contracts with Customers The arrangement for the sale of an IMAX Theater System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual theater, which are developed using historical data for the theater and, if necessary, comparable theaters and territories. (See Note 3(p) for a more detailed discussion of the Company’s accounting policy related to variable consideration.) The following table summarizes the activity related to variable consideration from contracts with customers for the years ended December 31, 2021, 2020, and 2019: (In thousands of U.S. Dollars) Balance as of January 1, 2019 $ 35,985 Variable consideration for newly recognized sales 9,948 Accretion to finance income 1,936 True-up of variable consideration receivable 979 Transferred to receivables from variable consideration assets (8,808 ) Balance as of December 31, 2019 40,040 Variable consideration for newly recognized sales 5,550 Accretion to finance income 2,133 Transferred to receivables from variable consideration assets (5,310 ) Movement in allowance for credit losses (see Note 5) (1,887 ) Balance as of December 31, 2020 40,526 Variable consideration for newly recognized sales 4,696 Accretion to finance income 1,985 Transferred to receivables from variable consideration assets (3,794 ) Movement in allowance for credit losses (see Note 5) 805 Balance as of December 31, 2021 $ 44,218

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	8. Inventories As of December 31, (In thousands of U.S. Dollars) 2021 2020 Raw materials $ 20,551 $ 30,096 Work-in-process 1,406 3,014 Finished goods 4,967 6,470 $ 26,924 $ 39,580 As of December 31, 2021, Inventories include finished goods of $2.6 million (December 31, 2020 — $2.1 million) for which title had passed to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. The following table summarizes the activity for the Company’s inventory valuation allowance account for the years ended December 31, 2021, 2020 and 2019: Balance at beginning of year Additions charged to expenses (1) Other deductions (2) Balance at end of year (In thousands of U.S. Dollars) Year ended December 31, 2021 $ 5,752 $ 629 $ (1,484 ) $ 4,897 Year ended December 31, 2020 $ 3,216 $ 3,028 $ (492 ) $ 5,752 Year ended December 31, 2019 $ 3,885 $ 446 $ (1,115 ) $ 3,216 (1) Excludes amounts charged directly to the Consolidated Statements of Operations of $0.3 million, $0.6 million, and $nil during the years ended December 31, 2021, 2020 and 2019, respectively. (2) Includes the write-off of amounts previously charged to valuation allowance.

Film Assets

Film Assets	12 Months Ended
	Dec. 31, 2021
Film Costs [Abstract]
Film Assets	9. Film Assets As of December 31, (In thousands of U.S. Dollars) 2021 2020 Completed and released films, net of accumulated amortization of $ 2,292 $ 2,678 $218,148 (2020 ― $201,832) Films in production 195 195 Films in development 1,754 2,904 $ 4,241 $ 5,777 The Company expects to amortize $4.1 million of the Film Asset balance within three years from December 31, 2021, including $3.5 million expected to be amortized in 2022, $0.5 million in 2023, and $0.1 million in 2024. In certain film arrangements, the Company co-produces a film with a third party with the third party retaining certain rights to the film. In 2021, the Company recorded impairment losses of $0.2 million related to the write-down of DMR related film assets. In 2020, the Company recorded impairment losses of $10.8 million (2019 — $1.4 million) principally to write-down the carrying value of certain documentary, alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	10. Property, Plant and Equipment As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: Theater system components (1)(2)(3) $ 346,517 $ 181,936 $ 164,581 Camera equipment 4,855 3,214 1,641 351,372 185,150 166,222 Assets under construction (4) 10,232 — 10,232 Right-of-use assets (5) 14,429 2,297 12,132 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,973 28,873 52,100 Office and production equipment (6) 39,017 31,169 7,848 Leasehold improvements 8,110 4,494 3,616 136,303 64,536 71,767 $ 512,336 $ 251,983 $ 260,353 As of December 31, 2020 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: Theater system components (1)(2)(3) $ 337,271 $ 158,647 $ 178,624 Camera equipment 5,399 4,653 746 342,670 163,300 179,370 Assets under construction (4) 5,660 — 5,660 Right-of-use assets (5) 15,553 1,642 13,911 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,875 25,921 54,954 Office and production equipment (6) 40,362 29,156 11,206 Leasehold improvements 8,061 3,968 4,093 137,501 59,045 78,456 $ 501,384 $ 223,987 $ 277,397 (1) Included in theater system components are assets with costs of $7.6 million (2020 — $7.6 million) and accumulated depreciation of $7.0 million (2020 — $6.8 million) that are leased to customers under operating leases. (2) Included in theater system components are assets with costs of $324.3 million (2020 — $315.4 million) and accumulated depreciation of $166.5 million (2020 — $144.7 million) that are used in joint revenue sharing arrangements. (3) In 2021, the Company recorded charges of $0.4 million (2020 — $1.8 million; 2019 — $2.2 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased IMAX Xenon Theater Systems which were taken out of service in connection with customer upgrades to IMAX Laser Theater Systems. (4) Included in assets under construction are components with costs of $9.2 million (2020 — $5.3 million) that will be utilized to construct assets to be used in joint revenue sharing arrangements. (5) The right-of-use assets primarily include operating leases for office and warehouse space. (6) Fully depreciated office and production equipment is still in use by the Company. In 2021, the Company identified and wrote off $0.5 million (2020 — $0.9 million) of office and production equipment that is fully depreciated and no longer in use. In 2021, the Company recorded a charge of $0.2 million (2020 — $0.2 million; 2019 — $0.2 million) reflecting Property, Plant and Equipment that was no longer in use.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2021
Other Assets [Abstract]
Other Assets	11. Other Assets As of December 31, (In thousands of U.S. Dollars) 2021 2020 Lease incentives provided to theater customers, net of accumulated amortization $ 14,834 $ 15,651 Commissions and other deferred selling expenses 1,418 2,608 Other investments 1,000 1,000 Foreign currency derivatives 184 1,979 Other 363 435 $ 17,799 $ 21,673

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes (a) Income (Loss) Before Taxes by Jurisdiction Income (loss) before taxes by tax jurisdiction for the years ended December 31, 2021, 2020, and 2019 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Canada $ (55,480 ) $ (104,166 ) $ 884 United States 3,218 (6,437 ) (234 ) China 53,792 (8,253 ) 51,809 Ireland 829 (7,473 ) 17,630 Other 8,628 (2,795 ) 5,247 $ 10,987 $ (129,124 ) $ 75,336 (b) Income Tax (Expense) Benefit Income tax (expense) benefit for the years ended December 31, 2021, 2020, and 2019 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Income tax (expense) benefit – current: Canada $ (915 ) $ 555 $ 2,369 United States (1,038 ) 488 595 China (11,045 ) (1,980 ) (11,789 ) Ireland (1,358 ) (1,462 ) (762 ) Other (3,212 ) (487 ) (419 ) Sub-total (17,568 ) (2,886 ) (10,006 ) Income tax (expense) benefit – deferred: Canada (1) (231 ) (10,801 ) (3,913 ) United States (1,268 ) 867 (949 ) China (2) (381 ) (15,756 ) (18 ) Ireland (997 ) 2,161 (1,923 ) Other (119 ) (89 ) 41 Sub-total (2,996 ) (23,618 ) (6,762 ) Total (3) $ (20,564 ) $ (26,504 ) $ (16,768 ) ( 1 ) A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is needed. (2) In 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $19.1 million in 2020 for the estimated applicable foreign withholding taxes associated with these historical earnings, which will become payable upon the repatriation of any such earnings. In 2021, the deferred tax liability for the applicable foreign withholding taxes was increased by $0.5 million due to an increase in the amount of distributable historical earnings. During the year ended December 31, 2021, $20.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.0 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2021 is $17.6 million. (3) For the year ended December 31, 2021, Income Tax (Expense) Benefit excludes a tax benefit of $0.3 million included in Other Comprehensive Income (2020 — benefit of $0.1 million; 2019 — expense of $(0.4) million). (c) Reconciliation of Income Tax Expense to Statutory Rates For the years ended December 31, 2021, 2020, and 2019, the Company’s effective tax rate and income tax expense differs from the combined Canadian federal and provincial statutory income tax rates due to the following factors: Years Ended December 31, 2021 2020 2019 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Amount Rate Income tax (expense) benefit at combined statutory rates $ (2,912 ) 26.5% $ 34,218 26.5% $ (19,964 ) 26.5% Adjustments resulting from: NCI share of partnership losses (1 ) 0.0% (1,229 ) (1.0%) (397 ) 0.5% Increase in valuation allowance (14,722 ) 134.0% (28,589 ) (22.1%) — 0.0% Changes to tax reserves 3,508 (31.9%) (2,699 ) (2.1%) 1,418 (1.9%) U.S. federal and state taxes (80 ) 0.7% (250 ) (0.2%) (300 ) 0.4% Withholding taxes (4,199 ) 38.2% (20,943 ) (16.2%) (1,071 ) 1.4% Income tax at different rates in foreign and other provincial jurisdictions 3,352 (30.5%) (2,607 ) (2.0%) 5,019 (6.7%) Investment and other tax credits (non-refundable) 413 (3.8%) 643 0.5% 701 (0.9%) Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments (5,336 ) 48.6% (1,219 ) (0.9%) (1,998 ) 2.7% Other non-deductible/non-taxable items (587 ) 5.4% (3,829 ) (3.0%) (176 ) 0.3% Income tax expense $ (20,564 ) 187.2% $ (26,504 ) (20.5%) $ (16,768 ) 22.3% (d) Deferred Tax Assets and Deferred Tax Liability As of December 31, 2021 and 2020, the Company’s deferred tax assets and deferred tax liability consists of the following: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Net operating loss carryforwards $ 21,219 $ 17,120 Investment tax credit and other tax credit carryforwards 3,919 1,344 Write-downs of other assets 1,223 1,219 Excess of tax accounting basis in various assets 13,929 9,692 Accrued pension liability 6,901 6,942 Accrued share-based compensation 7,728 7,350 Income recognition on net investment in leases (3,368 ) (2,018 ) Other accrued reserves 8,369 5,120 Total deferred income tax assets 59,920 46,769 Valuation allowance (46,014 ) (28,786 ) Deferred income tax asset net of valuation allowance 13,906 17,983 Deferred tax liability (17,642 ) (19,134 ) Net deferred tax liability $ (3,736 ) $ (1,151 ) As of December 31, 2021, deferred tax assets include of $0.3 million (December 31, 2020 — $0.6 million) associated with amounts recognized within Accumulated Other Comprehensive Income, including unrealized actuarial gains and losses related to the Company’s pension and other postretirement benefit plans and unrealized net gains and losses on cash flow hedging instruments. (e) Net Operating Loss Carryforwards Estimated United States and Canadian net operating loss carryforwards of $93.2 million can be used to reduce taxable income through 2041 and $21.9 million can be carried forward indefinitely. Investment tax credits and other tax credits can be carried forward to reduce income taxes payable through to 2041. (f) Change on Indefinitely Reinvested Assertion Income taxes are accrued for the earnings of non-Canadian affiliates and associated companies unless management determines that such earnings will be indefinitely reinvested outside of Canada. In 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $19.1 million in 2020 for the estimated applicable foreign withholding taxes associated with these historical earnings, which will become payable upon the repatriation of any such earnings. In 2021, the deferred income tax liability for the applicable foreign withholding taxes was increased by $0.5 million due to an increase in the amount of distributable historical earnings. During the year ended December 31, 2021, $20.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $2.0 million of foreign withholding taxes were paid to the relevant tax authorities (2020 — $nil). The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2021 is $17.6 million. (g) Valuation A llowance As of December 31, 2021, the Company’s Consolidated Balance Sheets include net deferred income tax assets of $13.9 million, net of a valuation allowance of $46.0 million (December 31, 2020 — $18.0 million, net of a valuation allowance of $28.8 million). For the years ended December 31, 2021 and 2020, the Company recorded a valuation allowance of $17.2 million and $28.6 million, respectively, where management cannot reliably forecast that sufficient future tax liabilities will arise in specific jurisdictions, which includes the long-term impact of the COVID-19 pandemic ( h ) Uncertain Tax Positions As of December 31, 2021 and December 31, 2020, the Company had total tax reserves (including interest and penalties) of $13.9 million and $17.4 million, respectively, for various uncertain tax positions. While the Company believes it has adequately provided for all tax positions, amounts asserted by taxing authorities could differ from the Company's accrued liability. Accordingly, additional provisions on federal, provincial, state and foreign tax-related matters may be required in the future as revised estimates are made or the underlying matters are settled or otherwise resolved. For the year ended December 31, 2021, the Company recorded a net decrease of $2.1 million related to reserves (excluding interest and penalties) for income taxes (2020 — $0.6 million, 2019 — $1.4 million). The Company has elected to classify interest and penalties related to income tax liabilities, when applicable, as part of the Income Tax Expense in its Consolidated Statements of Operations rather than Interest Expense. The Company reversed $1.4 million in potential interest and penalties associated with its provision for uncertain tax positions for the years ended December 31, 2021 (2020 — expensed $3.3 million; 2019 — expensed $0.2 million). The following table presents a reconciliation of the beginning and ending amount of tax reserves (excluding interest and penalties) for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Balance at beginning of the year $ 14,076 $ 14,718 $ 16,136 Additions based on tax positions related to the current year 37 2,301 812 Reductions for tax positions of prior years (991 ) — (2,230 ) Reductions resulting from lapse of applicable statute of limitations and administrative practices (1,183 ) (2,943 ) — Balance at the end of the year $ 11,939 $ 14,076 $ 14,718 The number of years with open tax audits varies depending on the tax jurisdiction. The Company's taxing jurisdictions include Canada, the province of Ontario, the United States (including multiple states), Ireland, and China. In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest. The Company's 2017 through 2021 tax years remain subject to examination by the IRS for United States federal tax purposes, and the 2016 through 2021 tax years remain subject to examination by the appropriate governmental agencies for Canadian federal tax purposes. There are other on-going audits in various other jurisdictions that are not material to the Consolidated Financial Statements. ( i ) Income Tax Effect on Other Comprehensive Income For the years ended December 31, 2021, 2020, and 2019, Income Tax Benefit (Expense) related to the components of Other Comprehensive Income is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized defined benefit plan actuarial (gain) loss $ (37 ) $ 276 $ (42 ) Unrealized postretirement benefit plans actuarial (gain) loss (35 ) 92 — Prior service cost arising during the period — — 145 Amortization of prior service cost (48 ) (23 ) (26 ) Unrealized change in cash flow hedging instruments (123 ) (132 ) (145 ) Realized change in cash flow hedging instruments 446 (158 ) (310 ) Reclassification of unrealized change in ineffective cash flow hedging instruments 83 — — $ 286 $ 55 $ (378 )

Other Intangible Assets

Other Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Other Intangible Assets	13. Other Intangible Assets As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Patents and trademarks $ 12,834 $ 9,406 $ 3,428 Licenses and intellectual property 26,168 13,642 12,526 Internal use software 28,571 21,544 7,027 Other 598 499 99 $ 68,171 $ 45,091 $ 23,080 As of December 31, 2020 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Patents and trademarks $ 12,714 $ 8,878 $ 3,836 Licenses and intellectual property 26,168 12,182 13,986 Internal use software 25,009 17,568 7,441 Other 1,445 463 982 $ 65,336 $ 39,091 $ 26,245 Fully amortized other intangible assets are still in use by the Company. In 2021, the Company identified and wrote off $0.1 million (2020 — $0.2 million) of patents and trademarks that are no longer in use. During 2021, the Company capitalized $4.1 million in other intangible assets, mainly related to the development of internal use software, as well as additions in patents and trademark and other intangible assets (2020 — $2.8 million). The weighted average amortization period for these additions is 2.3 years (2020 — 6.6 years). The net book value of the other intangible assets capitalized in 2021 was $3.9 million as of December 31, 2021 (2020 — $2.6 million). During 2021, the Company incurred costs of $0.1 million to renew or extend the term of acquired patents and trademarks which were recorded in Selling, General and Administrative expenses (2020 — $0.4 million). The estimated amortization expense for each of the next five years following the December 31, 2021 balance sheet date is as follows: (In thousands of U.S. Dollars) 2022 $ 6,225 2023 6,225 2024 4,899 2025 2,056 2026 1,704

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	14. Debt (a) Revolving Credit Facility Borrowings, net As of December 31, 2021 and 2020, Revolving Credit Facility Borrowings, net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Credit Facility borrowings $ — $ 300,000 Working Capital Facility borrowings 3,612 7,643 Unamortized debt issuance costs (1,140 ) (1,967 ) Revolving Credit Facility Borrowings, net $ 2,472 $ 305,676 Credit Agreement The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The Credit Facility provided by the Credit Agreement matures on June 28, 2023. The Credit Agreement has a revolving borrowing capacity of $300.0 million, and contains an uncommitted accordion feature allowing the Company to further expand its borrowing capacity to $440.0 million or greater, subject to certain conditions, depending on the mix of revolving and term loans comprising the incremental facility. In the first quarter of 2020, in response to uncertainties associated with the outbreak of the COVID-19 pandemic and its impact on the Company’s business, the Company drew down $280.0 million in available revolving borrowing capacity under the Credit Facility, resulting in total outstanding borrowings of $300.0 million, which remained outstanding as of December 31, 2020. During the first half of 2021, the Company completely repaid the $300.0 million of Credit Facility borrowings, using cash on hand following the issuance of the Convertible Notes (as discussed below). Accordingly, as of December 31, 2021, there were no outstanding borrowings under the Credit Facility. As of December 31, 2021, and December 31, 2020, the Company did not have any letters of credit or advance payment guarantees outstanding under the Credit Facility. The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as of the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00. In addition, the Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions. On March 15, 2021, the Company entered into the Second Amendment to the Credit Agreement (as previously amended by the First Amendment to the Credit Agreement, dated as of June 10, 2020). On July 28, 2021, and December 13, 2021, the Company entered into the Third and Fourth Amendments to the Credit Agreement, respectively (collectively, the “Amendments”). The Amendments, among other things, (i) suspend the Senior Secured Net Leverage Ratio covenant through the first quarter of 2022, (ii) re-establish the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of EBITDA for the corresponding quarters of 2021, (iii) add a $75.0 million minimum liquidity covenant measured at the end of each calendar month, (iv) restrict the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement, (v) permit the issuance of the Convertible Notes (as discussed below) and related transactions, including the capped call transactions, or other unsecured debt, in an amount not to exceed $290.0 million, (vi) allow $30.0 million in permitted repurchases of the Company’s common shares, subject to a $300.0 million pro forma minimum liquidity covenant, (vii) increase permitted repurchases of the common shares of IMAX China from $5.0 million to $20.0 million, subject to pro forma compliance with the existing financial covenants set forth in the Credit Agreement, and (viii) facilitate a transition from a LIBOR-based interest rate to an interest rate based on the Euro Interbank Offered Rate for non-USD denominated loans. The modifications to the negative covenants, the minimum liquidity covenant, permitted share repurchases and modifications to certain other provisions in the Credit Agreement pursuant to the Amendments are effective until the earlier of the delivery of the compliance certificate for the fourth quarter of 2022 or the date on which the Company, in its sole discretion, elects to calculate its compliance with the Senior Secured Net Leverage Ratio by using either its actual EBITDA or annualized EBITDA (the “Designated Period”). As of December 31, 2021, the Company was in compliance with all of its requirements under the Credit Agreement, as amended. Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the year ended December 31, 2021 was 2.64% (2020 — 2.38%). In addition, the Credit Facility has standby fees ranging from 0.25% to 0.38% per annum, based on the Company’s Total Leverage Ratio with respect to the unused portion of the Credit Facility; provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate following the end of the Designated Period, the standby fee will be 0.50% per annum. The Company incurred fees of approximately $1.6 million in connection with the Amendments, which are being amortized on a straight-line basis. Working Capital Facility On July 1, 2021, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Chinese Renminbi (“RMB”) (approximately $31.4 million), including RMB 10.0 million (approximately $1.6 million) for letters of guarantee, to fund ongoing working capital requirements (the “Working Capital Facility”). The Working Capital Facility expires in July 2022. As of December 31, 2021, outstanding Working Capital Facility borrowings were RMB 23.0 million ($3.6 million) and outstanding letters of guarantee were RMB 2.8 million ($0.5 million). As of December 31, 2020, outstanding Working Capital Facility borrowings were RMB 49.9 million ($7.6 million) and no letters of guarantee were issued. As of December 31, 2021, the amount available for future borrowings under the Working Capital Facility was RMB 167.0 million ($26.2 million) and the amount available for letters of guarantee was RMB 7.2 million ($1.1 million). The amount available for future borrowings under the Working Capital Facility is not subject to a standby fee. The effective interest rate for the year ended December 31, 2021 was 4.31% (2020 — 4.31%). Wells Fargo Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. As of December 31, 2021, the net unrealized gain on the Company’s outstanding foreign currency forward contracts was $0.1 million, representing the amount by which the fair value of these forward contracts exceeded their notional value (December 31, 2020 — $2.0 million). As of December 31, 2021, the notional value of the Company’s outstanding foreign currency forward contracts was $26.7 million (December 31, 2020 — $26.4 million). NBC Facility On October 28, 2019, the Company entered into a $5.0 million facility with the National Bank of Canada (the “NBC Facility”) fully insured by Export Development Canada for use solely in conjunction with the issuance of performance guarantees and letters of credit. The NBC Facility is renewed on an annual basis. It was renewed on October 15, 2021 for a one-year term on the same terms and conditions. The Company did not have any letters of credit or advance payment guarantees outstanding as of December 31, 2021 and 2020 under the NBC Facility. (b) Convertible Notes As of December 31, 2021 and December 31, 2020, Convertible Notes (as defined below) consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Convertible Notes $ 230,000 $ — Unamortized discounts and debt issuance costs (6,359 ) — Revolving Credit Facility Borrowings, net $ 223,641 $ — On March 19, 2021, the Company issued $230.0 million of 0.500% Convertible Senior Notes due 2026 (the “Convertible Notes”) in a private placement conducted pursuant to Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the issuance of the Convertible Notes were $223.7 million, after deducting the initial purchasers’ discounts and commissions. In addition, the Company paid $1.2 million of debt issuance costs associated with the Convertible Notes. The Company used a portion of the net proceeds from the issuance of the Convertible Notes to make a partial repayment of outstanding Credit Facility borrowings (as discussed above), and is using the remainder for working capital or other general corporate purposes. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The Convertible Notes will mature on April 1, 2026, unless they are redeemed or repurchased by the Company or converted on an earlier date. Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. T The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption. In addition, upon the occurrence of a “fundamental change” (as defined below ), holders may require the Company to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. Subject to the terms and conditions of the indenture governing the Convertible Notes, a “fundamental change” means, among other things, an event resulting in (i) a change of control, (ii) a transfer of all or substantially all of the assets of the Company, (iii) a merger, (iv) liquidation or dissolution of the Company, or (v) delisting of the Company’s common shares from a national securities exchange. On January 1, 2021, the Company elected to early adopt ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible debt that may be settled in cash. As a result, the Company recorded the Convertible Notes entirely as a liability in the Consolidated Balance Sheets, net of initial purchasers’ discounts and commissions and other debt issuance costs, with interest expense reflecting the cash coupon plus the amortization of the discounts and capitalized costs. Additionally, ASU 2020-06 modifies the treatment of convertible debt securities that may be settled in cash or shares by requiring the use of the “if-converted” method. Under the “if-converted” method, because the principal amount of the Convertible Notes is settled in cash and the conversion spread is settleable in the Company’s common shares, diluted earnings per share is calculated by including the net number of incremental shares that would be issued upon conversion of the Convertible Notes, using the average market price during the period. Accordingly, the application of the “if-converted” method may reduce the Company’s reported diluted earnings per share. In connection with the pricing of the Convertible Notes, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions. The Capped Call Transactions are expected to reduce potential dilution resulting from the common shares the Company is required to issue and/or to offset any potential cash payments the Company is required to make in excess of the principal amount of the Convertible Notes in the event that the market price per share of the Company’s common shares is greater than the strike price of the Capped Call Transactions with such reduction and/or offset subject to a cap. The Capped Call Transactions have an initial cap price of $37.2750 per share of the Company’s common shares, which represents a premium of 75% over the last reported sale price of the common shares when they were priced on March 16, 2021, and is subject to certain adjustments under the terms of the Capped Call Transactions. Collectively, the Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of the Company’s common shares underlying the Convertible Notes. The cost of the Capped Call Transactions was approximately $19.1 million. The Capped Call Transactions are separate transactions, and are not part of the terms of the Convertible Notes and will not affect any holder’s rights under the Convertible Notes. Holders of the Convertible Notes will not have any rights with respect to the Capped Call Transactions. The Capped Call Transactions meet all of the applicable criteria for equity classification in accordance with ASC 815-10-15-74(a), “Derivatives and Hedging—Embedded Derivatives—Certain Contracts Involving an Entity’s Own Equity,” and, as a result, the related $19.1 million cost was recorded as a reduction to Other Equity within Shareholders’ Equity on the Company’s Consolidated Statements of Shareholders’ Equity and Consolidated Balance Sheets.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments	15. Commitments In the ordinary course of its business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement. The following table presents a summary of the Company’s contractual obligations and commitments as of December 31, 2021: Payments Due by Period (In thousands of U.S. Dollars) Total Obligation Less Than One Year 1 to 3 years 3 to 5 years Thereafter Purchase obligations (1) $ 34,084 $ 33,907 $ 42 $ — $ 135 Pension obligations (2) 20,298 — 20,298 — — Operating lease obligations (3) 18,833 3,760 4,669 4,127 6,277 Working Capital Facility (4) 3,612 3,612 — — — Convertible Notes (5) 235,175 1,150 2,300 231,725 — Postretirement benefits obligations 3,066 117 266 262 2,421 $ 315,068 $ 42,546 $ 27,575 $ 236,114 $ 8,833 (1) Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced. (2) The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. ( See Note 23.) (3) Represents total minimum annual rental payments due under the Company’s operating leases, which almost entirely relates to leased office space in New York. (See Note 6.) (4) The Working Capital Facility (5) The Convertible Notes bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The Convertible Notes will mature on April 1, 2026, unless earlier repurchased, redeemed or converted. (See Note 14.) The Company compensates its sales force with both fixed and variable compensation. Commissions on the sale or lease of IMAX Theater Systems are payable in graduated amounts from the time of collection of the customer’s first payment to the Company up to the collection of the customer’s last initial payment. As of December 31, 2021, $1.1 million (December 31, 2020 — $1.6 million) of commissions have been accrued and will be payable in future periods.

Contingencies and Guarantees

Contingencies and Guarantees	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Contingencies and Guarantees	16. Contingencies and Guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. (a) In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking an order that the ICC award may not be recognized in India and on June 10, 2013, the Bombay High Court ruled that it had jurisdiction over the proceeding filed by E-City. The Company appealed that ruling to the Supreme Court of India, and on March 10, 2017, the Supreme Court set aside the Bombay High Court’s judgment and dismissed E-City’s petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties, which award the Company calculates to be $24.4 million, inclusive of interest, as of December 31, 2021. That matter is currently pending. The Company has also taken steps to enforce the ICC final award outside of India. In December 2011, the Ontario Superior Court of Justice issued an order recognizing the final award and requiring E-City to pay the Company $30,000 to cover the costs of the application, and in May 2012, the New York Supreme Court recognized the Canadian judgment and entered it as a New York judgment. The Company intends to continue pursuing its rights and seeking to enforce the award, although no assurances can be given with respect to the ultimate outcome. (b) On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. On February 7, 2017, the panel issued a Partial Final Award and on July 21, 2017, the panel issued a Final Award (collectively, the “Award”), which held that the parties had reached a binding settlement, and therefore the panel did not reach a decision regarding the merits of the dispute. On December 3, 2020, the District Judge entered a final judgment (the “Final Judgment”) against the Company in the total amount of As of December 31, 2020, the Company’s Consolidated Balance Sheets included a liability within Accrued and Other Liabilities of $11.3 million related to the Final Judgment, consisting of $7.2 million related to amounts previously collected from or owed to Giencourt principally in respect of theater systems that were not delivered and $4.1 million recorded within Legal Judgment and Arbitration Awards in the Company’s Consolidated Statements of Operations during the year ended December 31, 2020 in respect of the remaining amounts owed under the Final Judgment. On June 23, 2021, the Company entered into a final settlement agreement with Giencourt to fully resolve all disputes between the parties in the United States and Ontario (the “Settlement Agreement”). In the second quarter of 2021, the Company paid Giencourt $9.5 million as required by the terms of the Settlement Agreement. As a result of the Settlement Agreement, the Final Judgment has been vacated, all litigation between the parties in all jurisdictions has been dismissed and full and final releases have been exchanged by the parties. Accordingly, upon entry in the Settlement Agreement on June 23, 2021, the remaining $1.8 million liability recorded within Accrued and Other Liabilities was reversed and a corresponding $1.8 million benefit was recorded in the Company’s Condensed Consolidated Statements of Operations within Legal Judgment and Arbitration Awards (c) In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. (d) In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. A guarantee is a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. Financial Guarantees Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement. Product Warranties The Company’s accrual for product warranties, which is recorded within Accrued and Other Liabilities in the Consolidated Balance Sheets is $nil and $0.1 million as of December 31, 2021 and 2020, respectively. Director/Officer Indemnifications The Company’s by-laws contain an indemnification of its directors/officers, former directors/officers, and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act No Other Indemnification Agreements In the normal course of the Company’s operations, the Company provides indemnifications to counterparties in transactions such as: IMAX Theater System lease and sale agreements and the supervision of installation or servicing of IMAX Theater Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX Theater System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amounts have been accrued in the Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Capital Stock	17. Capital Stock (a) Authorized Common Shares The authorized capital of the Company consists of an unlimited number of common shares. The following is a summary of the rights, privileges, restrictions, and conditions of the common shares. The holders of common shares are entitled to receive dividends, if and when declared by the directors of the Company, subject to the rights of the holders of any other class of shares of the Company entitled to receive dividends in priority to the common shares. The holders of the common shares are entitled to one vote for each common share held at all meetings of the shareholders. (b) Settlements of Share-Based Compensation During the years ended December 31, 2021, 2020, and 2019, the Company settled the exercise of stock options and the vesting of RSUs with its common shares. These settlements were either through newly issued common shares from treasury or through the purchase of common shares in the open market by the IMAX LTIP trustee. The following table summarizes the settlement of stock option and RSU transactions: Years Ended December 31, (Cash proceeds in thousands of U.S. Dollars) 2021 2020 2019 Stock options Issued from treasury 41,613 — 19,088 Plan trustee purchases — — 67,840 Total stock options exercised 41,613 — 86,928 Cash proceeds from stock option exercises $ — $ — $ 1,752 RSUs Issued from treasury 531,629 42,982 — Plan trustee purchases 723 386,297 404,719 Shares withheld for tax withholdings 157,546 24,714 29,577 Total RSUs vested 689,898 453,993 434,296 (c) Share-Based Compensation The Company issues share-based compensation to eligible employees, directors, and consultants under the IMAX LTIP and the China LTIP, as summarized below. On June 3, 2020, the Company’s shareholders approved the IMAX LTIP at its Annual and Special Meeting. Awards under the IMAX LTIP may consist of stock options, RSUs, PSUs, and other awards. Stock options are no longer granted under the Company’s previously approved Stock Option Plan (“SOP”). For the year ended December 31, 2021, share-based compensation expense totaled $25.6 million (2020 — $21.5 million; 2019 — $22.8 million) and is reflected in the following accounts in the Consolidated Statements of Operations: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Cost and expenses applicable to revenues $ 1,490 $ 691 $ 1,709 Selling, general and administrative expenses 23,776 20,652 20,750 Research and development 348 150 371 $ 25,614 $ 21,493 $ 22,830 As of December 31, 2021, the Company has reserved a total of 5,807,445 (December 31, 2020 — 15,486,807) common shares for future issuance under the IMAX LTIP. Of this amount, 3,736,157 common shares are reserved for the future exercise of stock options (December 31, 2020 — 4,892,962), 613,405 common shares are reserved for the future vesting of PSUs (December 31, 2020 — 361,844), and 1,457,883 common shares are reserved for the future vesting of RSUs (December 31, 2020 — 1,564,838). As of December 31, 2021, stock options in respect of 3,488,107 (December 31, 2020 — 4,311,761) common shares were vested and exercisable. IMAX LTIP and SOP Stock Options The Company’s policy is to issue new common shares from treasury or shares purchased in the open market to satisfy stock options which are exercised. The Company no longer intends to issue new stock option awards. The Company utilizes a Binomial Model to determine the fair value of stock option awards on the grant date . The fair value determined by the Binomial Model is affected by the Company’s stock price , as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the award, and actual and projected employee stock option exercise behaviors. The Binomial Model also considers the expected exercise multiple which is the multiple of exercise price to grant price at which exercises are expected to occur on average. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because the Company’s employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the Binomial Model best provides a fair measure of the fair value of the Company’s employee stock options. All stock option awards are granted at the fair market value of the Company’s common shares on the date of grant. The fair market value of a common share on a given date is based on the higher of the closing price of a common share on either: (i) the grant date or (ii) the most recent trading date if the grant date is not a trading date on the New York Stock Exchange (“NYSE”) or such national exchange as may be designated by the Company’s Board of Directors. The stock options vest within 4 years and expire 10 years or less from the date of grant. The SOP and IMAX LTIP provide for double-trigger accelerated vesting in the event of a change in control, as defined in each plan. The Company recorded the following expenses related to stock options issued to employees and directors under the IMAX LTIP and SOP: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Stock option expense $ 1,064 $ 1,847 $ 8,329 For the year ended December 31, 2021, the Company’s Consolidated Statements of Operations includes an income tax benefit of $0.1 million related to stock option expense (2020 — $0.1 million; 2019 — $1.9 million). As of December 31, 2021, 2020, and 2019, unrecognized share-based compensation expense related to non-vested employee stock options is as follows: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense related to non-vested employee stock options $ 662 $ 2,029 $ 4,073 As of December 31, 2021, 2020, and 2019, unrecognized share-based compensation expense related to non-vested employee stock options is expected to be recognized over the following weighted-average periods: As of December 31, 2021 2020 2019 Weighted average period (in years) 1.1 1.8 2.7 During the years ended December 31, 2021 and 2020, the Company did not grant any stock options. During the year ended 2019, the weighted average fair value of stock options granted to employees and directors at the measurement date and the assumptions used to estimate the average fair value of the stock options are as follows: Years Ended December 31, 2021 2020 2019 Weighted average fair value per share N/A N/A $ 6.65 Average risk-free interest rate N/A N/A 2.64% Expected option life (in years) N/A N/A 6.73 - 10.00 Expected volatility N/A N/A 31% Dividend yield N/A N/A 0% The following table summarizes the stock option activity under the SOP and IMAX LTIP for the years ended December 31, 2021, 2020, and 2019: Weighted Average Exercise Number of Shares Price Per Share 2021 2020 2019 2021 2020 2019 Stock options outstanding, beginning of year 4,892,962 5,732,209 5,465,046 $ 26.81 $ 26.82 $ 27.63 Granted — — 1,016,882 — — 20.66 Exercised (41,613 ) — (86,928 ) 21.23 — 20.16 Forfeited (88,934 ) (34,678 ) (336,493 ) 22.49 22.49 23.63 Expired (903,038 ) (786,086 ) (299,134 ) 28.31 27.07 25.82 Cancelled (123,220 ) (18,483 ) (27,164 ) 26.68 27.97 31.13 Stock options outstanding, end of year 3,736,157 4,892,962 5,732,209 26.61 26.81 26.82 Stock options exercisable, end of year 3,488,107 4,311,761 4,801,272 26.93 27.30 27.40 As of December 31, 2021, 3,736,157 options outstanding included both fully vested and unvested options with a weighted average exercise price of $26.61, an aggregate intrinsic value of $nil and a weighted average remaining contractual life of 4.1 years. The intrinsic value of the 41,613 options exercised in 2021 was $0.1 million (2020 — nil; 2019 — $0.2 million). IMAX LTIP Restricted Share Units RSUs have been granted to employees and directors under the IMAX LTIP. Each RSU represents a contingent right to receive a common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date or the average closing price of the Company’s common stock for five days prior to the date of grant. For the years ended December 31, 2021, 2020, and 2019, the Company recorded the following expenses related to RSUs issued to employees and directors in the IMAX LTIP: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 RSU expenses $ 15,555 $ 13,761 $ 12,394 The Company’s actual tax benefits realized for the tax deductions related to the vesting of RSUs was $0.6 million for the year ended December 31, 2021 (2020 — $0.3 million; 2019 — $1.6 million). The Company’s accrued liability for granted RSUs was $2.6 million as of December 31, 2021 (December 31, 2020 — $2.1 million). Total share-based compensation expense related to non-vested RSUs not yet recognized and the weighted average period over which the awards are expected to be recognized are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense related to non-vested RSUs not yet recognized $ 15,913 $ 17,343 $ 23,548 Weighted average period awards are expected to be recognized (in years) 1.6 1.9 2.7 The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the years ended December 31, 2021, 2020, and 2019: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2019 2021 2020 2019 RSUs outstanding, beginning of year 1,564,838 1,065,347 1,033,871 $ 18.33 $ 23.17 $ 25.70 Granted 831,123 1,050,385 687,475 21.03 15.35 22.30 Vested and settled (689,872 ) (453,993 ) (434,296 ) 19.46 22.71 27.54 Forfeited (248,206 ) (96,901 ) (221,703 ) 19.38 18.81 23.68 RSUs outstanding, end of year 1,457,883 1,564,838 1,065,347 19.16 18.33 23.17 Historically, RSUs granted under the IMAX LTIP have vested between immediately and three years from the grant date. In connection with the second amendment and restatement of the IMAX LTIP at the Company’s annual and special meeting of the shareholders on June 3, 2020, the IMAX LTIP plan retained the minimum one-year Approved under the June 3, 2020 amended and restated IMAX LTIP 885,000 Issued during previous years (412,045 ) Issued during 2021 (70,867 ) Outstanding, December 31, 2021 402,088 Restricted Share Units to Non-Employees There were no RSU awards granted to non-employees in 2021 (2020 ― nil; 2019 ― 12,580). The Company did not record any expenses for the year ended December 31, 2021 related to RSU grants issued to advisors and strategic partners of the Company (2020 ― $0.1 million; 2019 ― $0.1 million). IMAX LTIP Performance Stock Units Summary In 2020, the Company expanded its share-based compensation program to include PSUs. The Company grants two types of PSUs awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of total shareholder return (“TSR”) targets. The achievement of the EBITDA and TSR targets in these PSUs is determined over a three-year performance period. At the conclusion of the three-year performance period, the number of PSUs that ultimately vest can range from 0% to a maximum vesting opportunity of 175% of the initial award, depending upon actual performance versus the established EBITDA and stock-price targets. The grant date fair value of PSUs with EBITDA-based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that considers the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the fair value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period that such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period that such determination is made. For the years ended December 31, 2021, 2020, and 2019, the Company recorded the following expenses related to outstanding PSUs, which includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 PSU expenses $ 5,322 $ 2,563 $ — The Company’s actual tax benefits realized for the tax deductions related to the vesting of PSUs was $nil for the year ended December 31, 2021 (2020 and 2019 ― $nil). As of December 31, 2021, total unrecognized share-based compensation expense related to unvested PSUs and the weighted average period over which the expense is expected to be recognized is $9.3 million and 1.7 years, respectively. The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 PSUs outstanding, beginning of year 361,844 — $ 15.68 $ — Granted 309,574 370,265 20.77 15.66 Forfeited (58,013 ) (8,421 ) 16.11 4.84 PSUs outstanding, end of year 613,405 361,844 18.21 15.68 As of December 31, 2021, the maximum number of shares of common stock that may be issued with respect to PSUs outstanding is 1,073,458, assuming full achievement of the EBITDA and stock-price targets. China Long-Term Incentive Plan Each stock option (“China Option”), RSU, or PSU issued under the China LTIP represents an opportunity to participate economically in the future growth and value creation of IMAX China. In connection with the IMAX China IPO and in accordance with the China LTIP, IMAX China adopted a post-IPO share option plan and a post-IPO restricted stock unit plan. Pursuant to these plans, IMAX China has issued additional China Options, China LTIP Performance Stock Units (“China PSUs”), and China LTIP Restricted Share Units (“China RSUs”). For the years ended December 31, 2021, 2020, and 2019, share-based compensation expense related to China Options, China RSUs and China PSUs was as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense China Options $ 285 $ 875 $ 320 China RSUs 2,810 2,093 — China PSUs 578 208 1,664 Total $ 3,673 $ 3,176 $ 1,984 In 2021, IMAX China modified the terms of certain fully vested stock options to extend their contractual life by one year (2020 ― two years) and recorded an associated expense of $0.1 million (2020 ― $0.7 million). Issuer Purchases of Equity Securities In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. In 2021, the Company repurchased 841,331 (2020 ― 2,484,123) common shares at an average price of $16.51 per share (2020 ― $14.72 per share), for a total of $13.9 million (2020 ― 36.6 million), excluding commissions. As of December 31, 2021, the Company has $75.5 million available under its approved repurchase program. The total number of shares purchased during the year ended December 31, 2020 does not include 200,000 common shares, purchased in the administration of employee share-based compensation plans, at an average price of $15.43 per share. For the year ended December 31, 2021, there were no shares purchases in the administration of employee share based plans. As of December 31, 2021, the IMAX LTIP trustee held nil shares. Any shares held with the trustee are recorded at cost and are reported as a reduction against Capital Stock on the Company’s Consolidated Balance Sheets. In 2021, IMAX China ’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6 , 20 21 ( shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time . In 2021 , IMAX China repurchased 6,664,700 ( 2020 ― 906,400 ) common shares at an average price of HKD 11.68 per share (U.S. $1.50 per share ) for a total of HKD million or U . S . $ 10.0 million ( 2020 ― HKD 13.07 per share or U.S . $ 1.68 per share , for a total of HKD 11.9 million or U.S . $ million). The change in non-controlling interest as a result of common shares repurchase d by IMAX China is recorded within Non-Controlling Interest in the Consolidated Balance Sheets and the Consolidated Statements of Shareholders’ Equity. The difference between the consideration paid and the ownership interest obtained as a result of IMAX China share repurchases is recorded within Other Equity in the Consolidated Balance Sheets and the Consolidated Statements of Shareholders’ Equity. ( See Note 3(a) .) (d) Basic and Diluted Weighted Average Shares Outstanding The following table reconciles the denominator of the basic and diluted weighted average share computations: Years Ended December 31, (In thousands) 2021 2020 2019 Issued and outstanding, beginning of period 58,921 61,176 61,434 Weighted average number of shares issued (repurchased), net 205 (1,939 ) (124 ) Weighted average number of shares outstanding - basic 59,126 59,237 61,310 Weighted average effect of potential common shares, if dilutive — — 179 Weighted average number of shares outstanding - diluted 59,126 59,237 61,489 For the year ended December 31, 2021, the calculation of diluted earnings per share excludes 6,131,792 (2020 and 2019 ― 6,999,667 and 5,809,468, respectively) shares that are issuable upon the vesting of 1,457,883 RSUs (2020 and 2019 ― 1,564,838 and 77,259, respectively), the vesting of 937,752 PSUs (2020 and 2019 ― 541,867), and the exercise of 3,736,157 stock options (2020 and 2019 ― 4,892,962 and 5,732,209, respectively), as the effect would be anti-dilutive. The calculation of diluted weighted average shares outstanding for the year ended December 31, 2021 also excludes any shares potentially issuable upon the conversion of the Convertible Notes as the average market price of the Company’s common shares during the period of time they were outstanding was less than the conversion price of the Convertible Notes. (See Note 14(b).) (e) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10% of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50% of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may During the year ended December 31, 2021, one of the Company’s PRC subsidiaries declared and paid dividends of RMB 131.6 million ($20.4 million). In 2021, upon passage of the requisite resolution of the Board of Directors, a statutory surplus reserve of RMB 36.4 million ($5.6 million) was recorded within Shareholders’ Equity as an appropriation of the PRC subsidiaries’ retained earnings, of which $3.9 million is attributable to the Company’s common shareholders and $1.7 million is attributable to non-controlling shareholders. The statutory surplus reserve of RMB 36.4 million ($5.6 million) has reached 50% of its PRC subsidiaries’ registered capital.

Consolidated Statements of Op_2

Consolidated Statements of Operations Supplemental Information	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidated Statements of Operations Supplemental Information	18. Consolidated Statements of Operations Supplemental Information (a) Selling Expenses The following table summarizes the Company’s selling expenses, including sales commissions and other selling expenses such as direct advertising and marketing expenses, which are recognized within Costs and Expenses Applicable to Revenues in the Consolidated Statements of Operations, for the years ended December 31, 2021, 2020 and 2019: Years Ended December 31, 2021 2020 2019 (In thousands of U.S. Dollars) Sales Commissions Other Selling Expenses Sales Commissions Other Selling Expenses Sales Commissions Other Selling Expenses Technology sales (1) $ 1,885 $ 989 $ 1,278 $ 1,077 $ 2,031 $ 1,072 Image enhancement and maintenance services (2) — 8,923 — 4,306 — 22,869 Technology rentals (3) 399 1,109 908 510 383 2,952 Total $ 2,284 $ 11,021 $ 2,186 $ 5,893 $ 2,414 $ 26,893 (1) Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX Theater System. Direct advertising and marketing costs for each theater are expensed as incurred. (2) Film exploitation costs, including advertising and marketing costs are expensed as incurred. (3) Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the theater system is installed. Direct advertising and marketing costs for each theater are expensed as incurred. (b) Foreign Exchange Included in Selling, General and Administrative Expenses for the year ended December 31, 2021 is a net gain of $1.3 million resulting from changes in exchange rates related to foreign currency denominated monetary assets and liabilities, as compared to a net gain of $0.8 million and a net loss of $0.9 million for the years ended December 31, 2020 and 2019, respectively. See Note 22(c) for additional information. (c) Collaborative Arrangements Joint Revenue Sharing Arrangements As of December 31, 2021, the Company has signed traditional and hybrid joint revenue sharing agreements with 43 exhibitors (2020 — 43) for a total of 1,225 IMAX Theater Systems (2020 — 1,232), of which 909 theaters (2020 — 890) were operational and included in the network as of that date. The terms of these arrangements are similar in nature, rights, and obligations. (See Note 6 for a description of the material terms of the Company’s collaborative joint revenue sharing arrangements.) The accounting policy for the Company’s joint revenue sharing arrangements is disclosed in Note 3(p). Revenue attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are recorded within Revenues – Technology Sales and Revenues – Technology Rentals. For the year ended December 31, 2021, such revenues totaled $51.6 million (2020 — $19.9 million; 2019 — $92.0 million). (See Note 20(a) for a disaggregated presentation of the Company’s revenues.) IMAX DMR In an IMAX DMR arrangement, the Company receives a percentage of the box office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX DMR format and distributing it through the IMAX network In 2021, the majority of IMAX DMR revenue was earned from the exhibition of 69 films (63 new and 6 carryovers) and the re-release of classic titles throughout the IMAX theater network, as compared to 35 films (31 new and 4 carryovers) and the re-release of classic titles in 2020, and 72 films (60 new and 12 carryovers) exhibited in 2019. The accounting policy for the Company’s IMAX DMR arrangements is disclosed in Note 3(p). Revenue attributable to transactions arising between the Company and its customers under IMAX DMR arrangements are included in Revenues – Image Enhancement and Maintenance Services. For the year ended December 31, 2021, such revenues totaled $70.7 million (2020 — $28.3 million; 2019 — $120.8 million). (See Note 20(a) for a disaggregated presentation of the Company’s revenues.) Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and certain other rights to the film. In some cases, the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute to the funding of the production, distribution and exploitation costs associated with the film. As of December 31, 2021, the Company is party to one co-produced film arrangement, which represents the VIE total assets balance of $1.6 million and liabilities balance of $0.3 million and three other co-produced film arrangements, the terms of which are similar. The accounting policies relating to co-produced film arrangements are disclosed in Notes 3(a) and 3(p). In 2021, an expense of $0.4 million (2020 — $2.0 million; 2019 — $0.6 million) attributable to transactions between the Company and other parties involved in the production of the films have been included in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. In 2017, the Company participated in one significant co-produced television arrangement. This arrangement was not a VIE. For the year ended December 31, 2021, revenues of $0.2 million (2020 — $0.3 million; 2019 — $0.4 million) and Costs and Expenses Applicable to Revenues of $nil (2020 — $nil; 2019 — less than $0.1 million) attributable to this collaborative arrangement were recorded within Revenue – Image Enhancement and Maintenance Services and Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows Supplemental Information	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Consolidated Statements of Cash Flows Supplemental Information	19. Consolidated Statements of Cash Flows Supplemental Information (a) Changes in other operating assets and liabilities Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 (Increase) decrease in: Financing receivables $ (7,637 ) $ (10,568 ) $ (320 ) Prepaid expenses (3,230 ) (979 ) (290 ) Variable consideration receivables (2,905 ) (2,361 ) (4,056 ) Other assets 1,003 (4,747 ) (2,063 ) (Decrease) increase in: Accounts payable (4,752 ) 414 (11,774 ) Accrued and other liabilities 15,167 (6,399 ) (8,505 ) $ (2,354 ) $ (24,640 ) $ (27,008 ) (b) Cash payments made on account Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Income taxes (1) $ 18,475 $ 4,763 $ 17,298 Interest $ 3,251 $ 5,773 $ 1,231 (1) In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest. (c) Depreciation and amortization Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Film assets $ 16,316 $ 8,838 $ 19,176 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 22,320 24,930 23,153 Other property, plant and equipment 9,479 11,225 12,477 Other intangible assets (1) 6,079 6,565 6,290 Other assets (2) 1,888 1,146 1,882 Total $ 56,082 $ 52,704 $ 62,978 (1) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Consolidated Statement of Operations of $1.3 million in the year ended December 31, 2021 ( 2020 — $1.3 million). (2) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements. (d) Write-downs, net of recoveries Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Inventories (1) $ 890 $ 3,632 $ 446 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (2) 364 1,784 2,207 Other property, plant and equipment 217 174 249 Other intangible assets 142 184 95 Film assets (3) 151 10,804 1,379 Other assets (4) — 1,151 — $ 1,764 $ 17,729 $ 4,376 (1) In 2021, the Company recorded write-downs of $0.9 million (2020 — $3.6 million; 2019 — $0.4 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory. (2) In 2021, the Company recorded charges (3) In 2021, the company recorded impairment losses of $0.2 million related to the write-down of DMR related film assets. In 2020, the Company recorded impairment losses of $10.8 million (2019 — $1.4 million) in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. (4) In 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such charge was recorded in 2021 and 2019. (e) Significant non-cash investing activities Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 1,009 $ (1,888 ) $ (2,013 ) Acquisition of other intangible assets (891 ) 792 (51 ) Purchases of property, plant and equipment (188 ) 158 496 $ (70 ) $ (938 ) $ (1,568 )

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	20. (a) The following tables summarize the Company’s revenues by type and reportable segment for the years ended December 31, 2021, 2020, and 2019: Year Ended December 31, 2021 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 37,900 $ 5,576 $ 11,392 $ — $ 54,868 Joint Revenue Sharing Arrangements, fixed fees — — 5,406 — 5,406 Other Theater Business 2,363 — — — 2,363 Other sales (2) 3,475 41 — — 3,516 Sub-total 43,738 5,617 16,798 — 66,153 Image enhancement and maintenance services IMAX DMR — 70,659 — — 70,659 IMAX Maintenance 53,339 — — — 53,339 Film Post-Production 4,260 — — — 4,260 Film Distribution 205 1,259 — — 1,464 Other 377 1,049 — — 1,426 Sub-total 58,181 72,967 — — 131,148 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 46,184 — 46,184 Other — — 606 — 606 Sub-total — — 46,790 — 46,790 Finance income IMAX Systems — — — 10,792 10,792 Total $ 101,919 $ 78,584 $ 63,588 $ 10,792 $ 254,883 Year Ended December 31, 2020 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(3) $ 33,869 $ 5,799 $ 4,271 $ — $ 43,939 Joint Revenue Sharing Arrangements, fixed fees — — 2,056 — 2,056 Other Theater Business 1,666 — — — 1,666 Other sales (2) 1,957 110 — — 2,067 Sub-total 37,492 5,909 6,327 — 49,728 Image enhancement and maintenance services IMAX DMR — 28,265 — — 28,265 IMAX Maintenance 21,999 — — — 21,999 Film Post-Production 3,878 — — — 3,878 Film Distribution 3,000 1,841 — — 4,841 Other — 335 — — 335 Sub-total 28,877 30,441 — — 59,318 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 17,841 — 17,841 Sub-total — — 17,841 — 17,841 Finance income IMAX Systems — — — 10,116 10,116 Total $ 66,369 $ 36,350 $ 24,168 $ 10,116 $ 137,003 Year Ended December 31, 2019 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(3) $ 77,058 $ 10,247 $ 9,105 $ — $ 96,410 Joint Revenue Sharing Arrangements, fixed fees — — 11,014 — 11,014 Other Theater Business 8,390 — — — 8,390 Other sales (2) 2,209 222 — — 2,431 Sub-total 87,657 10,469 20,119 — 118,245 Image enhancement and maintenance services IMAX DMR — 120,765 — — 120,765 IMAX Maintenance 53,151 — — — 53,151 Film Post-Production 7,392 — — — 7,392 Film Distribution — 4,818 — — 4,818 Other 2,421 — — 2,421 Sub-total 60,543 128,004 — — 188,547 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 76,673 — 76,673 Other — 25 1,263 — 1,288 Sub-total — 25 77,936 — 77,961 Finance income IMAX Systems — — — 10,911 10,911 Total $ 148,200 $ 138,498 $ 98,055 $ 10,911 $ 395,664 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Other sales include revenues associated with New Business Initiatives. (3) Prior period comparatives have been revised to appropriately classify $4.3 million and $9.1 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the years ended December 31, 2020 and 2019. (b) IMAX Theater System sale and lease arrangements include a requirement for the Company to provide maintenance services over the life of the arrangement, subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term’s maintenance fee, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments upon renewal each year are either prepaid or made in arrears and can vary in frequency from monthly to annually. As of December 31, 2021, $20.2 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2020 — $21.6 million and 2019 — $17.7 million). Maintenance revenue is recognized evenly over the contract term which coincides with the period over which maintenance services are provided. In the event of customer default, any payments made by the customer may be retained by the Company. In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the deferred revenue balance relates to payments received by the Company for IMAX Theater Systems where control of the system has not transferred to the customer. The deferred revenue balance related to an individual theater increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. Recognition dates are variable and depend on numerous factors, including some outside of the Company’s control.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	21. Segment Reporting The Company’s Chief Executive Officer (“CEO”) is its Chief Operating Decision Maker (“CODM”), as such term is defined under U.S. GAAP. The CODM, along with other members of management, assess segment performance based on segment revenues and gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangible assets, provision for (reversal of) current expected credit losses, certain write-downs, interest income, interest expense, and income tax (expense) benefit are not allocated to the Company’s segments. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; (vii) Film Post-Production; and (viii) New Business Initiatives. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangements (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) Film Distribution and Post-Production, which includes activities related to the distribution of large-format documentary films, primarily to institutional theaters, and the distribution of exclusive experiences ranging from live performances to interactive events with leading artists and creators (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-Production segment); and (iv) New Business Initiatives, which is a segment that includes activities related to the expansion of the IMAX brand across new lines of business and initiatives. The Company presents its segment information at a disaggregated level to provide more relevant information to the users of its financial statements. Transactions between the IMAX DMR segment and the Film Post-Production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. (a) Segment Financial Information The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, Revenue (1) Gross Margin (Margin Loss) (In thousands of U.S. Dollars) 2021 2020 2019 2021 2020 2019 IMAX Technology Network IMAX DMR $ 70,659 $ 28,265 $ 120,765 $ 44,782 $ 13,731 $ 78,592 Joint Revenue Sharing Arrangements, contingent rent 46,184 17,841 76,673 21,761 (9,500 ) 48,446 116,843 46,106 197,438 66,543 4,231 127,038 IMAX Technology Sales and Maintenance IMAX Systems (2) 65,660 54,055 107,321 34,981 24,816 58,168 Joint Revenue Sharing Arrangements, fixed fees 5,406 2,056 11,014 1,343 529 2,613 IMAX Maintenance (3) 53,339 21,999 53,151 27,572 3,068 23,010 Other Theater Business (4) 2,363 1,666 8,390 398 (438 ) 2,624 126,768 79,776 179,876 64,294 27,975 86,415 Film Distribution and Post-Production Film Distribution (5) 1,464 4,841 4,818 (1,121 ) (9,840 ) (2,942 ) Post-Production 4,260 3,878 7,392 1,969 (358 ) 1,680 5,724 8,719 12,210 848 (10,198 ) (1,262 ) New Business Initiatives 3,704 2,226 2,754 3,399 1,878 2,106 Sub-total for reportable segments 253,039 136,827 392,278 135,084 23,886 214,297 Other 1,844 176 3,386 (678 ) (2,346 ) (125 ) Total $ 254,883 $ 137,003 $ 395,664 $ 134,406 $ 21,540 $ 214,172 The following table presents the Company’s assets by category and reportable segment, reconciled to consolidated assets, as of December 31, 2021 and 2020: As of December 31, (In thousands of U.S. Dollars) 2021 2020 IMAX Technology Network IMAX DMR $ 48,299 $ 29,672 Joint Revenue Sharing Arrangements, contingent rent 196,789 195,822 IMAX Technology Sales and Maintenance IMAX Systems 249,672 240,972 Joint Revenue Sharing Arrangements, fixed fees 27,930 27,778 IMAX Maintenance 38,530 36,949 Other Theater Business 82 106 Film Distribution and Post-Production Film Distribution 7,185 5,984 Post-Production 31,575 35,526 New Business Initiatives 1,420 1,196 Sub-total for reportable segments 601,482 574,005 Corporate and other non-segment specific assets 281,765 423,745 Total $ 883,247 $ 997,750 The following table presents the Company’s amortization by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ 15,917 $ 10,269 $ 16,117 Joint Revenue Sharing Arrangements, contingent rent 24,208 26,076 25,036 IMAX Technology Sales and Maintenance IMAX Systems 2,076 3,548 3,878 IMAX Maintenance — 213 299 Film Distribution and Post-Production Film Distribution 600 1,213 3,894 Post-Production 924 1,281 1,301 New Business Initiatives — 11 58 Sub-total for reportable segments 43,725 42,611 50,583 Corporate and other non-segment specific assets (6) 12,357 10,093 12,395 Total $ 56,082 $ 52,704 $ 62,978 The following table presents the Company’s write-downs, including asset impairments and credit loss (reversal) expense, by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ 151 $ 1,057 $ — Joint Revenue Sharing Arrangements, contingent rent 364 1,784 2,207 IMAX Technology Sales and Maintenance IMAX Systems 837 2,872 276 IMAX Maintenance 53 510 170 Film Distribution and Post-Production Film Distribution — 9,997 1,379 Post-Production — — — New Business Initiatives — 52 96 Sub-total for reportable segments 1,405 16,272 4,128 Corporate and other non-segment specific assets (7) (3,592 ) 20,065 2,678 Total $ (2,187 ) $ 36,337 $ 6,806 The following table presents the Company’s purchases of Property, Plant and Equipment by category and reportable segment for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ — $ — $ 99 Joint Revenue Sharing Arrangements, contingent rent 10,094 6,654 40,489 IMAX Technology Sales and Maintenance IMAX Systems 621 50 452 IMAX Maintenance 25 — 311 Film Distribution and Post-Production Film Distribution 1,599 — — Post-Production 609 456 1,210 New Business Initiatives — — — Sub-total for reportable segments 12,948 7,160 42,561 Corporate and other non-segment specific assets 736 191 5,349 Total $ 13,684 $ 7,351 $ 47,910 (1 ) The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020. ( 2 ) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. (3 ) Due to the global reopening of the IMAX theater network and the substantial resumption of normal operations throughout the theatrical exhibition industry, as evidenced by box office totals for the fourth quarter of 2021 exceeding pre-pandemic levels, the Company ended the temporary relief program for its exhibitor customers and, as a result, recognized maintenance revenue of $6.3 million that had been due to the potential for the waiver or reduction of maintenance fees during the COVID-19 pandemic , including $2.5 million that had been deferred from 2020 with the remainder from the first nine months of 2021. (4) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. ( 5 ) During the year ended December 31, 2020, Film Distribution segment results were significantly influenced by impairment losses of $10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments (2019 ― $1.4 million). No such impairment losses were incurred in 2021. ( 6 ) Prior period comparatives have been revised to exclude the amortization of deferred financing costs of $0.9 million and $0.5 million, respectively, for the years ended December 31, 2020 and 2019. ( 7 ) During the year ended December 31, 2021, includes the net reversal of current expected credit losses of $4.0 million, which is excluded from the measurement of the Company’s segment performance (2020 ― provision of $18.6 million; 2019 ― provision of $2.4 million). (See Note 5.) (b) Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. The following table summarizes the Company’s revenues by geographic area for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Greater China $ 112,801 $ 52,331 $ 124,294 United States 73,499 30,157 121,264 Asia (excluding Greater China) 23,682 20,090 48,386 Western Europe 20,942 13,683 46,911 Russia & the CIS 7,308 2,927 16,124 Latin America 3,601 6,114 9,438 Canada 3,266 1,365 9,220 Rest of the World 9,784 10,336 20,027 Total $ 254,883 $ 137,003 $ 395,664 No single country in the Rest of the World, Western Europe, Latin America, and Asia (excluding Greater China) classifications comprise more than 10% of total revenue. The following table presents the breakdown of Property, Plant and Equipment by geography as of December 31, 2021 and 2020: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Greater China $ 100,182 $ 104,731 United States 91,856 100,495 Canada 32,643 31,624 Western Europe 21,684 25,487 Asia (excluding Greater China) 9,463 9,930 Rest of the World 4,525 5,130 Total $ 260,353 $ 277,397

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Investments All Other Investments [Abstract]
Financial Instruments	22. Financial Instruments (a) Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s $189.7 million balance of cash and cash equivalents as of December 31, 2021 includes $102.1 million in cash held outside of Canada (December 31, 2020 — $89.9 million), of which $76.3 million was held in the PRC (December 31, 2020 — $77.2 million). (b) Fair Value Measurements The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 189,711 $ 189,711 $ 317,379 $ 317,379 Equity securities (2) 1,087 1,087 13,633 13,633 Level 2 Net financed sales receivables (3) $ 112,657 $ 112,662 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 28,392 28,407 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,275 3,275 3,155 3,155 Foreign exchange contracts — (2) 79 79 1,635 1,635 Foreign exchange contracts — (2) — — 344 344 Working Capital Facility borrowings (1) (3,612 ) (3,612 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (223,100 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. The Company did not have any material amounts of Level 3 assets or liabilities as of December 31, 2021 and December 30, 2020. (c) Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority of the Company’s revenues is denominated in U.S. Dollars while a significant portion of its costs and expenses is denominated in Canadian Dollars. A portion of the Company’s net U.S. Dollar cash is converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in RMB and the Japanese Yen, respectively. Net cash flows are converted to and from U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, Canadian Dollars, and Euros which are converted to U.S. Dollars through the spot market. In addition, because IMAX films generate box office in 87 different countries, unfavourable exchange rates between applicable local currencies and the U.S. Dollar could have an impact on box office receipts and the Company’s revenues and results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests as of December 31, 2021 The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Other Comprehensive Income and reclassified to the Consolidated Statements of Operations when the forecasted transaction occurs. For foreign currency cash flow hedging instruments related to Inventories, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Other Comprehensive Income and reclassified to Inventories in the Consolidated Balance Sheets when the forecasted transaction occurs. For foreign currency cash flow hedging instruments related to capital expenditures, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Other Comprehensive Income and reclassified to Property, Plant and Equipment on the Consolidated Balance Sheets when the forecasted transaction occurs. . The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Consolidated Financial Statements: Notional value of foreign exchange contracts As of December 31, (In thousands of U.S. Dollars) 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 26,702 $ 26,358 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards — 5,552 $ 26,702 $ 31,910 Fair value of derivatives in foreign exchange contracts As of December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 184 $ 1,635 Accrued and other liabilities (105 ) — Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets — 344 $ 79 $ 1,979 Derivatives in foreign currency hedging relationships are as follows Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain — Forwards Recognized in OCI (Effective Portion) $ 468 $ 550 $ 552 Location of Derivative Gain (Loss) Reclassified from AOCI Years Ended December 31, (In thousands of U.S. Dollars) (Effective Portion) 2021 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 1,707 $ (578 ) $ (1,109 ) Inventories — (26 ) (42 ) Property, plant and equipment — — (32 ) $ 1,707 $ (604 ) $ (1,183 ) Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain (Loss) Recognized — Forwards In and out of OCI (Effective Portion) $ — $ 17 $ (22 ) Non-designated derivatives in foreign currency relationships are as follows Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ (318 ) $ — $ — Years Ended December 31, (In thousands of U.S. Dollars) Location of Derivative Gain 2021 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 398 $ 344 $ — The Company's estimated net amount of the existing gains as of December 31, 2021 is $0.1 million, which is expected to be reclassified to earnings within the next twelve months. (d) Investments in Equity Securities As of December 31, 2021, the Consolidated Balance Sheets includes $1.1 million (December 31, 2020 — $13.6 million) of investments in equity securities. On January 17, 2019, IMAX China (Hong Kong), Limited, a wholly-owned subsidiary of IMAX China, as an investor entered into a cornerstone investment agreement with Maoyan Entertainment (“Maoyan”) (as the issuer) and Morgan Stanley Asia Limited (as a sponsor, underwriter and the underwriters’ representative). Pursuant to this agreement, IMAX China (Hong Kong), Limited agreed to invest $15.2 million to subscribe for a certain number of shares of Maoyan at the final offer price pursuant to the global offering of the share capital of Maoyan, and this investment would be subject to a lock-up period of six months following the date of the global offering. On February 4, 2019, Maoyan completed its global offering, upon which, IMAX China (Hong Kong), Limited became a less than 1% shareholder in Maoyan. In February 2021, IMAX China (Hong Kong), Limited sold all of its 7,949,000 shares of Maoyan for gross proceeds of $17.8 million, which represents a $2.6 million gain relative to the Company’s acquisition cost and a $5.2 million gain compared to the fair value of the investment as of December 31, 2020. Prior to this sale, the Company accounted for its investment in Maoyan at fair value with any changes in fair value recorded to the Consolidated Statements of Operations. For the year ended December 31, 2020, the Company recorded a net unrealized loss of $2.1 million. As of December 31, 2020, the value of the Company’s investment in Maoyan was $12.6 million. The Company has an investment of $1.1 million (December 31, 2020 — $1.1 million) in the shares of an exchange traded fund. This investment is classified as an equity investment. As of December 31, 2021, the Company held investments in the preferred shares of enterprises which meet the criteria for classification as an equity security under FASB ASC 325, carried at historical cost, net of impairment charges. The carrying value of these equity security investments was $1.0 million as of December 31, 2021 (December 31, 2020 — $1.0 million) and is recorded in Other Assets.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	12 Months Ended
	Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Employees Pension and Postretirement Benefits	23. Employee's Pension and Postretirement Benefits (a) Defined Benefit Plan The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L. Gelfond. Under the terms of the SERP, if Mr. Gelfond’s employment is terminated other than for cause (as defined in his employment agreement), he is entitled to receive SERP benefits in the form of a lump sum payment. SERP benefit payments to Mr. Gelfond are subject to a deferral for six months after the termination of his employment, at which time Mr. Gelfond will be entitled to receive interest on the deferred amount credited at the applicable federal rate for short-term obligations. Pursuant to an amendment to his employment agreement dated November 1, 2019, the term of Mr. Gelfond’s employment was extended through December 31, 2022, although Mr. Gelfond has not informed the Company that he intends to retire at that time. Under the terms of this amendment to his employment agreement, the total benefit payable to Mr. Gelfond under the SERP was fixed at $20.3 million. As of December 31, 2021 and 2020 , the projected benefit obligation for SERP are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of period $ 20,116 $ 18,840 Interest cost 72 379 Actuarial (gain) loss (132 ) 897 Obligation, end of period and unfunded status $ 20,056 $ 20,116 As of December 31, 2021 2020 , the following amounts related to the SERP were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net periodic benefit cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial gain $ (679 ) $ (547 ) $ (1,444 ) Unamortized prior service cost 184 369 456 Net periodic benefit costs to be recognized in future periods $ (495 ) $ (178 ) $ (988 ) For the years ended December 31, 2021 2020 pension expense related to the SERP were as follows: Years ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 72 $ 379 $ 564 Amortization of prior service cost 185 87 — Pension expense $ 257 $ 466 $ 564 The following assumptions were used to determine the SERP obligation and any related costs as of and for the years ended December 31, 2021 , As of December 31, 2021 2020 2019 Discount rate 0.80 % 0.36 % 2.00 % Lump sum interest rate: First 25 years N/A N/A 2.12 % First 20 years N/A N/A N/A Thereafter N/A N/A 2.26 % Cost of living adjustment on benefits N/A N/A 1.20 % No contributions were made for the SERP during 2021. The Company expects interest costs of $0.2 million to be recognized as a component of pension cost for the year ended December 31, 2022. (b) Defined Contribution Pension Plan The Company also maintains defined contribution pension plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums. During 2021, the Company contributed and recorded expense of $1.1 million (2020 — $1.1 million; 2019 — $1.2 million) to its Canadian plan and $0.5 million (2020 — $0.6 million; 2019 — $0.6 million) to its defined contribution employee pension plan under Section 401(k) of the U.S. Internal Revenue Code. (c) Postretirement Benefits - Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, former Chairman of the Company’s Board of Directors (the “Executive Postretirement Benefit Plan”). The Executive Postretirement Benefit Plan provides that the Company will maintain health benefits for Mr. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplemental coverage as selected by Mr. Gelfond and Wechsler. Mr. Wechsler retired from the Company’s Board of Directors on June 9, 2021. The Company maintained Mr. Wechsler’s health benefits through December 31, 2021, and thereafter will provide him with Medicare supplemental coverage or its equivalent value. As of December 31, 2021 and 2020 , the Executive Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of year $ 710 $ 665 Interest cost 16 20 Benefits paid (16 ) (29 ) Actuarial (gain) loss (48 ) 54 Obligation, end of year and unfunded status $ 662 $ 710 For the years ended December 31, 2021 2020 Executive Postretirement Benefit Plan : Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 16 $ 20 $ 26 Amortization of actuarial gain — (17 ) — Pension expense $ 16 $ 3 $ 26 As of December 31, 2021 2020 , the following amounts related to the Executive Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial (gain) loss $ (27 ) $ 21 $ (50 ) As of December 31, 2021 2020 weighted average assumptions used to determine the benefit obligation related to the Executive Postretirement Benefit Plan are as follows: As of December 31, 2021 2020 2019 Discount rate 2.71 % 2.36 % 3.13 % For the years ended December 31, 2021 2020 weighted average assumptions used to determine the net postretirement benefit expense related to the Executive Postretirement Benefit Plan are as follows: Years Ended December 31, 2021 2020 2019 Discount rate 2.36 % 3.13 % 4.15 % The following benefit payments are expected to be made as per the current plan assumptions for the Executive Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) 2022 $ 9 2023 19 2024 20 2025 21 2026 23 Thereafter 938 Total $ 1,030 (d) Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements (the “Canadian Postretirement Benefit Plan”). The Company will provide eligible participants, upon retirement, with health and welfare benefits. As of December 31, 2021 2020 Canadian Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligations: Obligation, beginning of year $ 1,862 $ 1,581 Interest cost 42 47 Benefits paid (118 ) (110 ) Actuarial (gain) loss (92 ) 280 Unrealized foreign exchange loss 8 64 Obligation, end of year and unfunded status $ 1,702 $ 1,862 For the years ended December 31, 2021 2020 Canadian Postretirement Benefit Plan : Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 42 $ 47 $ 49 Pension expense $ 42 $ 47 $ 49 The Company expects interest costs of less than $0.1 million As of December 31, 2021 , 2020 , the following amounts related to the Canadian Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial loss (gain) $ 185 $ 277 $ (3 ) As December 31, 2021 2020 weighted average assumptions used to determine the benefit obligation Canadian Postretirement Benefit Plan are as follows: As of December 31, 2021 2020 2019 Discount rate 2.80 % 2.30 % 3.05 % For the years ended December 31, 2021 2020 weighted average assumptions used to determine the net postretirement benefit expense related to the Canadian Postretirement Benefit Plan are as follows: Years Ended December 31, 2021 2020 2019 Discount rate 2.30 % 3.05 % 3.80 % The following benefit payments are expected to be made as per the current plan assumptions for the Canadian Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) 2022 $ 108 2023 115 2024 112 2025 113 2026 105 Thereafter 1,483 Total $ 2,036 (e) Deferred Compensation Benefit Plan The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein). In 2018, the executive incurred a separation from service from the Company, and as such, the Retirement Plan benefits became fully vested as of December 31, 2018. As of December 31, 2021, the benefit obligation related to the Retirement Plan was $3.8 million (December 31, 2020 — $3.7 million) and is recorded on the Company’s Consolidated Balance Sheets within Accrued and Other Liabilities. As the Retirement Plan is fully vested, the benefit obligation is measured at the present value of the benefits expected to be paid in the future with the accretion of interest recognized in the Consolidated Statements of Operations within Retirement Benefits Non-Service Expenses. The Retirement Plan is funded by an investment in company-owned life insurance (“COLI”), which is recorded at its fair value on the Company’s Consolidated Balance Sheets within Prepaid Expenses. As of December 31, 2021, fair value of the COLI asset was $3.3 million (December 31, 2020 — $3.2 million). Gains and losses resulting from changes in the cash surrender value of the COLI asset are recognized in the Consolidated Statements of Operations within Realized and Unrealized Investment Gains (Losses).

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests	24. Non-Controlling Interests (a) IMAX China Non-Controlling Interest As of December 31, 2021, the Company indirectly owns 71.11% of IMAX China, whose shares trade on the Hong Kong Stock Exchange (December 31, 2020 — 69.89%). IMAX China remains a consolidated subsidiary of the Company. The balance of non-controlling interest in IMAX China as of December 31, 2021 is $73.5 million (December 31, 2020 — $70.0 million). The net income attributable to non-controlling interest of IMAX China for the year ended December 31, 2021 is $12.8 million (December 31, 2020 — loss of $(8.6) million; December 31, 2019 — income of $13.3 million). (b) Other Non-Controlling Interests The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014, and has reached its maximum contribution. Through December 31, 2021, the Original Film Fund has invested $22.3 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. (c) Non-Controlling Interest in Temporary Equity The following summarizes the movement of the non-controlling interest in temporary equity, in the Original Film Fund for the years ended December 31, 2021, 2020 and 2019: (In thousands of U.S. Dollars) Balance as of January 1, 2019 $ 6,439 Return of capital to non-controlling interests (243 ) Share issuance costs from the issuance of subsidiary shares to a non-controlling interest 1,350 Net loss (1,638 ) Balance as of December 31, 2019 5,908 Return of capital to non-controlling interests (10 ) Net loss (5,139 ) Balance as of December 31, 2020 759 Return of capital to non-controlling interests — Net loss (1 ) Balance as of December 31, 2021 $ 758

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Revision of Prior Year Amounts and Other Reclassifications	(a) Revision of prior year amounts and other reclassifications In the current year’s Consolidated Balance Sheets and Consolidated Statements of Shareholders’ Equity, the Company revised the December 31, 2020 and December 31, 2019 balances of Total Shareholders’ Equity Attributable to Common Shareholders and Non-Controlling Interests. The revisions were principally made to properly reflect changes in the Company’s ownership interest in IMAX China as a result of common share repurchases and the amortization of share-based compensation related to IMAX China. The revisions resulted in a $0.5 million reclassification between the January 1, 2019 balances of Other Equity and Non-Controlling Interests, as well as reclassifications of $8.5 million and $8.4 million, respectively, between the balances of Other Equity and Non-Controlling Interests as of December 31, 2020 and 2019. There is no change in Total Shareholders’ Equity as a result of the revisions.
Principles of Consolidation	(b) Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has interests in ten film production companies, which have been identified as VIEs The Company is the primary beneficiary of and consolidates of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant relating to these production companies The Company does not consolidate the other film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Consolidated Financial Statements. A loss in value of an equity method investment that is other than temporary is recognized as a charge in the Consolidated Statements of Operations. As of December 31, 2021 and 2020, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Total assets $ 1,576 $ 1,543 Total liabilities $ 259 $ 230
Estimates and Assumptions	(c) Estimates and Assumptions The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying notes. Management’s judgments, assumptions, and estimates are based on historical experience, future expectations and other factors that are believed to be reasonable as of the date of the Consolidated Financial Statements. Actual results may ultimately differ from management’s original estimates, as future events and circumstances sometimes do not develop as expected, and the differences may be material. Significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX Theater System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Theater Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements theater system equipment supporting joint revenue sharing arrangements The COVID-19 pandemic resulted in significantly lower levels of revenues, earnings, and operating cash flows for the Company during 2020 and, to a lesser extent, during 2021, when compared to periods prior to the onset of the pandemic , as described in Note 2. Although judgments, assumptions, and estimates used by management in preparing the Company’s Consolidated Financial Statements
Cash and Cash Equivalents	(d) Cash and Cash Equivalents The Company considers all highly liquid investments convertible to a known amount of cash and with an original maturity of three months or less to be cash equivalents.
Receivable	(e) Receivables In 2016, the Financial Accounting Standards Board (“FASB”) issued No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The standard requires financial assets measured on the amortized cost basis to be presented at the net amount expected to be collected. The Company’s accounts receivable, financing receivables and variable consideration receivables are within the scope of ASU No. 2016-13. The Company adopted ASU No. 2016-13 and several associated ASUs on January 1, 2020 with no required cumulative-effect adjustment to accumulated deficit. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. (See Note 5 for more information related to the Company’s receivables and current expected credit losses.)
Inventories	(f) Inventories Inventories are carried at the lower of cost, determined on an average cost basis, and net realizable value except for raw materials, which are carried at the lower of cost and replacement cost. Finished goods and work-in-process includes the cost of raw materials, direct labor, theater design costs, and an applicable share of manufacturing overhead costs. The costs related to IMAX Theater Systems under sales and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues – Technology Sales in the period when the sale is recognized in the Consolidated Statements of Operations. The costs related to IMAX Theater Systems under joint revenue sharing arrangements are transferred from Inventories to assets under construction in Property, Plant and Equipment when allocated to a signed joint revenue sharing arrangement. The Company records write-downs for excess and obsolete inventory based upon management’s judgments regarding future events and business conditions, including the anticipated installation dates for the current backlog of theater system contracts, contracts in negotiation, technological developments, growth prospects within the customers’ ultimate marketplace and anticipated market acceptance of the Company’s current and pending theater systems. Finished goods inventories includes IMAX Theater Systems for which title has passed to the Company’s customer in situations when the theater system has been delivered to the customer, but the criteria for revenue recognition were not met as of the balance sheet date.
Film Assets	(g) Film Assets Film Assets consist of: (i) capitalized costs associated with the digital remastering of films where the copyright is owned by a third party, including labor and allocated overhead, and (ii) capitalized costs associated with the production of films, including labor, allocated overhead, and the cost of acquiring film rights. Production financing provided by third parties that acquire substantive rights in the film is recorded as a reduction of the cost of the film. Capitalized film costs are amortized and participation costs are accrued to Costs and Expenses Applicable to Revenues using the individual-film-forecast method, which amortizes such costs in the same ratio as the associated ultimate revenue. Estimates of ultimate revenues are prepared on a title-by-title basis and reviewed regularly by management and revised where necessary to reflect the most current information. Ultimate revenues reflect management’s estimates of future revenue over a period not to exceed ten years following the date of the film’s initial release. The recoverability of the Company’s film assets is dependent upon the commercial acceptance of the underlying films and the resulting level of box office results and, in certain situations, ancillary revenues If management’s projections of future net cash flows resulting from the exploitation of a film indicate that the carrying value of the film asset is not recoverable, the film asset is written down to its fair value. Film exploitation costs, including advertising costs, are expensed as incurred to Costs and Expenses Applicable to Revenues.
Property, Plant and Equipment	(h) Property, Plant and Equipment Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life (7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements. The cost of theater system components and related equipment expected to be used in future joint revenue sharing arrangements, including related direct labor costs and an allocation of direct production costs, are recorded within assets under construction until the underlying IMAX Theater System is installed and in working condition. These assets are depreciated to Costs and Expenses Applicable to Revenues on a straight-line basis over the lesser of the term of the joint revenue sharing arrangement and the equipment’s expected useful life. The estimated useful lives of the theater system components and related equipment used in joint revenue sharing arrangements are reviewed periodically to determine if any adjustments are required. Property, Plant and Equipment is grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating such assets for impairment include a current expectation that it is more likely than not that the long-lived asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the long-lived asset, and a significant change in the extent or manner in which the long-lived asset is being used.
Investment in Equity Securities	(i) Investment in Equity Securities Equity securities with readily determinable fair values are reported at fair value with changes in fair value recorded within Gain (Loss) in Fair Value of Investments in the Consolidated Statements of Operations.
Other Assets	(j) Other Assets Other Assets principally includes lease incentives provided to certain theater customers under joint revenue sharing arrangements classified as an operating lease, as well as sales commissions and other deferred selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses. To a much lesser extent Other Assets also includes various investments and foreign currency derivatives. Capitalized lease incentives are amortized on a straight-line basis over the term of the lease as a reduction to rental revenue. Sales commissions and other selling expenses paid prior to the recognition of the related revenue are deferred and recognized within Costs and Expenses Applicable to Revenues upon the client acceptance of the IMAX Theater System or the abandonment of the sale arrangement. Foreign currency derivatives are accounted for at fair value using quoted prices in active markets. In periods when there are no outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are recorded within Other Assets and amortized on a straight-line basis over the term of the facility. In periods when there are outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are reclassified to reduce the principal amount of outstanding borrowings and amortized on a straight-line basis over the term of the facility. (See Note 14 for information related to the Company’s revolving credit facilities.)
Goodwill	(k) Goodwill Goodwill represents the excess of the purchase price paid over the fair value of net assets acquired in a business combination. Goodwill is not amortized, but is tested annually for impairment at the reporting unit level in the fourth quarter of the year and between annual tests if indicators of potential impairment exist. These indicators could include a decline in the Company’s stock price and market capitalization, a significant change in the outlook for the reporting unit's business, including projections of future box office results and IMAX Theater System installations, lower than expected operating results, increased competition, legal factors, or the sale or disposition of a significant portion of a reporting unit. For reporting units with goodwill, an impairment loss is recognized for the amount by which the reporting unit's carrying value, including goodwill, exceeds its fair value. assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. In the fourth quarter of 2021, the Company performed its annual goodwill impairment test considering the latest available information and determined that its goodwill was not impaired. As of December 31, 2021 , the Company’s total Goodwill was $39.0 million, of which $19.1 million relates to the IMAX Systems reporting unit, $13.5 million relates to the Joint Revenue Sharing Arrangements reporting unit, and $6.4 million relates to the IMAX Maintenance reporting unit. assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. Actual results may materially differ from management’s estimates, especially due to the
Other Intangible Assets	(l) Other Intangible Assets Patents, trademarks, and other intangible assets are recorded at cost and generally amortized on a straight-line basis over estimated useful lives ranging from 4 to 10 years except for intangible assets that have an identifiable pattern of consumption of the economic benefit of the asset. Such intangible assets are amortized over the consumption pattern. The Company capitalizes costs associated with internally developed and/or purchased software systems for internal use that have reached the application development stage. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages are charged to expense. These capitalized costs are amortized on a straight-line basis over the estimated useful life. Intangible Assets are grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating intangible assets for impairment include a current expectation that it is more likely than not that the intangible asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the intangible asset, and a significant change in the extent or manner in which the intangible asset is being used.
Deferred Revenue	(m) Deferred Revenue In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. To a lesser extent, the Deferred Revenue balance also relates to situations when a theater customer
Statutory Surplus Reserve	(n) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10% of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50% of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may
Income Taxes	(o) Income Taxes Income taxes are accounted for under the liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the Company’s Consolidated Financial Statements in the period in which the change is enacted. Investment tax credits are recognized as a reduction of income tax expense. The Company assesses the realization of deferred income tax assets and based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. In assessing the need for a valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If management determines that sufficient negative evidence exists (for example, if the Company experiences cumulative three-year losses in a certain jurisdiction), then management will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, management’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove more difficult to support the realization of these deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on the Company’s effective income tax rate and results. Conversely, if, after recording a valuation allowance, management determines that sufficient positive evidence exists in the jurisdiction in which a valuation allowance is recorded (for example, if the Company is no longer in a three-year cumulative loss position in the jurisdiction, and management expects to have future taxable income in that jurisdiction based upon management’s forecasts and the expected timing of deferred tax asset reversals), the Company may reverse all or a portion of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on the Company’s effective income tax rate and results in the period such determination was made. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Tax benefits are recognized only when it is more likely than not, based on the technical merits, that the benefits will be sustained on examination. Tax benefits that meet the more-likely-than-not recognition threshold are measured using a probability weighting of the largest amount of tax benefit that has greater than 50% likelihood of being realized upon settlement. Whether the more-likely-than-not recognition threshold is met for a particular tax benefit is a matter of judgment based on the individual facts and circumstances evaluated in light of all available evidence as of the balance sheet date. Although management believes that the Company has adequately accounted for its uncertain tax positions, tax audits can result in subsequent assessments where the ultimate resolution may result in the Company owing additional taxes above what was originally recognized in its financial statements. Tax reserves for uncertain tax positions are adjusted by the Company to reflect its best estimate of the outcome of examinations and assessments and in light of changing facts and circumstances, such as the completion of a tax audit, expiration of a statute of limitations, the refinement of an estimate, and interest accruals associated with the uncertain tax positions until they are resolved. Some of these adjustments require significant judgment in estimating the timing and amount of the additional tax expense.
Revenue Recognition	(p) Revenue Recognition IMAX Theater Systems The Company evaluates each of the performance obligations in an IMAX Theater System arrangement to determine which are considered distinct, either individually or in a group, for accounting purposes and which of the deliverables represent separate performance obligations. The Company’s “System Obligation” consists of the following: (i) an IMAX Theater System, which includes the projector, sound system, screen system and, if applicable, a 3D glasses cleaning machine; (ii) services associated with the IMAX Theater System, including theater design support, the supervision of installation services, and projectionist training; and (iii) a license to use the IMAX brand to market the theater. The System Obligation, as a group, is a distinct performance obligation. The Company is not responsible for the physical installation of the equipment in the customer’s facility; however, it supervises the installation by the customer. The customer has the right to use the IMAX brand from the date the Company and the customer enter into an arrangement. IMAX Theater System arrangements also include a requirement for the Company to provide maintenance services and an extended warranty over the life of the arrangement in exchange for an annual maintenance fee, which is subject to a consumer price index increase on renewal each year. Consideration related to the provision of maintenance services is included in the allocation of the transaction price to the separate performance obligations in the arrangement at contract inception, as discussed in more detail below. The Company’s maintenance services are a stand ready obligation and, as a result, are recognized on a straight-line basis over the contract term. The transaction price in an IMAX Theater System arrangement is allocated to each good or service that is identified as a separate performance obligation based on estimated standalone selling prices. This allocation is based on observable prices when the Company sells the good or service separately. The Company has established standalone prices for the System Obligation and maintenance and extended warranty services, as well as for film license arrangements. The Company uses an adjusted market assessment approach for separate performance obligations that do not have standalone selling prices or third-party evidence of estimated standalone selling prices. The Company considers multiple factors including its historical pricing practices, product class, market competition and geography. IMAX Theater System arrangements involve either the lease or the sale of an IMAX Theater System. The transaction price for the System Obligation, other than for IMAX Theater Systems delivered pursuant to joint revenue sharing arrangements, consist of upfront or initial payments made before and after the final installation of the system and ongoing payments throughout the term of the arrangement. The Company estimates the transaction price, including an estimate of future variable consideration, received in exchange for the goods delivered or services rendered. The arrangement for the sale of an IMAX Theater System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual theater, which are developed using historical data for the theater and, if necessary, comparable theaters and territories IMAX Theater System arrangements are non-cancellable unless the Company fails to perform its obligations. In the absence of a material default by the Company, there is no right to any remedy for the customer under the Company’s arrangements. If a material default by the Company exists, the customer has the right to terminate the arrangement and seek a refund only if the customer provides notice to the Company of a material default and only if the Company does not cure the default within a specified period. Sales Arrangements For IMAX Theater System arrangements that qualify as a sale, the transaction price allocated to the System Obligation is recognized in the Consolidated Statements of Operations upon the transfer of control of the system to the customer, which is when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater. The initial revenue recognized in a sales arrangement consists of payments made before and in connection with the installation of the IMAX Theater System and the present value of any future payments, including ongoing fixed minimum payments, which are subject to indexed increases over the term of the arrangement, and potential additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. Potential payments based on the future box office receipts of the customer are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal (see “Constraints on the Recognition of Variable Consideration” below). The Company has also agreed, on occasion, to sell equipment under lease or at the end of a lease term. The transaction price agreed to for these lease buyouts is reflected in the Company’s Consolidated Statements of Operations within Revenues – Technology Sales. Taxes assessed by governmental authorities that are both imposed on and concurrent with the specific revenue-producing transactions and collected by the Company have been excluded from the measurement of the transaction prices discussed above. Constraints on the Recognition of Variable Consideration The recognition of variable consideration involves a significant amount of judgment. Variable consideration is recognized subject to appropriate constraints to avoid a significant reversal of revenue in future periods. The Company reviews its variable consideration assets on at least a quarterly basis considering recent box office performance and, when applicable, updated box office projections for future periods. The relevant accounting guidance identifies the following examples of situations when constraining the amount of variable consideration is appropriate: • The amount of consideration is highly susceptible to factors outside the entity’s influence; • The uncertainty about the amount of consideration is not expected to be resolved for a long period of time; • The Company’s experience (or other evidence) with similar types of contracts is limited, or that experience has limited predictive value; and • The entity has a practice of either offering a broad range of price concessions or changing the payment terms and conditions of similar contracts in similar circumstances. As discussed above, the Company’s significant streams of variable consideration relate to arrangements for the sale of IMAX Theater Systems which include indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include variable consideration based on a percentage of the customer’s box office receipts over the term of the arrangement. Variable consideration related to indexed minimum payment increases is outside of the Company’s control, but the movement in the rates is historically well documented and economic trends in inflation are easily accessible. For each contract subject to an indexed minimum payment increase, the Company estimates the most likely amount using published indices. The amount of the estimated minimum payment increase is then recorded at its present value as of the date of recognition using the customer’s implied borrowing rate. Variable consideration related to the level of the customer’s box office receipts is outside of the Company’s control as it is dependent upon the future commercial success of the film s released to the IMAX network . The estimated variable consideration initially recognized by the Company is based on management’s box office projections for the theater, which are developed using historical box office data for that theater and, if necessary, comparable theaters and territories. Using this data, management applies its understanding of these theater markets to estimate the most likely amount of variable consideration to be earned over the term of the arrangement. Management then applies a constraint to this estimate by reducing the projection by a percentage factor for theaters or markets with no or limited historical box office experience. In cases where direct historical experience can be observed, average historical box office results , eliminating significant outliers, is used. The resulting amount of variable consideration is then recorded at its present value as of the date of recognition using a risk-weighted discount rate.
Revenue Recognition Leases	Lease Arrangements As a lessor, the Company provides IMAX Theater Systems to customers through long-term lease arrangements. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. A lease arrangement that transfers substantially all of the benefits and risks incident to ownership of the IMAX Theater System is classified as a sales-type lease; otherwise the lease is classified as an operating lease. Prior to commencement of the lease term, the Company may modify certain payment terms or make concessions. If these circumstances occur, the Company reassesses the classification of the lease based on the modified terms and conditions. For sales-type leases, the revenue allocated to the System Obligation is recognized when the lease term commences, which the Company deems to be when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of the written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater, provided collectability is reasonably assured. The initial revenue recognized for sales-type leases consists of the initial payments received and the present value of future initial payments and fixed minimum ongoing payments computed at the interest rate implicit in the lease. Contingent payments in excess of the fixed minimum payments are recognized when reported by theater operators, provided collectability is reasonably assured. For joint revenue sharing arrangements that are classified as operating leases, initial payments and fixed minimum ongoing payments are recognized as revenue on a straight-line basis over the lease term. For these leases, the lease term is considered to commence when all of the following conditions have been met: (i) the projector, sound system and screen system have been installed and are in full working condition; (ii) the 3D glasses cleaning machine, if applicable, has been delivered; (iii) projectionist training has been completed; and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater. Contingent payments in excess of fixed minimum ongoing payments are recognized as revenue when reported by theater operators, provided collectability is reasonably assured. On April 10, 2020, the FASB staff issued a question-and-answer document to address stakeholder questions on the application of the lease accounting guidance for lease concessions related to the effects of the COVID-19 pandemic. The guidance allows concessions related to the timing of payments, where the total consideration has not changed, to not be accounted for as lease modifications. Instead, any such concessions can be accounted for as if no change was made to the contract or as variable lease payments. Entities do not have to adopt the FASB relief guidance for all lease concessions related to the effects of the COVID-19 pandemic and can choose to apply the FASB relief guidance consistently to leases with similar characteristics and in similar circumstances and should apply reasonable judgment in doing so. The Company elected to account for any such lease concessions as if no change was made to the underlying contracts except for the sales-type leases of which IMAX China
Revenue Recognition Finance Income	Finance Income Finance Income is recognized over the term of the sales-type lease or financed sale receivable, provided collectability is reasonably assured. A theater operator that is classified within the “All Transactions Suspended” category under the Company’s internal credit quality guidelines is placed on nonaccrual status and Finance Revenue recognition related to the theater is stopped.
Improvements and Modifications	Improvements and Modifications Improvements and modifications to an IMAX Theater System after installation are treated as a separate performance obligation, if and when the Company is requested to perform these services. Revenue is recognized for these services once they have been provided.
Cost and Expenses Applicable to Revenues - Technology Sales	Cost and Expenses Applicable to Revenues – Technology Sales Cost and Expenses Applicable to Revenues – Technology Sales relates to sales and sales-type leases of IMAX Theater Systems and other equipment, and includes the cost of the equipment and costs related to project management, design, delivery and installation supervision services, as applicable. The costs related to IMAX Theater Systems under sales and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues in the period when the sale is recognized in the Consolidated Statements of Operations. Sales commissions and other selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses are deferred and recognized in the Consolidated Statements of Operations upon the client acceptance of the IMAX Theater System. The Company may have warranty obligations at or after the time revenue is recognized which require the replacement of certain parts that do not affect the functionality of the theater system or services. The costs for warranty obligations for known issues are accrued as charges to Costs and Expenses Applicable to Revenues – Technology Sales at the time revenue is recognized based on the Company’s past historical experience and cost estimates.
Cost and Expenses Applicable to Revenues - Technology Rentals	Cost and Expenses Applicable to Revenues – Technology Rentals Cost and Expenses Applicable to Revenues – Technology Rentals relates to joint revenue sharing arrangements classified as operating leases, and primarily includes the depreciation of theater system components and related equipment used in the joint revenue sharing arrangement. Impairment losses, if any, are also included in Cost and Expenses Applicable to Revenues – Technology Rentals. Sales commissions related to these arrangements are deferred and recognized as Costs and Expenses Applicable to Revenues – Technology Rentals in the month they are earned by the salesperson, which is typically the month of installation. Direct advertising and marketing costs for each theater are charged to Costs and Expenses Applicable to Revenues – Technology Rentals as incurred.
Terminations, Consensual Buyouts and Concessions	Terminations, Consensual Buyouts and Concessions The Company enters into IMAX Theater System arrangements with customers that contain customer payment obligations prior to the scheduled installation of the theater system. During the period of time between signing and the installation of the IMAX Theater System, which may extend several years, certain customers may be unable to, or may elect not to, proceed with the theater system installation for a number of reasons including business considerations, or the inability to obtain certain consents, approvals or financing. Once the determination is made that the customer will not proceed with installation, the arrangement may be terminated under the default provisions of the arrangement or by mutual agreement between the Company and the customer (a “consensual buyout”). Terminations by default are situations when a customer does not meet the payment obligations under an arrangement and the Company retains the amounts paid by the customer. Under a consensual buyout, the Company and the customer agree, in writing, to a settlement and to release each other of any further obligations under the arrangement or an arbitrated settlement is reached. Any initial payments retained or additional payments received by the Company are recognized as revenue when the settlement arrangements are executed and the cash is received, respectively. In addition, the Company may agree with a customer to convert its obligations for one type of IMAX Theater System configuration that has not yet been installed to an arrangement to acquire or lease a different type of IMAX Theater System. The Company considers these situations to be the termination of the original arrangement and the origination of a new arrangement. The Company may offer certain incentives to customers to complete IMAX T heater S ystem transactions including payment concessions or free services and products such as film licenses or 3D glasses. Reductions in, and deferral of, payments are taken into account in determining the transaction price either by a direct reduction in the sales price or a reduction of payments to be discounted. Free products and services are accounted for as separate performance obligations .
Maintenance And Extended Warranty Services	Maintenance and Extended Warranty Services Maintenance and extended warranty services may be provided under an arrangement with multiple performance obligations or as a separately priced contract. Revenues related to these services are deferred and recognized on a straight-line basis over the contract period and are recognized within Revenues – Image Enhancement and Maintenance Services in the Consolidated Statements of Operations. Maintenance and extended warranty services includes maintenance of the customer’s equipment and replacement parts. Under certain maintenance arrangements, maintenance services may include additional training services to the customer’s technicians. All costs associated with this maintenance and extended warranty program are expensed as incurred. A loss on maintenance and extended warranty services is recognized if the expected cost of providing the services under the contract exceeds the related deferred revenue. As the maintenance services are a stand ready obligation with the cost of providing the service expected to increase throughout the term, revenue is recognized over the term of the arrangement such that increased amounts are recognized in later periods.
Films Revenue Recognition	IMAX DMR Services In an IMAX DMR arrangement, the Company receives a percentage of the box office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX DMR format and distributing it through the IMAX network. In these arrangements, although the Company does not hold rights to the intellectual property in the form of the film content, it is compensated for the application of its intellectual property in the form of its patented DMR processes to create new intellectual property in the form of an IMAX DMR version of film. Revenues associated with IMAX DMR arrangements qualify for the variable consideration exemption for sales- or usage-based royalties in the relevant accounting guidance and are recognized within Revenues – Image Enhancement and Maintenance Services in the period when the corresponding box office sales occur. Losses on IMAX DMR services are recognized as Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services in the period when it is determined that the Company’s estimate of total revenues to be realized by the remastered film will not exceed the corresponding cost of IMAX DMR services. Film Production Services In certain film arrangements, the Company produces a film financed by third parties whereby the third party retains the copyright and the Company obtains exclusive distribution rights. Under these arrangements, the Company is entitled to receive a fixed fee or retain as a fee the excess of gross revenue over the cost of the production (the “production fee”). The third party receives a portion of the revenues received by the Company from distributing the film, which is charged to Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. Production fees are deferred and recognized as a reduction in the cost of the film based on the ratio of the Company’s distribution revenues recognized in the current period to the ultimate distribution revenues expected from the film. Film exploitation costs, including advertising and marketing, are recorded in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services as incurred. Revenue from film production services where the Company does not hold the associated distribution rights are recognized in Revenues – Image Enhancement and Maintenance Services when performance obligations associated with the contractual service are satisfied. Losses on film production services are recognized as Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services in the period when it is determined that the Company’s estimate of total revenues to be realized by the Company will not exceed estimated total production costs to be expended on the film production. Film Distribution Services In a Film Distribution arrangement, the Company distributes large-format documentary films, primarily to institutional theaters, and distributes exclusive entertainment experiences ranging from live performances to interactive events with leading artists and creators . Revenue from the licensing of films qualifies for the variable consideration exemption for sales- or usage-based royalties in the relevant accounting guidance and is recognized within Revenues – Image Enhancement and Maintenance Services when all performance obligations have been satisfied, which includes the completion and delivery of the film and the commencement of the license period. In situations when film license fees are based on a percentage of box-office receipts, revenue is recognized when box-office receipts are reported by the exhibitor. Film exploitation costs, including advertising and marketing, are expensed as incurred within Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. Film Post-Production Services Revenues from post-production film services are recognized within Revenues – Image Enhancement and Maintenance Services when performance of the contracted services is completed.
Leases	(q) Leases As a lessee, the Company’s lease arrangements principally involve office and warehouse space, which are classified as operating leases The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Research and Development Expense	(r) Research and Development Research and development costs, which are expensed as incurred, primarily include projector and sound parts, labor, consulting fees, allocation of overheads, and other related materials which pertain to the Company’s development of new products and services. Research and development costs pertaining to fixed and intangible assets that have alternative future uses are capitalized and amortized under their related policies.
Foreign Currency Translations	(s) Foreign Currency Translation Monetary assets and liabilities that are denominated in a currency other than the entity’s functional currency are translated into the relevant functional currency using the exchange rate prevailing at the end of the period. Foreign exchange translation gains and losses are included in the determination of earnings in the period in which they arise. Assets and liabilities recorded in foreign currencies are translated at the exchange rate on the balance sheet date. Revenues, expenses, gains, and losses recorded in foreign currencies are translated using the exchange rates prevailing during the period in which they are recognized. Translation adjustments resulting from this process are recorded to Other Comprehensive Income and reported on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income until the subsidiary is sold or liquidated, at which point the adjustments are recognized in Consolidated Statements of Operations. Foreign currency derivatives are recognized and measured in the Consolidated B alance S heet s at their fair value. Changes in the fair value ( i.e., gains or losses) are recognized in the C onsolidated S tatement s of O perations except for derivatives designated and qualifying as foreign currency hedging instruments. For foreign currency hedging instruments, the gain or loss related to the effective portion of the hedge of a forecasted transaction is reported with in O ther C omprehensive I ncome and reclassified to the C onsolidated S tatement s of O perations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the C onsolidated S tatement s of O perations.
Share-Based Compensation	(t) Share-Based Compensation The Company issues share-based compensation to eligible employees, directors, and consultants under the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, the “IMAX LTIP”) and the China Long-Term Incentive Plan (the “China LTIP”) as summarized in Note 17. The IMAX LTIP is the Company’s governing document and awards to employees, directors, and consultants under this plan may consist of stock options, restricted share units (“ RSUs”), performance stock units (“PSUs”) and other awards. A separate stock option plan, the China LTIP, was adopted by a subsidiary of the Company in October 2012. The Company measures share-based compensation expense using the grant date fair value of the award (see below), which is recognized as an expense in the Consolidated Statements of Operations on a straight-line basis over the requisite service period. Share-based compensation expense is not adjusted for estimated forfeitures, but is instead adjusted when and if actual forfeitures occur. Stock Options The Company utilizes a lattice-binomial option-pricing model (“Binomial Model”) to determine the fair value of stock option awards on the grant date. The fair value determined by the Binomial Model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the award, and actual and projected employee stock option exercise behaviors. The Binomial Model also considers the expected exercise multiple which is the multiple of exercise price to grant price at which exercises are expected to occur on average The Company stratifies its employees into homogeneous groups in order to calculate the grant date fair value of stock options using the Binomial Model. As a result, ranges of assumptions are used for the expected life of the option. The Company uses historical data to estimate option exercise behavior within the Binomial Model and various groups of employees that have similar historical exercise behavior are grouped together for valuation purposes. The expected volatility rate is estimated based on a blended volatility method which takes into consideration the Company’s historical share price volatility, the Company’s implied volatility which is determined in reference to observed current market prices for the Company’s traded options and the Company’s peer group volatility. (See Note 17(c) for the assumptions used to determine the fair value of the Company’s stock options.) Restricted Share Units The fair value of RSU awards is equal to the closing price of the Company’s common stock on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant Performance Stock Units The Company grants two types of PSU awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of targets. three-year At the conclusion of the three-year performance period, the number of PSUs that ultimately vest can range from 0% to a maximum vesting opportunity of 175% of the initial award, depending upon actual performance versus the established EBITDA and share-price targets. The Company’s PSUs are classified as equity. The grant date fair value of PSUs with EBITDA -based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that considers the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the dollar value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood and timing of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period such determination is made. Share-Based Payment Awards to Non-Employees Share-based payment awards for services provided by non-employees are measured at grant date fair value of the equity instruments that the Company is obligated to issue when the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. The grant date is the date which the Company and the non-employees reach a mutual understanding of the key terms and conditions of the share-based payment awards. When there are performance conditions related to the vesting of the share-based awards, the Company assesses the probability of vesting at each reporting date and adjusts the compensation costs based on the probability assessment.
Pension and Other Postretirement Plans	(u) Pension Plans and Postretirement Benefits The Company has a defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”). As the Company’s SERP is unfunded, as of December 31, 2021, a liability is recognized for the benefit obligation. Assumptions used in computing the defined benefit obligations are reviewed annually by management in consultation with its actuaries and adjusted for current conditions. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefits cost are recognized as a component of Other Comprehensive Income. Amounts recognized in Accumulated Other Comprehensive Income including unrecognized actuarial gains or losses and prior service costs are adjusted as they are subsequently recognized in the Consolidated Statements of Operations as components of net periodic benefit cost. Prior service costs resulting from the pension plan inception or amendments are amortized over the expected future service life of the employees, cumulative actuarial gains and losses in excess of 10% of the projected benefit obligation are amortized over the expected average remaining service life of the employees, and current service costs are expensed when earned. The remaining weighted average future service life of the employee used in computing the defined benefit obligation for the year ended December 31, 2021 was 1.0 year. For defined contribution pension plans, required contributions by the Company are recorded as an expense within Selling, General and Administrative Expenses in the Company’s Consolidated Statements of Operations. A liability is recognized for the unfunded accumulated benefit obligation of the postretirement benefits plan. Assumptions used in computing the accumulated benefit obligation are reviewed by management in consultation with its actuaries and adjusted for current conditions. Net benefit cost is split between operating income and non-operating income, where only the service cost is included in income from operations and the non-service components are included in Retirement Benefits Non-Service Expenses. Actuarial gains and losses are recognized as a component of Other Comprehensive Income. Amounts recognized in Accumulated Other Comprehensive Income including unrecognized actuarial gains or losses are adjusted as they are subsequently recognized within Retirement Benefits Non-Service Expense in the Consolidated Statements of Operations.
Guarantees, Indemnifications and Warranties	(v) Guarantees In situations when the Company acts as a guarantor, at the inception of a guarantee, it recognizes a liability for the fair value of the underlying guarantee. Disclosures as required under the relevant accounting guidance have been included in Note 16(d).
Recently Issued Accounting Standards Not Yet Adopted	In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2020-04 is to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of ASU 2020-04. An entity may elect to apply the amendments prospectively through December 31, 2022. The only contract held by the Company that references the London Interbank Offered Rate ( LIBOR) is the Credit Agreement (as defined in Note 14), which utilizes USD LIBOR to determine the interest rate applicable to borrowings. The Credit Agreement matures on June 28, 2023, prior to the date that USD LIBOR rates will cease publication on June 30, 2023. Accordingly, the Company does not expect ASU 2020-04 to have a material effect on its Consolidated Financial Statements. In July 2021, the FASB issued ASU No. 2021-05, “Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments” (“ASU 2021-05”), which requires sales-type or direct financing leases that have variable payments (that do not depend on a rate or an index) and result in a day-one loss to be classified as operating leases. When a lease is classified as operating, the lessor does not recognize a net investment in the lease, does not derecognize the underlying asset, and, therefore, does not recognize a selling profit or loss. The amendments are effective for annual periods beginning after December 15, 2021 including interim periods within those periods. Early adoption is permitted. The Company has not yet adopted ASU 2021-05, but has determined that the impact of adopting this guidance will not have a material impact on its Consolidated Financial Statements. In November 2021, the FASB issued ASU No. 2021-10, “2021-10: Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The amendments are effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company will adopt ASU 2021-10 for the year ending December 31, 2022 and will provide the required disclosures, if material. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standards updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Consolidated Financial Statements for the year ended December 31, 2021.
Credit Risk	The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category , but are not in as good condition as the receivables in the Credit Watch category. In certain situation s , a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of finance income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of finance income for Financing Receivables.
Commitments and Contingencies	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Segment Reporting	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; (vii) Film Post-Production; and (viii) New Business Initiatives. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangements (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) Film Distribution and Post-Production, which includes activities related to the distribution of large-format documentary films, primarily to institutional theaters, and the distribution of exclusive experiences ranging from live performances to interactive events with leading artists and creators (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-Production segment); and (iv) New Business Initiatives, which is a segment that includes activities related to the expansion of the IMAX brand across new lines of business and initiatives.
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 189,711 $ 189,711 $ 317,379 $ 317,379 Equity securities (2) 1,087 1,087 13,633 13,633 Level 2 Net financed sales receivables (3) $ 112,657 $ 112,662 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 28,392 28,407 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,275 3,275 3,155 3,155 Foreign exchange contracts — (2) 79 79 1,635 1,635 Foreign exchange contracts — (2) — — 344 344 Working Capital Facility borrowings (1) (3,612 ) (3,612 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (223,100 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. The Company did not have any material amounts of Level 3 assets or liabilities as of December 31, 2021 and December 30, 2020.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
VIEs Total Assets and Liabilities	As of December 31, 2021 and 2020, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Total assets $ 1,576 $ 1,543 Total liabilities $ 259 $ 230
Summary of Estimated Useful Lives	Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life (7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements.

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Summary of Allowance For Credit Losses Related to Accounts Receivable	The following tables summarize the activity in the Allowance for Credit Losses related to Accounts Receivable for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Beginning balance $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period provision (reversal), net 793 (1,913 ) (332 ) (1,452 ) Write-offs (357 ) (551 ) (19 ) (927 ) Foreign exchange 63 (23 ) (10 ) 30 Ending balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Year Ended December 31, 2020 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Beginning balance $ 3,302 $ 893 $ 943 $ 5,138 Current period provision, net 5,793 3,393 522 9,708 Write-offs (975 ) — — (975 ) Foreign exchange 248 195 (19 ) 424 Ending balance $ 8,368 $ 4,481 $ 1,446 $ 14,295
Schedule of Financing Receivables	. As of December 31, 2021 and 2020, financing receivables consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Net investment in leases Gross minimum payments due under sales-type leases $ 29,953 $ 20,830 Unearned finance income (763 ) (859 ) Present value of minimum payments due under sales-type leases 29,190 19,971 Allowance for credit losses (798 ) (557 ) Net investment in leases 28,392 19,414 Financed sales receivables Gross minimum payments due under financed sales 152,315 150,917 Unearned finance income (34,244 ) (31,247 ) Present value of minimum payments due under financed sales 118,071 119,670 Allowance for credit losses (5,414 ) (7,274 ) Net financed sales receivables 112,657 112,396 Total financing receivables $ 141,049 $ 131,810 Net financed sales receivables due within one year $ 29,115 $ 34,937 Net financed sales receivables due after one year 83,542 77,459 Total financed sales receivables $ 112,657 $ 112,396
Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate	As of December 31, 2021 and 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: December 31, December 31, 2021 2020 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.6 8.3 Weighted-average interest rate Sales-type lease arrangements 6.56 % 6.56 % Financed sales receivables 8.79 % 8.92 %
Schedule of Net Investment In Leases by Credit Quality Indicator	The tables below provide information on the Company’s net investment in leases by credit quality indicator as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 1,928 $ 28,319 Credit Watch — — — — — — — Pre-approved transactions — — — — — — — Transactions suspended — — — — — 871 871 Total net investment in leases $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 2,799 $ 29,190 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,143 $ 1,190 $ 2,730 $ — $ — $ 1,826 $ 7,889 Credit Watch 2,005 7,278 — 988 — 1,047 11,318 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 764 764 Total net investment in leases $ 4,148 $ 8,468 $ 2,730 $ 988 $ — $ 3,637 $ 19,971
Schedule of Financed Sale Receivables by Credit Quality Indicator	The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 12,520 $ 8,251 $ 10,593 $ 13,278 $ 12,615 $ 47,950 $ 105,207 Credit Watch — — — — 321 1,292 1,613 Pre-approved transactions — — 743 418 2,098 3,650 6,909 Transactions suspended — — 335 — 680 3,327 4,342 Total financed sales receivables $ 12,520 $ 8,251 $ 11,671 $ 13,696 $ 15,714 $ 56,219 $ 118,071 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,830 $ 5,480 $ 3,547 $ 3,740 $ 5,072 $ 12,660 $ 37,329 Credit Watch 1,986 6,501 11,356 12,520 11,446 34,351 78,160 Pre-approved transactions — — — — 613 755 1,368 Transactions suspended — — — 987 728 1,098 2,813 Total financed sales receivables $ 8,816 $ 11,981 $ 14,903 $ 17,247 $ 17,859 $ 48,864 $ 119,670
Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables	The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of December 31, 2021 and 2020: As of December 31, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 225 $ 156 $ 1,267 $ 1,648 $ 27,542 $ 29,190 $ (798 ) $ 28,392 Financed sales receivables 1,750 989 8,378 11,117 106,954 118,071 (5,414 ) 112,657 Total $ 1,975 $ 1,145 $ 9,645 $ 12,765 $ 134,496 $ 147,261 $ (6,212 ) $ 141,049 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 298 $ 180 $ 689 $ 1,167 $ 18,804 $ 19,971 $ (557 ) $ 19,414 Financed sales receivables 3,307 1,943 10,699 15,949 103,721 119,670 (7,274 ) 112,396 Total $ 3,605 $ 2,123 $ 11,388 $ 17,116 $ 122,525 $ 139,641 $ (7,831 ) $ 131,810
Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income	The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of December 31, 2021 and 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of December 31, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 143 $ 132 $ 825 $ 1,100 $ 12,619 $ (176 ) $ 13,543 Financed sales receivables 959 729 6,190 7,878 41,439 (1,413 ) 47,904 Total $ 1,102 $ 861 $ 7,015 $ 8,978 $ 54,058 $ (1,589 ) $ 61,447 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 231 $ 162 $ 359 $ 752 $ 13,912 $ (310 ) $ 14,354 Financed sales receivables 2,026 1,551 10,249 13,826 62,602 (4,434 ) 71,994 Total $ 2,257 $ 1,713 $ 10,608 $ 14,578 $ 76,514 $ (4,744 ) $ 86,348
Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status	The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of December 31, 2021 and 2020: As of December 31, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 871 $ (309 ) $ 562 $ 764 $ (18 ) $ 746 Net financed sales receivables 8,642 (2,357 ) 6,285 2,813 (1,482 ) 1,331 Total $ 9,513 $ (2,666 ) $ 6,847 $ 3,577 $ (1,500 ) $ 2,077
Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables	The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for years ended December 31, 2021 and 2020: Year Ended December 31, 2021 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 557 $ 7,274 Current period provision (reversal), net 235 (1,947 ) Foreign exchange 6 87 Ending balance $ 798 $ 5,414 Year Ended December 31, 2020 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 155 $ 915 Current period provision, net 451 6,574 Write-offs (69 ) (330 ) Foreign exchange 20 115 Ending balance $ 557 $ 7,274
Summary of Allowance For Credit Losses Related to Variable Consideration Receivables	The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the years ended December 31, 2021 and 2020: Year Ended December 31, (In thousands of U.S. Dollars) 2021 2020 Beginning balance $ 1,887 $ — Current period (reversal) provision, net (787 ) 1,875 Foreign Exchange (18 ) 12 Ending balance $ 1,082 $ 1,887

Lease Arrangements (Tables)

Lease Arrangements (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Components of Lease Expense	For the years ended December 31, 2021, 2020, and 2019 the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Operating lease cost (1) $ 713 $ 540 $ 850 Amortization of lease assets 2,791 3,114 2,370 Interest on lease liabilities 937 1,052 1,102 Total lease cost $ 4,441 $ 4,706 $ 4,322 (1) Includes short-term leases and variable lease costs, which are not significant for the years ended December 31, 2021, 2020, and 2019.
Supplemental Cash and Non-Cash Flow Information Related to Leases	For the years ended December 31, 2021, 2020 upplemental cash and non-cash information related to leases is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 3,839 $ 3,743 $ 3,607 Right-of-use assets obtained in exchange for lease obligations (1) $ 1,047 $ 563 $ 17,147 (1) For the ASC Topic
Lessee Operating Lease Balance Sheet Amounts and Lines	As of December 31, 2021 , December 31, (In thousands of U.S. Dollars) 2021 2020 Assets Balance Sheet Classification Right-of-Use-Assets Property, plant and equipment $ 12,132 $ 13,911 Liabilities Balance Sheet Classification Operating Leases Accrued and other liabilities $ 14,691 $ 16,634
Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate	As of December 31, 2021 and 2020 December 31, 2021 2019 Weighted-average remaining lease term (years) 7.0 7.6 Weighted-average discount rate 5.97 % 5.91 %
Lessee Operating Lease, Maturity	As of December 31, 2021, the maturities of the Company’s operating lease liabilities are as follows: (In thousands of U.S. Dollars) 2022 $ 3,364 2023 2,449 2024 2,226 2025 2,075 2026 2,051 Thereafter 5,982 Total lease payments $ 18,147 Less: interest expense (3,456 ) Present value of operating lease liabilities $ 14,691
Schedule of Maturities of Lease Receivables	The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) Sales-Type Leases Joint Revenue Sharing Arrangements 2022 $ 3,590 $ 190 2023 3,145 128 2024 3,086 — 2025 2,933 — 2026 2,694 — Thereafter 14,505 — Total $ 29,953 $ 318

Variable Consideration Receiv_2

Variable Consideration Receivable from Contracts With Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Change In Contract With Customer Asset [Abstract]
Summary of Variable Consideration Receivable from Contracts With Customers	The following table summarizes the activity related to variable consideration from contracts with customers for the years ended December 31, 2021, 2020, and 2019: (In thousands of U.S. Dollars) Balance as of January 1, 2019 $ 35,985 Variable consideration for newly recognized sales 9,948 Accretion to finance income 1,936 True-up of variable consideration receivable 979 Transferred to receivables from variable consideration assets (8,808 ) Balance as of December 31, 2019 40,040 Variable consideration for newly recognized sales 5,550 Accretion to finance income 2,133 Transferred to receivables from variable consideration assets (5,310 ) Movement in allowance for credit losses (see Note 5) (1,887 ) Balance as of December 31, 2020 40,526 Variable consideration for newly recognized sales 4,696 Accretion to finance income 1,985 Transferred to receivables from variable consideration assets (3,794 ) Movement in allowance for credit losses (see Note 5) 805 Balance as of December 31, 2021 $ 44,218

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	As of December 31, (In thousands of U.S. Dollars) 2021 2020 Raw materials $ 20,551 $ 30,096 Work-in-process 1,406 3,014 Finished goods 4,967 6,470 $ 26,924 $ 39,580
Summary of Inventory Valuation Allowance Account	The following table summarizes the activity for the Company’s inventory valuation allowance account for the years ended December 31, 2021, 2020 and 2019: Balance at beginning of year Additions charged to expenses (1) Other deductions (2) Balance at end of year (In thousands of U.S. Dollars) Year ended December 31, 2021 $ 5,752 $ 629 $ (1,484 ) $ 4,897 Year ended December 31, 2020 $ 3,216 $ 3,028 $ (492 ) $ 5,752 Year ended December 31, 2019 $ 3,885 $ 446 $ (1,115 ) $ 3,216

Film Assets (Tables)

Film Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Film Costs [Abstract]
Film Assets	As of December 31, (In thousands of U.S. Dollars) 2021 2020 Completed and released films, net of accumulated amortization of $ 2,292 $ 2,678 $218,148 (2020 ― $201,832) Films in production 195 195 Films in development 1,754 2,904 $ 4,241 $ 5,777

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: Theater system components (1)(2)(3) $ 346,517 $ 181,936 $ 164,581 Camera equipment 4,855 3,214 1,641 351,372 185,150 166,222 Assets under construction (4) 10,232 — 10,232 Right-of-use assets (5) 14,429 2,297 12,132 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,973 28,873 52,100 Office and production equipment (6) 39,017 31,169 7,848 Leasehold improvements 8,110 4,494 3,616 136,303 64,536 71,767 $ 512,336 $ 251,983 $ 260,353 As of December 31, 2020 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: Theater system components (1)(2)(3) $ 337,271 $ 158,647 $ 178,624 Camera equipment 5,399 4,653 746 342,670 163,300 179,370 Assets under construction (4) 5,660 — 5,660 Right-of-use assets (5) 15,553 1,642 13,911 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,875 25,921 54,954 Office and production equipment (6) 40,362 29,156 11,206 Leasehold improvements 8,061 3,968 4,093 137,501 59,045 78,456 $ 501,384 $ 223,987 $ 277,397 (1) Included in theater system components are assets with costs of $7.6 million (2020 — $7.6 million) and accumulated depreciation of $7.0 million (2020 — $6.8 million) that are leased to customers under operating leases. (2) Included in theater system components are assets with costs of $324.3 million (2020 — $315.4 million) and accumulated depreciation of $166.5 million (2020 — $144.7 million) that are used in joint revenue sharing arrangements. (3) In 2021, the Company recorded charges of $0.4 million (2020 — $1.8 million; 2019 — $2.2 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased IMAX Xenon Theater Systems which were taken out of service in connection with customer upgrades to IMAX Laser Theater Systems. (4) Included in assets under construction are components with costs of $9.2 million (2020 — $5.3 million) that will be utilized to construct assets to be used in joint revenue sharing arrangements. (5) The right-of-use assets primarily include operating leases for office and warehouse space. (6) Fully depreciated office and production equipment is still in use by the Company. In 2021, the Company identified and wrote off $0.5 million (2020 — $0.9 million) of office and production equipment that is fully depreciated and no longer in use.

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Other Assets [Abstract]
Schedule of Other Assets	As of December 31, (In thousands of U.S. Dollars) 2021 2020 Lease incentives provided to theater customers, net of accumulated amortization $ 14,834 $ 15,651 Commissions and other deferred selling expenses 1,418 2,608 Other investments 1,000 1,000 Foreign currency derivatives 184 1,979 Other 363 435 $ 17,799 $ 21,673

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Taxes by Jurisdiction	(a) Income (Loss) Before Taxes by Jurisdiction Income (loss) before taxes by tax jurisdiction for the years ended December 31, 2021, 2020, and 2019 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Canada $ (55,480 ) $ (104,166 ) $ 884 United States 3,218 (6,437 ) (234 ) China 53,792 (8,253 ) 51,809 Ireland 829 (7,473 ) 17,630 Other 8,628 (2,795 ) 5,247 $ 10,987 $ (129,124 ) $ 75,336
Schedule of Income Tax (Expense) Benefit	(b) Income Tax (Expense) Benefit Income tax (expense) benefit for the years ended December 31, 2021, 2020, and 2019 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Income tax (expense) benefit – current: Canada $ (915 ) $ 555 $ 2,369 United States (1,038 ) 488 595 China (11,045 ) (1,980 ) (11,789 ) Ireland (1,358 ) (1,462 ) (762 ) Other (3,212 ) (487 ) (419 ) Sub-total (17,568 ) (2,886 ) (10,006 ) Income tax (expense) benefit – deferred: Canada (1) (231 ) (10,801 ) (3,913 ) United States (1,268 ) 867 (949 ) China (2) (381 ) (15,756 ) (18 ) Ireland (997 ) 2,161 (1,923 ) Other (119 ) (89 ) 41 Sub-total (2,996 ) (23,618 ) (6,762 ) Total (3) $ (20,564 ) $ (26,504 ) $ (16,768 ) ( 1 ) A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is needed. (2) In 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $19.1 million in 2020 for the estimated applicable foreign withholding taxes associated with these historical earnings, which will become payable upon the repatriation of any such earnings. In 2021, the deferred tax liability for the applicable foreign withholding taxes was increased by $0.5 million due to an increase in the amount of distributable historical earnings. During the year ended December 31, 2021, $20.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.0 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2021 is $17.6 million. (3) For the year ended December 31, 2021, Income Tax (Expense) Benefit excludes a tax benefit of $0.3 million included in Other Comprehensive Income (2020 — benefit of $0.1 million; 2019 — expense of $(0.4) million).
Schedule of Reconciliation of Income Tax Expense to Statutory Rates	(c) Reconciliation of Income Tax Expense to Statutory Rates For the years ended December 31, 2021, 2020, and 2019, the Company’s effective tax rate and income tax expense differs from the combined Canadian federal and provincial statutory income tax rates due to the following factors: Years Ended December 31, 2021 2020 2019 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Amount Rate Income tax (expense) benefit at combined statutory rates $ (2,912 ) 26.5% $ 34,218 26.5% $ (19,964 ) 26.5% Adjustments resulting from: NCI share of partnership losses (1 ) 0.0% (1,229 ) (1.0%) (397 ) 0.5% Increase in valuation allowance (14,722 ) 134.0% (28,589 ) (22.1%) — 0.0% Changes to tax reserves 3,508 (31.9%) (2,699 ) (2.1%) 1,418 (1.9%) U.S. federal and state taxes (80 ) 0.7% (250 ) (0.2%) (300 ) 0.4% Withholding taxes (4,199 ) 38.2% (20,943 ) (16.2%) (1,071 ) 1.4% Income tax at different rates in foreign and other provincial jurisdictions 3,352 (30.5%) (2,607 ) (2.0%) 5,019 (6.7%) Investment and other tax credits (non-refundable) 413 (3.8%) 643 0.5% 701 (0.9%) Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments (5,336 ) 48.6% (1,219 ) (0.9%) (1,998 ) 2.7% Other non-deductible/non-taxable items (587 ) 5.4% (3,829 ) (3.0%) (176 ) 0.3% Income tax expense $ (20,564 ) 187.2% $ (26,504 ) (20.5%) $ (16,768 ) 22.3%
Deferred Tax Assets and Deferred Tax Liability	(d) Deferred Tax Assets and Deferred Tax Liability As of December 31, 2021 and 2020, the Company’s deferred tax assets and deferred tax liability consists of the following: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Net operating loss carryforwards $ 21,219 $ 17,120 Investment tax credit and other tax credit carryforwards 3,919 1,344 Write-downs of other assets 1,223 1,219 Excess of tax accounting basis in various assets 13,929 9,692 Accrued pension liability 6,901 6,942 Accrued share-based compensation 7,728 7,350 Income recognition on net investment in leases (3,368 ) (2,018 ) Other accrued reserves 8,369 5,120 Total deferred income tax assets 59,920 46,769 Valuation allowance (46,014 ) (28,786 ) Deferred income tax asset net of valuation allowance 13,906 17,983 Deferred tax liability (17,642 ) (19,134 ) Net deferred tax liability $ (3,736 ) $ (1,151 )
Reconciliation of Beginning and Ending Amount of Tax Reserves (excluding interest and penalties)	The following table presents a reconciliation of the beginning and ending amount of tax reserves (excluding interest and penalties) for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Balance at beginning of the year $ 14,076 $ 14,718 $ 16,136 Additions based on tax positions related to the current year 37 2,301 812 Reductions for tax positions of prior years (991 ) — (2,230 ) Reductions resulting from lapse of applicable statute of limitations and administrative practices (1,183 ) (2,943 ) — Balance at the end of the year $ 11,939 $ 14,076 $ 14,718
Income Tax Benefit (Expense) in Other Comprehensive Income	For the years ended December 31, 2021, 2020, and 2019, Income Tax Benefit (Expense) related to the components of Other Comprehensive Income is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized defined benefit plan actuarial (gain) loss $ (37 ) $ 276 $ (42 ) Unrealized postretirement benefit plans actuarial (gain) loss (35 ) 92 — Prior service cost arising during the period — — 145 Amortization of prior service cost (48 ) (23 ) (26 ) Unrealized change in cash flow hedging instruments (123 ) (132 ) (145 ) Realized change in cash flow hedging instruments 446 (158 ) (310 ) Reclassification of unrealized change in ineffective cash flow hedging instruments 83 — — $ 286 $ 55 $ (378 )

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Other Intangible Assets	As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Patents and trademarks $ 12,834 $ 9,406 $ 3,428 Licenses and intellectual property 26,168 13,642 12,526 Internal use software 28,571 21,544 7,027 Other 598 499 99 $ 68,171 $ 45,091 $ 23,080 As of December 31, 2020 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Patents and trademarks $ 12,714 $ 8,878 $ 3,836 Licenses and intellectual property 26,168 12,182 13,986 Internal use software 25,009 17,568 7,441 Other 1,445 463 982 $ 65,336 $ 39,091 $ 26,245
Summary of Estimated Amortization Expenses	The estimated amortization expense for each of the next five years following the December 31, 2021 balance sheet date is as follows: (In thousands of U.S. Dollars) 2022 $ 6,225 2023 6,225 2024 4,899 2025 2,056 2026 1,704

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Revolving Credit Facility Borrowings	As of December 31, 2021 and 2020, Revolving Credit Facility Borrowings, net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Credit Facility borrowings $ — $ 300,000 Working Capital Facility borrowings 3,612 7,643 Unamortized debt issuance costs (1,140 ) (1,967 ) Revolving Credit Facility Borrowings, net $ 2,472 $ 305,676
Summary of Convertible Notes	As of December 31, 2021 and December 31, 2020, Convertible Notes (as defined below) consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2021 2020 Convertible Notes $ 230,000 $ — Unamortized discounts and debt issuance costs (6,359 ) — Revolving Credit Facility Borrowings, net $ 223,641 $ —

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Company's Contractual Obligations and Commitments	The following table presents a summary of the Company’s contractual obligations and commitments as of December 31, 2021: Payments Due by Period (In thousands of U.S. Dollars) Total Obligation Less Than One Year 1 to 3 years 3 to 5 years Thereafter Purchase obligations (1) $ 34,084 $ 33,907 $ 42 $ — $ 135 Pension obligations (2) 20,298 — 20,298 — — Operating lease obligations (3) 18,833 3,760 4,669 4,127 6,277 Working Capital Facility (4) 3,612 3,612 — — — Convertible Notes (5) 235,175 1,150 2,300 231,725 — Postretirement benefits obligations 3,066 117 266 262 2,421 $ 315,068 $ 42,546 $ 27,575 $ 236,114 $ 8,833 (1) Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced. (2) The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. ( See Note 23.) (3) Represents total minimum annual rental payments due under the Company’s operating leases, which almost entirely relates to leased office space in New York. (See Note 6.) (4) The Working Capital Facility (5) The Convertible Notes bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The Convertible Notes will mature on April 1, 2026, unless earlier repurchased, redeemed or converted. (See Note 14.)

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Changes During the Year	The following table summarizes the settlement of stock option and RSU transactions: Years Ended December 31, (Cash proceeds in thousands of U.S. Dollars) 2021 2020 2019 Stock options Issued from treasury 41,613 — 19,088 Plan trustee purchases — — 67,840 Total stock options exercised 41,613 — 86,928 Cash proceeds from stock option exercises $ — $ — $ 1,752 RSUs Issued from treasury 531,629 42,982 — Plan trustee purchases 723 386,297 404,719 Shares withheld for tax withholdings 157,546 24,714 29,577 Total RSUs vested 689,898 453,993 434,296
Stock Compensation	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Cost and expenses applicable to revenues $ 1,490 $ 691 $ 1,709 Selling, general and administrative expenses 23,776 20,652 20,750 Research and development 348 150 371 $ 25,614 $ 21,493 $ 22,830
Stock Option Plan	The Company recorded the following expenses related to stock options issued to employees and directors under the IMAX LTIP and SOP: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Stock option expense $ 1,064 $ 1,847 $ 8,329
Non vested stock options	As of December 31, 2021, 2020, and 2019, unrecognized share-based compensation expense related to non-vested employee stock options is as follows: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense related to non-vested employee stock options $ 662 $ 2,029 $ 4,073 As of December 31, 2021, 2020, and 2019, unrecognized share-based compensation expense related to non-vested employee stock options is expected to be recognized over the following weighted-average periods: As of December 31, 2021 2020 2019 Weighted average period (in years) 1.1 1.8 2.7
Options to Employees	During the years ended December 31, 2021 and 2020, the Company did not grant any stock options. During the year ended 2019, the weighted average fair value of stock options granted to employees and directors at the measurement date and the assumptions used to estimate the average fair value of the stock options are as follows: Years Ended December 31, 2021 2020 2019 Weighted average fair value per share N/A N/A $ 6.65 Average risk-free interest rate N/A N/A 2.64% Expected option life (in years) N/A N/A 6.73 - 10.00 Expected volatility N/A N/A 31% Dividend yield N/A N/A 0%
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the stock option activity under the SOP and IMAX LTIP for the years ended December 31, 2021, 2020, and 2019: Weighted Average Exercise Number of Shares Price Per Share 2021 2020 2019 2021 2020 2019 Stock options outstanding, beginning of year 4,892,962 5,732,209 5,465,046 $ 26.81 $ 26.82 $ 27.63 Granted — — 1,016,882 — — 20.66 Exercised (41,613 ) — (86,928 ) 21.23 — 20.16 Forfeited (88,934 ) (34,678 ) (336,493 ) 22.49 22.49 23.63 Expired (903,038 ) (786,086 ) (299,134 ) 28.31 27.07 25.82 Cancelled (123,220 ) (18,483 ) (27,164 ) 26.68 27.97 31.13 Stock options outstanding, end of year 3,736,157 4,892,962 5,732,209 26.61 26.81 26.82 Stock options exercisable, end of year 3,488,107 4,311,761 4,801,272 26.93 27.30 27.40
RSU Expenses	RSUs have been granted to employees and directors under the IMAX LTIP. Each RSU represents a contingent right to receive a common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date or the average closing price of the Company’s common stock for five days prior to the date of grant. For the years ended December 31, 2021, 2020, and 2019, the Company recorded the following expenses related to RSUs issued to employees and directors in the IMAX LTIP: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 RSU expenses $ 15,555 $ 13,761 $ 12,394
RSU Unrecognized Expenses	Total share-based compensation expense related to non-vested RSUs not yet recognized and the weighted average period over which the awards are expected to be recognized are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense related to non-vested RSUs not yet recognized $ 15,913 $ 17,343 $ 23,548 Weighted average period awards are expected to be recognized (in years) 1.6 1.9 2.7
Restricted Stock Units Issued under the IMAX LTIP	The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the years ended December 31, 2021, 2020, and 2019: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2019 2021 2020 2019 RSUs outstanding, beginning of year 1,564,838 1,065,347 1,033,871 $ 18.33 $ 23.17 $ 25.70 Granted 831,123 1,050,385 687,475 21.03 15.35 22.30 Vested and settled (689,872 ) (453,993 ) (434,296 ) 19.46 22.71 27.54 Forfeited (248,206 ) (96,901 ) (221,703 ) 19.38 18.81 23.68 RSUs outstanding, end of year 1,457,883 1,564,838 1,065,347 19.16 18.33 23.17
RSU Carve out Balance	The following table summarizes the number of RSUs issued from the carve-out balance: Approved under the June 3, 2020 amended and restated IMAX LTIP 885,000 Issued during previous years (412,045 ) Issued during 2021 (70,867 ) Outstanding, December 31, 2021 402,088
PSU Expenses	For the years ended December 31, 2021, 2020, and 2019, the Company recorded the following expenses related to outstanding PSUs, which includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 PSU expenses $ 5,322 $ 2,563 $ —
Performance Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 PSUs outstanding, beginning of year 361,844 — $ 15.68 $ — Granted 309,574 370,265 20.77 15.66 Forfeited (58,013 ) (8,421 ) 16.11 4.84 PSUs outstanding, end of year 613,405 361,844 18.21 15.68
China LTIP Activity	For the years ended December 31, 2021, 2020, and 2019, share-based compensation expense related to China Options, China RSUs and China PSUs was as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Expense China Options $ 285 $ 875 $ 320 China RSUs 2,810 2,093 — China PSUs 578 208 1,664 Total $ 3,673 $ 3,176 $ 1,984
Basic and Diluted Per-share Computations	The following table reconciles the denominator of the basic and diluted weighted average share computations: Years Ended December 31, (In thousands) 2021 2020 2019 Issued and outstanding, beginning of period 58,921 61,176 61,434 Weighted average number of shares issued (repurchased), net 205 (1,939 ) (124 ) Weighted average number of shares outstanding - basic 59,126 59,237 61,310 Weighted average effect of potential common shares, if dilutive — — 179 Weighted average number of shares outstanding - diluted 59,126 59,237 61,489

Consolidated Statements of Op_3

Consolidated Statements of Operations Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Selling Expenses, Including Sales Commissions and Other Selling Expenses	The following table summarizes the Company’s selling expenses, including sales commissions and other selling expenses such as direct advertising and marketing expenses, which are recognized within Costs and Expenses Applicable to Revenues in the Consolidated Statements of Operations, for the years ended December 31, 2021, 2020 and 2019: Years Ended December 31, 2021 2020 2019 (In thousands of U.S. Dollars) Sales Commissions Other Selling Expenses Sales Commissions Other Selling Expenses Sales Commissions Other Selling Expenses Technology sales (1) $ 1,885 $ 989 $ 1,278 $ 1,077 $ 2,031 $ 1,072 Image enhancement and maintenance services (2) — 8,923 — 4,306 — 22,869 Technology rentals (3) 399 1,109 908 510 383 2,952 Total $ 2,284 $ 11,021 $ 2,186 $ 5,893 $ 2,414 $ 26,893

Consolidated Statements of Ca_3

Consolidated Statements of Cash Flows Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Summary of Changes in Other Operating Assets and Liabilities	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 (Increase) decrease in: Financing receivables $ (7,637 ) $ (10,568 ) $ (320 ) Prepaid expenses (3,230 ) (979 ) (290 ) Variable consideration receivables (2,905 ) (2,361 ) (4,056 ) Other assets 1,003 (4,747 ) (2,063 ) (Decrease) increase in: Accounts payable (4,752 ) 414 (11,774 ) Accrued and other liabilities 15,167 (6,399 ) (8,505 ) $ (2,354 ) $ (24,640 ) $ (27,008 )
Cash Payments	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Income taxes (1) $ 18,475 $ 4,763 $ 17,298 Interest $ 3,251 $ 5,773 $ 1,231 (1) In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest.
Summary of Depreciation and Amortization	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Film assets $ 16,316 $ 8,838 $ 19,176 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 22,320 24,930 23,153 Other property, plant and equipment 9,479 11,225 12,477 Other intangible assets (1) 6,079 6,565 6,290 Other assets (2) 1,888 1,146 1,882 Total $ 56,082 $ 52,704 $ 62,978 (1) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Consolidated Statement of Operations of $1.3 million in the year ended December 31, 2021 ( 2020 — $1.3 million). (2) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.
Write Downs, Net of Recoveries	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Inventories (1) $ 890 $ 3,632 $ 446 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (2) 364 1,784 2,207 Other property, plant and equipment 217 174 249 Other intangible assets 142 184 95 Film assets (3) 151 10,804 1,379 Other assets (4) — 1,151 — $ 1,764 $ 17,729 $ 4,376 (1) In 2021, the Company recorded write-downs of $0.9 million (2020 — $3.6 million; 2019 — $0.4 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory. (2) In 2021, the Company recorded charges (3) In 2021, the company recorded impairment losses of $0.2 million related to the write-down of DMR related film assets. In 2020, the Company recorded impairment losses of $10.8 million (2019 — $1.4 million) in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. (4) In 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such charge was recorded in 2021 and 2019.
Significant Non-cash Investing Activities	Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 1,009 $ (1,888 ) $ (2,013 ) Acquisition of other intangible assets (891 ) 792 (51 ) Purchases of property, plant and equipment (188 ) 158 496 $ (70 ) $ (938 ) $ (1,568 )

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Disaggregation of Revenue by Segment	The following tables summarize the Company’s revenues by type and reportable segment for the years ended December 31, 2021, 2020, and 2019: Year Ended December 31, 2021 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 37,900 $ 5,576 $ 11,392 $ — $ 54,868 Joint Revenue Sharing Arrangements, fixed fees — — 5,406 — 5,406 Other Theater Business 2,363 — — — 2,363 Other sales (2) 3,475 41 — — 3,516 Sub-total 43,738 5,617 16,798 — 66,153 Image enhancement and maintenance services IMAX DMR — 70,659 — — 70,659 IMAX Maintenance 53,339 — — — 53,339 Film Post-Production 4,260 — — — 4,260 Film Distribution 205 1,259 — — 1,464 Other 377 1,049 — — 1,426 Sub-total 58,181 72,967 — — 131,148 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 46,184 — 46,184 Other — — 606 — 606 Sub-total — — 46,790 — 46,790 Finance income IMAX Systems — — — 10,792 10,792 Total $ 101,919 $ 78,584 $ 63,588 $ 10,792 $ 254,883 Year Ended December 31, 2020 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(3) $ 33,869 $ 5,799 $ 4,271 $ — $ 43,939 Joint Revenue Sharing Arrangements, fixed fees — — 2,056 — 2,056 Other Theater Business 1,666 — — — 1,666 Other sales (2) 1,957 110 — — 2,067 Sub-total 37,492 5,909 6,327 — 49,728 Image enhancement and maintenance services IMAX DMR — 28,265 — — 28,265 IMAX Maintenance 21,999 — — — 21,999 Film Post-Production 3,878 — — — 3,878 Film Distribution 3,000 1,841 — — 4,841 Other — 335 — — 335 Sub-total 28,877 30,441 — — 59,318 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 17,841 — 17,841 Sub-total — — 17,841 — 17,841 Finance income IMAX Systems — — — 10,116 10,116 Total $ 66,369 $ 36,350 $ 24,168 $ 10,116 $ 137,003 Year Ended December 31, 2019 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed consideration Variable consideration Revenue from Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(3) $ 77,058 $ 10,247 $ 9,105 $ — $ 96,410 Joint Revenue Sharing Arrangements, fixed fees — — 11,014 — 11,014 Other Theater Business 8,390 — — — 8,390 Other sales (2) 2,209 222 — — 2,431 Sub-total 87,657 10,469 20,119 — 118,245 Image enhancement and maintenance services IMAX DMR — 120,765 — — 120,765 IMAX Maintenance 53,151 — — — 53,151 Film Post-Production 7,392 — — — 7,392 Film Distribution — 4,818 — — 4,818 Other 2,421 — — 2,421 Sub-total 60,543 128,004 — — 188,547 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 76,673 — 76,673 Other — 25 1,263 — 1,288 Sub-total — 25 77,936 — 77,961 Finance income IMAX Systems — — — 10,911 10,911 Total $ 148,200 $ 138,498 $ 98,055 $ 10,911 $ 395,664 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Other sales include revenues associated with New Business Initiatives. (3) Prior period comparatives have been revised to appropriately classify $4.3 million and $9.1 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the years ended December 31, 2020 and 2019.

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Reporting Information by Category and Reportable Segment	The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, Revenue (1) Gross Margin (Margin Loss) (In thousands of U.S. Dollars) 2021 2020 2019 2021 2020 2019 IMAX Technology Network IMAX DMR $ 70,659 $ 28,265 $ 120,765 $ 44,782 $ 13,731 $ 78,592 Joint Revenue Sharing Arrangements, contingent rent 46,184 17,841 76,673 21,761 (9,500 ) 48,446 116,843 46,106 197,438 66,543 4,231 127,038 IMAX Technology Sales and Maintenance IMAX Systems (2) 65,660 54,055 107,321 34,981 24,816 58,168 Joint Revenue Sharing Arrangements, fixed fees 5,406 2,056 11,014 1,343 529 2,613 IMAX Maintenance (3) 53,339 21,999 53,151 27,572 3,068 23,010 Other Theater Business (4) 2,363 1,666 8,390 398 (438 ) 2,624 126,768 79,776 179,876 64,294 27,975 86,415 Film Distribution and Post-Production Film Distribution (5) 1,464 4,841 4,818 (1,121 ) (9,840 ) (2,942 ) Post-Production 4,260 3,878 7,392 1,969 (358 ) 1,680 5,724 8,719 12,210 848 (10,198 ) (1,262 ) New Business Initiatives 3,704 2,226 2,754 3,399 1,878 2,106 Sub-total for reportable segments 253,039 136,827 392,278 135,084 23,886 214,297 Other 1,844 176 3,386 (678 ) (2,346 ) (125 ) Total $ 254,883 $ 137,003 $ 395,664 $ 134,406 $ 21,540 $ 214,172 The following table presents the Company’s assets by category and reportable segment, reconciled to consolidated assets, as of December 31, 2021 and 2020: As of December 31, (In thousands of U.S. Dollars) 2021 2020 IMAX Technology Network IMAX DMR $ 48,299 $ 29,672 Joint Revenue Sharing Arrangements, contingent rent 196,789 195,822 IMAX Technology Sales and Maintenance IMAX Systems 249,672 240,972 Joint Revenue Sharing Arrangements, fixed fees 27,930 27,778 IMAX Maintenance 38,530 36,949 Other Theater Business 82 106 Film Distribution and Post-Production Film Distribution 7,185 5,984 Post-Production 31,575 35,526 New Business Initiatives 1,420 1,196 Sub-total for reportable segments 601,482 574,005 Corporate and other non-segment specific assets 281,765 423,745 Total $ 883,247 $ 997,750 The following table presents the Company’s amortization by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ 15,917 $ 10,269 $ 16,117 Joint Revenue Sharing Arrangements, contingent rent 24,208 26,076 25,036 IMAX Technology Sales and Maintenance IMAX Systems 2,076 3,548 3,878 IMAX Maintenance — 213 299 Film Distribution and Post-Production Film Distribution 600 1,213 3,894 Post-Production 924 1,281 1,301 New Business Initiatives — 11 58 Sub-total for reportable segments 43,725 42,611 50,583 Corporate and other non-segment specific assets (6) 12,357 10,093 12,395 Total $ 56,082 $ 52,704 $ 62,978 The following table presents the Company’s write-downs, including asset impairments and credit loss (reversal) expense, by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ 151 $ 1,057 $ — Joint Revenue Sharing Arrangements, contingent rent 364 1,784 2,207 IMAX Technology Sales and Maintenance IMAX Systems 837 2,872 276 IMAX Maintenance 53 510 170 Film Distribution and Post-Production Film Distribution — 9,997 1,379 Post-Production — — — New Business Initiatives — 52 96 Sub-total for reportable segments 1,405 16,272 4,128 Corporate and other non-segment specific assets (7) (3,592 ) 20,065 2,678 Total $ (2,187 ) $ 36,337 $ 6,806 The following table presents the Company’s purchases of Property, Plant and Equipment by category and reportable segment for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 IMAX Technology Network IMAX DMR $ — $ — $ 99 Joint Revenue Sharing Arrangements, contingent rent 10,094 6,654 40,489 IMAX Technology Sales and Maintenance IMAX Systems 621 50 452 IMAX Maintenance 25 — 311 Film Distribution and Post-Production Film Distribution 1,599 — — Post-Production 609 456 1,210 New Business Initiatives — — — Sub-total for reportable segments 12,948 7,160 42,561 Corporate and other non-segment specific assets 736 191 5,349 Total $ 13,684 $ 7,351 $ 47,910 (1 ) The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020. ( 2 ) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. (3 ) Due to the global reopening of the IMAX theater network and the substantial resumption of normal operations throughout the theatrical exhibition industry, as evidenced by box office totals for the fourth quarter of 2021 exceeding pre-pandemic levels, the Company ended the temporary relief program for its exhibitor customers and, as a result, recognized maintenance revenue of $6.3 million that had been due to the potential for the waiver or reduction of maintenance fees during the COVID-19 pandemic , including $2.5 million that had been deferred from 2020 with the remainder from the first nine months of 2021. (4) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. ( 5 ) During the year ended December 31, 2020, Film Distribution segment results were significantly influenced by impairment losses of $10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments (2019 ― $1.4 million). No such impairment losses were incurred in 2021. ( 6 ) Prior period comparatives have been revised to exclude the amortization of deferred financing costs of $0.9 million and $0.5 million, respectively, for the years ended December 31, 2020 and 2019. ( 7 ) During the year ended December 31, 2021, includes the net reversal of current expected credit losses of $4.0 million, which is excluded from the measurement of the Company’s segment performance (2020 ― provision of $18.6 million; 2019 ― provision of $2.4 million). (See Note 5.)
Geographic Information	Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. The following table summarizes the Company’s revenues by geographic area for the years ended December 31, 2021, 2020, and 2019: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Greater China $ 112,801 $ 52,331 $ 124,294 United States 73,499 30,157 121,264 Asia (excluding Greater China) 23,682 20,090 48,386 Western Europe 20,942 13,683 46,911 Russia & the CIS 7,308 2,927 16,124 Latin America 3,601 6,114 9,438 Canada 3,266 1,365 9,220 Rest of the World 9,784 10,336 20,027 Total $ 254,883 $ 137,003 $ 395,664
Schedule of Property Plant and Equipment By Geographic Areas	The following table presents the breakdown of Property, Plant and Equipment by geography as of December 31, 2021 and 2020: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Greater China $ 100,182 $ 104,731 United States 91,856 100,495 Canada 32,643 31,624 Western Europe 21,684 25,487 Asia (excluding Greater China) 9,463 9,930 Rest of the World 4,525 5,130 Total $ 260,353 $ 277,397

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments Gain Loss [Line Items]
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 189,711 $ 189,711 $ 317,379 $ 317,379 Equity securities (2) 1,087 1,087 13,633 13,633 Level 2 Net financed sales receivables (3) $ 112,657 $ 112,662 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 28,392 28,407 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,275 3,275 3,155 3,155 Foreign exchange contracts — (2) 79 79 1,635 1,635 Foreign exchange contracts — (2) — — 344 344 Working Capital Facility borrowings (1) (3,612 ) (3,612 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (223,100 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.
Notional Amount of Derivative	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Consolidated Financial Statements: Notional value of foreign exchange contracts As of December 31, (In thousands of U.S. Dollars) 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 26,702 $ 26,358 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards — 5,552 $ 26,702 $ 31,910
Fair Value of Foreign Exchange Contracts	Fair value of derivatives in foreign exchange contracts As of December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 184 $ 1,635 Accrued and other liabilities (105 ) — Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets — 344 $ 79 $ 1,979
Derivatives in Foreign Currency Hedging Relationships	Derivatives in foreign currency hedging relationships are as follows Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain — Forwards Recognized in OCI (Effective Portion) $ 468 $ 550 $ 552 Location of Derivative Gain (Loss) Reclassified from AOCI Years Ended December 31, (In thousands of U.S. Dollars) (Effective Portion) 2021 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 1,707 $ (578 ) $ (1,109 ) Inventories — (26 ) (42 ) Property, plant and equipment — — (32 ) $ 1,707 $ (604 ) $ (1,183 ) Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain (Loss) Recognized — Forwards In and out of OCI (Effective Portion) $ — $ 17 $ (22 )
Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivatives in Foreign Currency Hedging Relationships	Non-designated derivatives in foreign currency relationships are as follows Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ (318 ) $ — $ — Years Ended December 31, (In thousands of U.S. Dollars) Location of Derivative Gain 2021 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 398 $ 344 $ —

Employees Pension and Postret_2

Employees Pension and Postretirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2021
SERP Benefits [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2021 and 2020 , the projected benefit obligation for SERP are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of period $ 20,116 $ 18,840 Interest cost 72 379 Actuarial (gain) loss (132 ) 897 Obligation, end of period and unfunded status $ 20,056 $ 20,116
Summary of Accumulated Other Comprehensive Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2021 2020 , the following amounts related to the SERP were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net periodic benefit cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial gain $ (679 ) $ (547 ) $ (1,444 ) Unamortized prior service cost 184 369 456 Net periodic benefit costs to be recognized in future periods $ (495 ) $ (178 ) $ (988 )
Summary of Disclosure of Pension Expense	For the years ended December 31, 2021 2020 pension expense related to the SERP were as follows: Years ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 72 $ 379 $ 564 Amortization of prior service cost 185 87 — Pension expense $ 257 $ 466 $ 564
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	The following assumptions were used to determine the SERP obligation and any related costs as of and for the years ended December 31, 2021 , As of December 31, 2021 2020 2019 Discount rate 0.80 % 0.36 % 2.00 % Lump sum interest rate: First 25 years N/A N/A 2.12 % First 20 years N/A N/A N/A Thereafter N/A N/A 2.26 % Cost of living adjustment on benefits N/A N/A 1.20 %
Postretirement Benefits Executives [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2021 and 2020 , the Executive Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of year $ 710 $ 665 Interest cost 16 20 Benefits paid (16 ) (29 ) Actuarial (gain) loss (48 ) 54 Obligation, end of year and unfunded status $ 662 $ 710
Summary of Accumulated Other Comprehensive Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2021 2020 , the following amounts related to the Executive Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial (gain) loss $ (27 ) $ 21 $ (50 )
Summary of Disclosure of Pension Expense	For the years ended December 31, 2021 2020 Executive Postretirement Benefit Plan : Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 16 $ 20 $ 26 Amortization of actuarial gain — (17 ) — Pension expense $ 16 $ 3 $ 26
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	As of December 31, 2021 2020 weighted average assumptions used to determine the benefit obligation related to the Executive Postretirement Benefit Plan are as follows: As of December 31, 2021 2020 2019 Discount rate 2.71 % 2.36 % 3.13 % For the years ended December 31, 2021 2020 weighted average assumptions used to determine the net postretirement benefit expense related to the Executive Postretirement Benefit Plan are as follows: Years Ended December 31, 2021 2020 2019 Discount rate 2.36 % 3.13 % 4.15 %
Summary of Benefit Payment are Expected in Next Five Year	The following benefit payments are expected to be made as per the current plan assumptions for the Executive Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) 2022 $ 9 2023 19 2024 20 2025 21 2026 23 Thereafter 938 Total $ 1,030
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2021 2020 Canadian Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligations: Obligation, beginning of year $ 1,862 $ 1,581 Interest cost 42 47 Benefits paid (118 ) (110 ) Actuarial (gain) loss (92 ) 280 Unrealized foreign exchange loss 8 64 Obligation, end of year and unfunded status $ 1,702 $ 1,862
Summary of Accumulated Other Comprehensive Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2021 , 2020 , the following amounts related to the Canadian Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Unrealized actuarial loss (gain) $ 185 $ 277 $ (3 )
Summary of Disclosure of Pension Expense	For the years ended December 31, 2021 2020 Canadian Postretirement Benefit Plan : Years Ended December 31, (In thousands of U.S. Dollars) 2021 2020 2019 Interest cost $ 42 $ 47 $ 49 Pension expense $ 42 $ 47 $ 49
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	As December 31, 2021 2020 weighted average assumptions used to determine the benefit obligation Canadian Postretirement Benefit Plan are as follows: As of December 31, 2021 2020 2019 Discount rate 2.80 % 2.30 % 3.05 % For the years ended December 31, 2021 2020 weighted average assumptions used to determine the net postretirement benefit expense related to the Canadian Postretirement Benefit Plan are as follows: Years Ended December 31, 2021 2020 2019 Discount rate 2.30 % 3.05 % 3.80 %
Summary of Benefit Payment are Expected in Next Five Year	The following benefit payments are expected to be made as per the current plan assumptions for the Canadian Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2021 balance sheet date: (In thousands of U.S. Dollars) 2022 $ 108 2023 115 2024 112 2025 113 2026 105 Thereafter 1,483 Total $ 2,036

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Summary of Movement of the Non-controlling Interest in Temporary Equity in Original Film Fund	The following summarizes the movement of the non-controlling interest in temporary equity, in the Original Film Fund for the years ended December 31, 2021, 2020 and 2019: (In thousands of U.S. Dollars) Balance as of January 1, 2019 $ 6,439 Return of capital to non-controlling interests (243 ) Share issuance costs from the issuance of subsidiary shares to a non-controlling interest 1,350 Net loss (1,638 ) Balance as of December 31, 2019 5,908 Return of capital to non-controlling interests (10 ) Net loss (5,139 ) Balance as of December 31, 2020 759 Return of capital to non-controlling interests — Net loss (1 ) Balance as of December 31, 2021 $ 758

Description of the Business - A

Description of the Business - Additional Information (Details)	Dec. 31, 2021TheaterSystemCountryMultiplexDestinationInstitutionallocation	Dec. 31, 2020TheaterSystemCountryMultiplexDestinationInstitutionallocation
Description of Business (Textuals) [Abstract]
Number of theater systems operating | TheaterSystem	1,683	1,650
Number of Countries and Territories in which Entity Operates | Country	87	84
Number of commercial multiplexes | Multiplex	1,599	1,562
Number of commercial destinations | Destination	12	12
Number of institutional locations | Institutionallocation	72	76
IMAX China Noncontrolling Interest
Description of Business (Textuals) [Abstract]
Minority Interest Ownership Percentage By Company	71.11%	69.89%

Impact of COVID-19 Pandemic - A

Impact of COVID-19 Pandemic - Additional Information (Details)	Mar. 19, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)Country	Dec. 31, 2020USD ($)	Dec. 31, 2021USD ($)
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from issuance of convertible notes, net			$ 223,675,000
Convertible Notes [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Debt instrument, principal amount	$ 230,000,000	$ 230,000,000	230,000,000		$ 230,000,000
Proceeds from issuance of convertible notes, net	$ 223,700,000	$ 223,700,000
Impact of COVID-19 Pandemic [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies					$ 10,900,000
Impact of COVID-19 Pandemic [Member] | Selling, General and Administrative Expenses [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies			2,900,000	$ 6,000,000
Impact of COVID-19 Pandemic [Member] | Costs and Expenses Applicable to Revenues [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies			$ 900,000	1,000,000
Impact of COVID-19 Pandemic [Member] | Research and Development [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies				$ 100,000
Impact of COVID-19 Pandemic [Member] | IMAX [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open			95.00%		95.00%
Number of countries in which global theater network open | Country			75
Impact of COVID-19 Pandemic [Member] | IMAX [Member] | United States and Canada [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open			99.00%		99.00%
Impact of COVID-19 Pandemic [Member] | IMAX [Member] | Greater China [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open			95.00%		95.00%
Impact of COVID-19 Pandemic [Member] | IMAX [Member] | Rest of the World [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open			91.00%		91.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)Lease	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Significant Accounting Policies [Line Items]
Other equity	$ 174,620	$ 188,845
Non-controlling interests	73,531	70,004
Total shareholders' equity	$ 429,614	464,008	$ 637,187
Number of variable interest entities	ten
Period of revenue estimation from initial film release	10 years
Goodwill	$ 39,027	39,027
Percentage of statutory net profits to statutory surplus reserve to be appropriated	10.00%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital, percent	50.00%
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in the leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Leases include options to purchase leased property | Lease	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Pension policy details	10.00%
Remaining weighted average service life of employee	1.0 year
Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period	3 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life	4 years
Lessee, operating lease, renewal term	1 year
Minimum [Member] | Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage	0.00%
Maximum [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life	10 years
Lessee, operating lease, renewal term	5 years
Maximum [Member] | Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage	175.00%
IMAX Systems Reporting Unit [Member]
Significant Accounting Policies [Line Items]
Goodwill	$ 19,100
Joint Revenue Sharing Arrangements Reporting Unit [Member]
Significant Accounting Policies [Line Items]
Goodwill	13,500
IMAX Maintenance Reporting Unit [Member]
Significant Accounting Policies [Line Items]
Goodwill	$ 6,400
Variable Interest Entity, Primary Beneficiary [Member]
Significant Accounting Policies [Line Items]
Number of variable interest entities primary beneficiary	five
Variable Interest Entity, Not Primary Beneficiary [Member]
Significant Accounting Policies [Line Items]
Number of variable interest entities not a primary beneficiary	five
Revision of Prior Period, Reclassification, Adjustment
Significant Accounting Policies [Line Items]
Other equity		8,500	8,400	$ 500
Non-controlling interests		$ 8,500	$ 8,400	$ 500
Total shareholders' equity	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - VIEs Total Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 883,247	$ 997,750
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	452,875	532,983
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,576	1,543
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	$ 259	$ 230

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2021
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant And Equipment, Useful Life, Maximum	over the shorter of the initial term of the underlying leases plus any reasonably assured renewal terms, and the useful life of the asset
Minimum [Member] | Theater System Components [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years	[1]
Minimum [Member] | Camera Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Buildings [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Minimum [Member] | Office and Production Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Theater System Components [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years	[1]
Maximum [Member] | Camera Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Buildings [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years
Maximum [Member] | Office and Production Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
[1]	Includes equipment under joint revenue sharing arrangements.

Recently Issued Accounting St_2

Recently Issued Accounting Standards Not Yet Adopted - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Credit facility maturity date	Jun. 28, 2023
ASU 2020-04
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Credit facility maturity date	Jun. 28, 2023

Receivables - Summary of Allowa

Receivables - Summary of Allowance For Credit Losses Related to Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 14,295	$ 5,138
Current period provision (reversal), net	(1,452)	9,708
Write-offs	(927)	(975)
Foreign exchange	30	424
Ending balance	11,946	14,295
Theatre Operators [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	8,368	3,302
Current period provision (reversal), net	793	5,793
Write-offs	(357)	(975)
Foreign exchange	63	248
Ending balance	8,867	8,368
Studios [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	4,481	893
Current period provision (reversal), net	(1,913)	3,393
Write-offs	(551)
Foreign exchange	(23)	195
Ending balance	1,994	4,481
Other [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,446	943
Current period provision (reversal), net	(332)	522
Write-offs	(19)
Foreign exchange	(10)	(19)
Ending balance	$ 1,085	$ 1,446

Receivables - Additional Inform

Receivables - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current Expected Credit Losses [Line Items]
Finance income related to net investment in leases with billed amounts past due	$ 0.1	$ 0.2
Finance income related to financed sale receivables with billed amounts past due	3.7	5.7
Finance Income related to the financed sales receivables in nonaccrual status	0.2
Maximum [Member]
Current Expected Credit Losses [Line Items]
Finance Income related to the net investment in leases in nonaccrual status		0.1
Finance Income related to the financed sales receivables in nonaccrual status		0.1
Theatre And Foreign Movie Studio [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, accounts receivables	(2.3)	9.2
Theatre Operators [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, variable consideration receivables	(0.8)	1.9
Theatre Operators [Member] | Variable Consideration Receivables [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) investment in leases and financed sale receivables provision for current expected credit losses	$ (1.6)	$ 6.8

Receivables - Schedule of Finan

Receivables - Schedule of Financing Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net investment in leases
Gross minimum payments due under sales-type leases	$ 29,953	$ 20,830
Unearned finance income	(763)	(859)
Present value of minimum payments due under sales-type leases	29,190	19,971
Allowance for credit losses	(798)	(557)
Net investment in leases	28,392	19,414
Financed sales receivables
Gross minimum payments due under financed sales	152,315	150,917
Unearned finance income	(34,244)	(31,247)
Present value of minimum payments due under financed sales	118,071	119,670
Allowance for credit losses	(5,414)	(7,274)
Net financed sales receivables	112,657	112,396
Total financing receivables	141,049	131,810
Net financed sales receivables due within one year	29,115	34,937
Net financed sales receivables due after one year	83,542	77,459
Net financed sales receivables	$ 112,657	$ 112,396

Receivables - Schedule of Weigh

Receivables - Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Weighted-average remaining lease term (in years)
Sales-type lease arrangements	9 years 7 months 6 days	8 years 3 months 18 days
Weighted-average interest rate
Sales-type lease arrangements	6.56%	6.56%
Financed sales receivables	8.79%	8.92%

Receivables - Schedule of Net I

Receivables - Schedule of Net Investment In Leases by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	$ 11,030	$ 4,148
Net investment leases, By Origination Year, Before latest fiscal year	3,991	8,468
Net investment leases, By Origination Year, Two years before latest fiscal year	7,973	2,730
Net investment leases, By Origination Year, Three years before latest fiscal year	2,574	988
Net investment leases, By Origination Year, Four years before latest fiscal year	823
Net investment leases, By Origination Year, Prior	2,799	3,637
Net Investment in Lease, Total	29,190	19,971
In Good Standing [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	11,030	2,143
Net investment leases, By Origination Year, Before latest fiscal year	3,991	1,190
Net investment leases, By Origination Year, Two years before latest fiscal year	7,973	2,730
Net investment leases, By Origination Year, Three years before latest fiscal year	2,574
Net investment leases, By Origination Year, Four years before latest fiscal year	823
Net investment leases, By Origination Year, Prior	1,928	1,826
Net Investment in Lease, Total	28,319	7,889
Credit Watch [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year		2,005
Net investment leases, By Origination Year, Before latest fiscal year		7,278
Net investment leases, By Origination Year, Three years before latest fiscal year		988
Net investment leases, By Origination Year, Prior		1,047
Net Investment in Lease, Total		11,318
Transactions Suspended [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	871	764
Net Investment in Lease, Total	$ 871	$ 764

Receivables - Schedule of Fin_2

Receivables - Schedule of Financed Sale Receivables by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	$ 12,520	$ 8,816
Financed sales receivables, By Origination Year, Before lastest fiscal year	8,251	11,981
Financed sales receivables, By Origination Year, Two year before latest fiscal year	11,671	14,903
Financed sales receivables, By Origination Year, Three year before latest fiscal year	13,696	17,247
Financed sales receivables, By Origination Year, Four year before latest fiscal year	15,714	17,859
Financed sales receivables, By Origination Year, Prior	56,219	48,864
Financed sales receivables, Total	147,261	139,641
Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	118,071	119,670
In Good Standing [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	12,520	6,830
Financed sales receivables, By Origination Year, Before lastest fiscal year	8,251	5,480
Financed sales receivables, By Origination Year, Two year before latest fiscal year	10,593	3,547
Financed sales receivables, By Origination Year, Three year before latest fiscal year	13,278	3,740
Financed sales receivables, By Origination Year, Four year before latest fiscal year	12,615	5,072
Financed sales receivables, By Origination Year, Prior	47,950	12,660
In Good Standing [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	105,207	37,329
Credit Watch [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year		1,986
Financed sales receivables, By Origination Year, Before lastest fiscal year		6,501
Financed sales receivables, By Origination Year, Two year before latest fiscal year		11,356
Financed sales receivables, By Origination Year, Three year before latest fiscal year		12,520
Financed sales receivables, By Origination Year, Four year before latest fiscal year	321	11,446
Financed sales receivables, By Origination Year, Prior	1,292	34,351
Credit Watch [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	1,613	78,160
Pre-Approved Transactions [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Two year before latest fiscal year	743
Financed sales receivables, By Origination Year, Three year before latest fiscal year	418
Financed sales receivables, By Origination Year, Four year before latest fiscal year	2,098	613
Financed sales receivables, By Origination Year, Prior	3,650	755
Pre-Approved Transactions [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	6,909	1,368
Transactions Suspended [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Two year before latest fiscal year	335
Financed sales receivables, By Origination Year, Three year before latest fiscal year		987
Financed sales receivables, By Origination Year, Four year before latest fiscal year	680	728
Financed sales receivables, By Origination Year, Prior	3,327	1,098
Transactions Suspended [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	$ 4,342	$ 2,813

Receivables - Schedule of Aging

Receivables - Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 12,765	$ 17,116
Unbilled	134,496	122,525
Financed sales receivables, Total	147,261	139,641
Allowance for Credit Losses	(6,212)	(7,831)
Total financing receivables	141,049	131,810
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,648	1,167
Unbilled	27,542	18,804
Financed sales receivables, Total	29,190	19,971
Allowance for Credit Losses	(798)	(557)	$ (155)
Total financing receivables	28,392	19,414
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	11,117	15,949
Unbilled	106,954	103,721
Financed sales receivables, Total	118,071	119,670
Allowance for Credit Losses	(5,414)	(7,274)	$ (915)
Total financing receivables	112,657	112,396
Accrued and Current [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,975	3,605
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	225	298
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,750	3,307
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,145	2,123
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	156	180
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	989	1,943
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	9,645	11,388
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,267	689
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 8,378	$ 10,699

Receivables - Schedule of Net_2

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 12,765	$ 17,116
Unbilled	134,496	122,525
Allowance for Credit Losses	(6,212)	(7,831)
Total financing receivables	141,049	131,810
Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,975	3,605
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,145	2,123
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	9,645	11,388
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,648	1,167
Unbilled	27,542	18,804
Allowance for Credit Losses	(798)	(557)	$ (155)
Total financing receivables	28,392	19,414
Net Investment in Leases [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	225	298
Net Investment in Leases [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	156	180
Net Investment in Leases [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,267	689
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	11,117	15,949
Unbilled	106,954	103,721
Allowance for Credit Losses	(5,414)	(7,274)	$ (915)
Total financing receivables	112,657	112,396
Net Financed Sales Receivables [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,750	3,307
Net Financed Sales Receivables [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	989	1,943
Net Financed Sales Receivables [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	8,378	10,699
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	8,978	14,578
Unbilled	54,058	76,514
Allowance for Credit Losses	(1,589)	(4,744)
Total financing receivables	61,447	86,348
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,102	2,257
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	861	1,713
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	7,015	10,608
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,100	752
Unbilled	12,619	13,912
Allowance for Credit Losses	(176)	(310)
Total financing receivables	13,543	14,354
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	143	231
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	132	162
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	825	359
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	7,878	13,826
Unbilled	41,439	62,602
Allowance for Credit Losses	(1,413)	(4,434)
Total financing receivables	47,904	71,994
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	959	2,026
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	729	1,551
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 6,190	$ 10,249

Receivables - Schedule of Net_3

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	$ 9,513	$ 3,577
Allowance for Credit Losses	(2,666)	(1,500)
Net	6,847	2,077
Net Investment in Leases [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	871	764
Allowance for Credit Losses	(309)	(18)
Net	562	746
Net Financed Sales Receivables [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	8,642	2,813
Allowance for Credit Losses	(2,357)	(1,482)
Net	$ 6,285	$ 1,331

Receivables - Summary of Allo_2

Receivables - Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	$ 7,831
Ending balance	6,212	$ 7,831
Net Investment in Leases [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	557	155
Current period provision (reversal), net	235	451
Write-offs		(69)
Foreign exchange	6	20
Ending balance	798	557
Net Financed Sales Receivables [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	7,274	915
Current period provision (reversal), net	(1,947)	6,574
Write-offs		(330)
Foreign exchange	87	115
Ending balance	$ 5,414	$ 7,274

Receivables - Summary of Allo_3

Receivables - Summary of Allowance For Credit Losses Related to Variable Consideration Receivables (Details) - Theatre Operators [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 1,887
Current period (reversal) provision, net	(787)	$ 1,875
Foreign Exchange	(18)	12
Ending balance	$ 1,082	$ 1,887

Lease Arrangements - Additional

Lease Arrangements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021Lease
Leases [Line Items]
Lessee, operating lease description	The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term.
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in the leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Leases include options to purchase leased property	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor, sales-type lease description	The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system.
Minimum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	1 year
Sales-type lease, lease term	10 years
Non-cancellable term of joint revenue sharing arrangements	10 years
Maximum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	5 years
Sales-type lease, lease term	20 years
Non-cancellable term of joint revenue sharing arrangements	or longer

Lease Arrangements - Components

Lease Arrangements - Components of Lease Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Line Items]
Operating lease cost	[1]	$ 713	$ 540	$ 850
Amortization of lease assets		2,791	3,114	2,370
Interest on lease liabilities		937	1,052	1,102
Total lease cost		$ 4,441	$ 4,706	$ 4,322
[1]	Includes short-term leases and variable lease costs, which are not significant for the years ended December 31, 2021, 2020, and 2019.

Lease Arrangements - Supplement

Lease Arrangements - Supplemental Cash and Non-Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities		$ 3,839	$ 3,743	$ 3,607
Right-of-use assets obtained in exchange for lease obligations	[1]	$ 1,047	$ 563	$ 17,147
[1]	For the ASC Topic

Lease Arrangements - Lessee Ope

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Line Items]
Right-of-Use-Assets	$ 12,132	$ 13,911
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net of accumulated depreciation	Property, plant and equipment, net of accumulated depreciation
Operating Leases	$ 14,691
Accrued and other liabilities [Member]
Leases [Line Items]
Operating Leases	$ 14,691	$ 16,634

Lease Arrangements - Lessee O_2

Lease Arrangements - Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate (Details)	Dec. 31, 2021	Dec. 31, 2019
Lease Cost [Abstract]
Weighted-average remaining lease term (years)	7 years	7 years 7 months 6 days
Weighted-average discount rate	5.97%	5.91%

Lease Arrangements - Lessee O_3

Lease Arrangements - Lessee Operating Lease, Maturity (Details) $ in Thousands	Dec. 31, 2021USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2022	$ 3,364
2023	2,449
2024	2,226
2025	2,075
2026	2,051
Thereafter	5,982
Total lease payments	18,147
Less: interest expense	(3,456)
Present value of operating lease liabilities	$ 14,691
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Accrued and other liabilities

Lease Arrangements - Schedule o

Lease Arrangements - Schedule of Maturities of Lease Receivables (Details) $ in Thousands	Dec. 31, 2021USD ($)
Sales-type leases
2022	$ 3,590
2023	3,145
2024	3,086
2025	2,933
2026	2,694
Thereafter	14,505
Total	29,953
Joint Revenue Sharing Arrangements
2022	190
2023	128
Total	$ 318

Variable Consideration Receiv_3

Variable Consideration Receivable from Contracts With Customers - Summary of Variable Consideration Receivable from Contracts With Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Change In Contract With Customer Asset [Abstract]
Balance Beginning	$ 40,526	$ 40,040	$ 35,985
Variable consideration for newly recognized sales	4,696	5,550	9,948
Accretion to finance income	1,985	2,133	1,936
True-up of variable consideration receivable			979
Transferred to receivables from variable consideration assets	(3,794)	(5,310)	(8,808)
Movement in allowance for credit losses	805	(1,887)
Balance Ending	$ 44,218	$ 40,526	$ 40,040

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 20,551	$ 30,096
Work-in-process	1,406	3,014
Finished goods	4,967	6,470
Total	$ 26,924	$ 39,580

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventories (Textuals) [Abstract]
Finished goods inventory with title passed to customer	$ 2.6	$ 2.1

Inventories - Summary of Invent

Inventories - Summary of Inventory Valuation Allowance Account (Details) - Inventory Valuation Allowance [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Balance at beginning of year		$ 5,752	$ 3,216	$ 3,885
Additions charged to expenses	[1]	629	3,028	446
Other deductions	[2]	(1,484)	(492)	(1,115)
Balance at end of year		$ 4,897	$ 5,752	$ 3,216
[1]	Excludes amounts charged directly to the Consolidated Statements of Operations of $0.3 million, $0.6 million, and $nil during the years ended December 31, 2021, 2020 and 2019, respectively.
[2]	Includes the write-off of amounts previously charged to valuation allowance.

Inventories - Summary of Inve_2

Inventories - Summary of Inventory Valuation Allowance Account (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inventory [Abstract]
Inventory charged to statement of operation	$ 0.3	$ 0.6

Film Assets - Film Assets (Deta

Film Assets - Film Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Film Costs [Abstract]
Completed and released films, net of accumulated amortization of $218,148 (2020 - $202,832)	$ 2,292	$ 2,678
Films in production	195	195
Films in development	1,754	2,904
Film Costs, Total	$ 4,241	$ 5,777

Film Assets - Film Assets (Pare

Film Assets - Film Assets (Parenthetical) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Film Costs [Abstract]
Accumulated amortization	$ 218,148	$ 201,832

Film Assets - Additional Inform

Film Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Film Assets [Line Items]
Film costs expected to be amortized within three years from balance sheet date				$ 4.1
Amount of participation payments expected to be made to third parties in the next operating cycle				3.3	$ 2.7
Documentary film asset impairments				$ 0.2	$ 10.8	$ 1.4
Forecast [Member]
Film Assets [Line Items]
Film costs, amortized in next operating cycle	$ 0.1	$ 0.5	$ 3.5

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
Property, plant and equipment
Cost		$ 512,336	$ 501,384
Accumulated Depreciation		251,983	223,987
Net Book Value		260,353	277,397
Theater System Components [Member]
Property, plant and equipment
Cost	[1],[2],[3]	346,517	337,271
Accumulated Depreciation	[1],[2],[3]	181,936	158,647
Net Book Value	[1],[2],[3]	164,581	178,624
Camera Equipment [Member]
Property, plant and equipment
Cost		4,855	5,399
Accumulated Depreciation		3,214	4,653
Net Book Value		1,641	746
Equipment leased or held for use [Member]
Property, plant and equipment
Cost		351,372	342,670
Accumulated Depreciation		185,150	163,300
Net Book Value		166,222	179,370
Asset under Construction [Member]
Property, plant and equipment
Cost	[4]	10,232	5,660
Accumulated Depreciation	[4]	0	0
Net Book Value	[4]	10,232	5,660
Right Of Use Assets
Property, plant and equipment
Cost	[5]	14,429	15,553
Accumulated Depreciation	[5]	2,297	1,642
Net Book Value	[5]	12,132	13,911
Land [Member]
Property, plant and equipment
Cost		8,203	8,203
Accumulated Depreciation		0	0
Net Book Value		8,203	8,203
Buildings [Member]
Property, plant and equipment
Cost		80,973	80,875
Accumulated Depreciation		28,873	25,921
Net Book Value		52,100	54,954
Office and Production Equipment [Member]
Property, plant and equipment
Cost	[6]	39,017	40,362
Accumulated Depreciation	[6]	31,169	29,156
Net Book Value	[6]	7,848	11,206
Leasehold Improvements [Member]
Property, plant and equipment
Cost		8,110	8,061
Accumulated Depreciation		4,494	3,968
Net Book Value		3,616	4,093
Other property, plant and equipment [Member]
Property, plant and equipment
Cost		136,303	137,501
Accumulated Depreciation		64,536	59,045
Net Book Value		$ 71,767	$ 78,456
[1]	In 2021, the Company recorded charges of $0.4 million (2020 — $1.8 million; 2019 — $2.2 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased IMAX Xenon Theater Systems which were taken out of service in connection with customer upgrades to IMAX Laser Theater Systems.
[2]	Included in theater system components are assets with costs of $324.3 million (2020 — $315.4 million) and accumulated depreciation of $166.5 million (2020 — $144.7 million) that are used in joint revenue sharing arrangements.
[3]	Included in theater system components are assets with costs of $7.6 million (2020 — $7.6 million) and accumulated depreciation of $7.0 million (2020 — $6.8 million) that are leased to customers under operating leases.
[4]	Included in assets under construction are components with costs of $9.2 million (2020 — $5.3 million) that will be utilized to construct assets to be used in joint revenue sharing arrangements.
[5]	The right-of-use assets primarily include operating leases for office and warehouse space.
[6]	Fully depreciated office and production equipment is still in use by the Company. In 2021, the Company identified and wrote off $0.5 million (2020 — $0.9 million) of office and production equipment that is fully depreciated and no longer in use.

Property, Plant and Equipment_2

Property, Plant and Equipment - Property, Plant and Equipment (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Theater System Components [Member]
Property, plant and equipment
Assets leased to customers under operating lease, Gross	$ 7.6	$ 7.6
Accumulated Depreciation, assets leased to customers under operating lease	7	6.8
Assets under joint revenue sharing arrangements included in Theater system components	324.3	315.4
Accumulated Depreciation , Assets under joint revenue sharing arrangements included in Theater system components	166.5	144.7
Theater system components written off in Costs and expenses	0.4	1.8	$ 2.2
Asset under Construction [Member]
Property, plant and equipment
Assets under joint revenue sharing arrangements included in Assets under construction	9.2	5.3
Office and Production Equipment [Member]
Property, plant and equipment
Fully amortized office and production equipment written off in the period	$ 0.5	$ 0.9

Property, Plant and Equipment_3

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other property, plant and equipment [Member]
Property Plant And Equipment [Line Items]
Property plant and equipment write downs no longer in use	$ 0.2	$ 0.2	$ 0.2

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Assets [Abstract]
Lease incentives provided to theater customers, net of accumulated amortization	$ 14,834	$ 15,651
Commissions and other deferred selling expenses	1,418	2,608
Other investments	1,000	1,000
Foreign currency derivatives	184	1,979
Other	363	435
Other assets, total	$ 17,799	$ 21,673

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Taxes by Jurisdiction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	$ 10,987	$ (129,124)	$ 75,336
Canada [Member]
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	(55,480)	(104,166)	884
United States [Member]
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	3,218	(6,437)	(234)
China [Member]
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	53,792	(8,253)	51,809
Ireland [Member]
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	829	(7,473)	17,630
Other [Member]
Income Taxes Disclosure [Line Items]
Income (loss) before income taxes	$ 8,628	$ (2,795)	$ 5,247

Income Taxes - Schedule of In_2

Income Taxes - Schedule of Income Tax (Expense) Benefit (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		$ (17,568)	$ (2,886)	$ (10,006)
Deferred income tax (expense) benefit, Total		(2,996)	(23,618)	(6,762)
Total	[1]	(20,564)	(26,504)	(16,768)
Canada [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(915)	555	2,369
Deferred income tax (expense) benefit, Total	[2]	(231)	(10,801)	(3,913)
United States [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(1,038)	488	595
Deferred income tax (expense) benefit, Total		(1,268)	867	(949)
China [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(11,045)	(1,980)	(11,789)
Deferred income tax (expense) benefit, Total	[3]	(381)	(15,756)	(18)
Ireland [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(1,358)	(1,462)	(762)
Deferred income tax (expense) benefit, Total		(997)	2,161	(1,923)
Other [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(3,212)	(487)	(419)
Deferred income tax (expense) benefit, Total		$ (119)	$ (89)	$ 41
[1]	For the year ended December 31, 2021, Income Tax (Expense) Benefit excludes a tax benefit of $0.3 million included in Other Comprehensive Income (2020 — benefit of $0.1 million; 2019 — expense of $(0.4) million).
[2]	A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is needed.
[3]	In 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $19.1 million in 2020 for the estimated applicable foreign withholding taxes associated with these historical earnings, which will become payable upon the repatriation of any such earnings. In 2021, the deferred tax liability for the applicable foreign withholding taxes was increased by $0.5 million due to an increase in the amount of distributable historical earnings. During the year ended December 31, 2021, $20.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.0 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2021 is $17.6 million

Income Taxes - Schedule of In_3

Income Taxes - Schedule of Income Tax (Expense) Benefit (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Disclosure [Line Items]
Deferred tax asset, valuation allowance	$ 46,014	$ 28,786
Deferred income tax asset, valuation allowance change	17,200
Deferred tax liability	17,642	19,134
Increase in applicable foreign withholding taxes of deferred tax liability	500
Deferred income tax (benefit) expense	2,996	23,618	$ 6,762
Payment of foreign withholding taxes	2,000
Other comprehensive income, income tax effect	286	55	(378)
Canada [Member]
Income Taxes Disclosure [Line Items]
Deferred tax asset, valuation allowance	17,200	28,600
Foreign Country [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax (benefit) expense	1,268	(867)	$ 949
Foreign Country [Member] | China [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax (benefit) expense	20,400	20,400
Shareholder's Equity [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax asset, valuation allowance change	2,500
Income Tax Expense [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax asset, valuation allowance change	$ 14,700	$ 28,600

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Expense to Statutory Rates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]
Income tax (expense) benefit at combined statutory rates, Amount	$ (2,912)	$ 34,218	$ (19,964)
NCI share of partnership losses, Amount	(1)	(1,229)	(397)
Increase in valuation allowance, Amount	(14,722)	(28,589)	0
Changes to tax reserves, Amount	3,508	(2,699)	1,418
U.S. federal and state taxes, Amount	(80)	(250)	(300)
Withholding taxes, Amount	(4,199)	(20,943)	(1,071)
Income tax at different rates in foreign and other provincial jurisdictions, Amount	3,352	(2,607)	5,019
Investment and other tax credits (non-refundable), Amount	413	643	701
Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments, Amount	(5,336)	(1,219)	(1,998)
Other non-deductible/non-taxable items, Amount	(587)	(3,829)	(176)
Income tax expense	$ (20,564)	$ (26,504)	$ (16,768)
Income tax (expense) benefit at combined statutory rates, Rate	26.50%	26.50%	26.50%
NCI share of partnership losses, Rate	0.00%	(1.00%)	0.50%
Increase in valuation allowance, Rate	134.00%	(22.10%)	0.00%
Changes to tax reserves, Rate	(31.90%)	(2.10%)	(1.90%)
U.S. federal and state taxes, Rate	0.70%	(0.20%)	0.40%
Withholding taxes, Rate	38.20%	(16.20%)	1.40%
Income tax at different rates in foreign and other provincial jurisdictions, Rate	(30.50%)	(2.00%)	(6.70%)
Investment and other tax credits (non-refundable), Rate	(3.80%)	0.50%	(0.90%)
Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments, Rate	48.60%	(0.90%)	2.70%
Other non-deductible/non-taxable items, Rate	5.40%	(3.00%)	0.30%
Income tax expense	187.20%	(20.50%)	22.30%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets Net [Abstract]
Net operating loss carryforwards	$ 21,219	$ 17,120
Investment tax credit and other tax credit carryforwards	3,919	1,344
Write-downs of other assets	1,223	1,219
Excess of tax accounting basis in various assets	13,929	9,692
Accrued pension liability	6,901	6,942
Accrued share-based compensation	7,728	7,350
Income recognition on net investment in leases	(3,368)	(2,018)
Other accrued reserves	8,369	5,120
Total deferred income tax assets	59,920	46,769
Valuation allowance	(46,014)	(28,786)
Deferred income tax asset net of valuation allowance	13,906	17,983
Deferred tax liability	(17,642)	(19,134)
Net deferred tax liability	$ (3,736)	$ (1,151)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Income Tax Contingency [Line Items]
Deferred tax assets, Other	$ 300	$ 300		$ 600
Investment tax credits and other tax credit carryforward, expiration period		2041
Net Operating Loss Carryforwards, Limitations on Use		Estimated United States and Canadian net operating loss carryforwards of $93.2 million can be used to reduce taxable income through 2041 and $21.9 million can be carried forward indefinitely. Investment tax credits and other tax credits can be carried forward to reduce income taxes payable through to 2041.
Deferred tax liability	17,642	$ 17,642		19,134
Increase in applicable foreign withholding taxes of deferred tax liability		500
Deferred income tax asset after valuation allowance	13,906	13,906		17,983
Deferred tax asset, valuation allowance	46,014	46,014		28,786
Deferred income tax asset, valuation allowance change		17,200
Deferred income tax (benefit) expense		2,996		23,618		$ 6,762
Payment of foreign withholding taxes		2,000
Provision for uncertain tax positions recorded to income tax provision		2,100		600		1,400
Total tax reserves (including interest and penalties)	13,900	13,900		17,400
Interest and penalty associated with tax reserves		(1,400)		3,300		200
Payment of income taxes	8,900	18,475	[1]	4,763	[1]	17,298	[1]
Income tax receivable	8,900	8,900
Canada Revenue Agency [Member]
Income Tax Contingency [Line Items]
Payment of income taxes	1,600
Income tax receivable	1,600	$ 1,600
Canada Revenue Agency [Member] | Minimum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction		2016
Canada Revenue Agency [Member] | Maximum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction		2021
Internal Revenue Service (IRS) [Member] | Minimum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction		2017
Internal Revenue Service (IRS) [Member] | Maximum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction		2021
Impact of COVID-19 Pandemic [Member]
Income Tax Contingency [Line Items]
Deferred tax asset, valuation allowance	17,200	$ 17,200		28,600
Shareholder's Equity [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change		2,500
Income Tax Expense [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change		$ 14,700		28,600
United States and Canada [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards, expiration period		2041
Net Operating Loss Carryforwards	93,200	$ 93,200
Remaining net operating loss carryforwards	21,900	21,900
Foreign Country [Member]
Income Tax Contingency [Line Items]
Deferred income tax (benefit) expense		1,268		(867)		$ 949
Payment of income taxes	$ 8,900
Foreign Country [Member] | China [Member]
Income Tax Contingency [Line Items]
Deferred income tax (benefit) expense		$ 20,400		$ 20,400
[1]	In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest.

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Beginning and Ending Amount of Tax Reserves (excluding interest and penalties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of beginning and ending amount of tax reserves (excluding interest and penalties)
Balance at beginning of the year	$ 14,076	$ 14,718	$ 16,136
Additions based on tax positions related to the current year	37	2,301	812
Reductions for tax positions of prior years	(991)		(2,230)
Reductions resulting from lapse of applicable statute of limitations and administrative practices	(1,183)	(2,943)
Balance at the end of the year	$ 11,939	$ 14,076	$ 14,718

Income Taxes - Income Tax Benef

Income Taxes - Income Tax Benefit (Expense) Included in the Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Unrealized defined benefit plan actuarial (gain) loss	$ (37)	$ 276	$ (42)
Unrealized postretirement benefit plans actuarial (gain) loss	(35)	92	0
Prior service cost arising during the period	0	0	145
Amortization of prior service cost	(48)	(23)	(26)
Unrealized change in cash flow hedging instruments	(123)	(132)	(145)
Realized change in cash flow hedging instruments	446	(158)	(310)
Reclassification of unrealized change in ineffective cash flow hedging instruments	83	0	0
Income tax effect on comprehensive (loss) income	$ 286	$ 55	$ (378)

Other Intangible Assets - Summa

Other Intangible Assets - Summary of Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Intangible Assets
Other Intangible Assets, Cost	$ 68,171	$ 65,336
Other Intangible Assets, Accumulated Amortization	45,091	39,091
Other Intangible Assets, Net Book Value	23,080	26,245
Patents and Trademarks [Member]
Other Intangible Assets
Other Intangible Assets, Cost	12,834	12,714
Other Intangible Assets, Accumulated Amortization	9,406	8,878
Other Intangible Assets, Net Book Value	3,428	3,836
Licenses and Intellectual Property [Member]
Other Intangible Assets
Other Intangible Assets, Cost	26,168	26,168
Other Intangible Assets, Accumulated Amortization	13,642	12,182
Other Intangible Assets, Net Book Value	12,526	13,986
Internal Use Software [Member]
Other Intangible Assets
Other Intangible Assets, Cost	28,571	25,009
Other Intangible Assets, Accumulated Amortization	21,544	17,568
Other Intangible Assets, Net Book Value	7,027	7,441
Other [Member]
Other Intangible Assets
Other Intangible Assets, Cost	598	1,445
Other Intangible Assets, Accumulated Amortization	499	463
Other Intangible Assets, Net Book Value	$ 99	$ 982

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Net book value of patents and trademarks disposed of in the year	$ 100	$ 200
Capitalized other intangible assets, cost	68,171	65,336
Net book value of other intangible assets capitalized	$ 3,900	$ 2,600
Weighted average amortization period for additions to other intangible assets	2 years 3 months 18 days	6 years 7 months 6 days
Costs incurred to renew or extend the term of acquired patents and trademarks	$ 100	$ 400
Internal Use Software, Patents And Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized other intangible assets, cost	$ 4,100	$ 2,800

Other Intangible Assets - Sum_2

Other Intangible Assets - Summary of Estimated Amortization Expenses (Details) $ in Thousands	Dec. 31, 2021USD ($)
Other Intangible Assets Additional Textuals [Abstract]
2022	$ 6,225
2023	6,225
2024	4,899
2025	2,056
2026	$ 1,704

Debt - Revolving Credit Facilit

Debt - Revolving Credit Facility Borrowings, Net (Details) $ in Thousands	Dec. 31, 2021USD ($)	Dec. 31, 2021CNY (¥)	Dec. 31, 2020USD ($)	Dec. 31, 2020CNY (¥)
Bank indebtedness [Line Items]
Unamortized debt issuance costs	$ (1,140)		$ (1,967)
Revolving Credit Facility Borrowings, net	2,472		305,676
Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings			300,000
Working Capital Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 3,612	¥ 23,000,000	$ 7,600	¥ 49,900,000

Debt - Additional Information (

Debt - Additional Information (Details)

Jul. 28, 2021USD ($)

Jul. 27, 2021USD ($)

Mar. 19, 2021USD ($)

Jun. 10, 2020

Mar. 31, 2021USD ($)

Jun. 30, 2021USD ($)

Dec. 31, 2021USD ($)$ / shares

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2021CNY (¥)

Jul. 01, 2021USD ($)

Jul. 01, 2021CNY (¥)

Dec. 31, 2020CNY (¥)

Oct. 28, 2019USD ($)

Borrowings (Textual) [Abstract]

Current borrowing capacity

$ 300,000,000

Credit facility description

The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The Credit Facility provided by the Credit Agreement matures on June 28, 2023.

Credit facility maturity date

Jun. 28, 2023

Repayment of outstanding indebtedness

$ 307,609,000

$ 55,000,000

Line of credit facility covenant terms

The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as of the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00.

Effective interest rate

2.64%

2.38%

Letters of guarantee outstanding

$ 500,000

$ 0

¥ 2,800,000

Proceeds from issuance of convertible notes, net

223,675,000

Debt issuance costs paid

$ 527,000

1,073,000

Working Capital Facility [Member]

Borrowings (Textual) [Abstract]

Current borrowing capacity

$ 31,400,000

¥ 200,000,000

Credit facility description

On July 1, 2021, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Chinese Renminbi (“RMB”) (approximately $31.4 million), including RMB 10.0 million (approximately $1.6 million) for letters of guarantee, to fund ongoing working capital requirements (the “Working Capital Facility”).

Borrowings

$ 3,612,000

$ 7,600,000

23,000,000

¥ 49,900,000

Effective interest rate

4.31%

4.31%

Letters of guarantee outstanding

$ 1,600

¥ 10,000

Line of credit facility expiration period

2022-07

Remaining borrowing capacity

$ 26,200,000

¥ 167,000,000

Convertible Notes [Member]

Borrowings (Textual) [Abstract]

Borrowings

230,000,000

Debt instrument, principal amount

$ 230,000,000

$ 230,000,000

$ 230,000,000

Debt instrument, annual interest rate

0.50%

0.50%

0.50%

Proceeds from issuance of convertible notes, net

$ 223,700,000

$ 223,700,000

Debt issuance costs paid

$ 1,200,000

Debt instrument, frequency of periodic interest payment

semi-annually

Debt instrument, payment terms

The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.

Debt instrument, date of first required payment

Oct. 1, 2021

Debt instrument, maturity date

Apr. 1, 2026

Debt instrument, convertible, terms of conversion feature

Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $28.75 per common share, and is subject to adjustment upon the occurrence of certain events.

Debt instrument, initial conversion rate per $1,000 principal amount

34.7766

Convertible notes principal amount

$ 1,000

Debt instrument, initial conversion price | $ / shares

$ 28.75

Debt instrument, redemption, description

The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption

Convertible Notes [Member] | Call Option [Member]

Borrowings (Textual) [Abstract]

Cap price of capped call transactions | $ / shares

37.2750

Percentage of premium of cap price over last reported sale price per common share on March 16, 2021

75.00%

Cost of capped call transactions

$ 19,100,000

Reduction to other equity

19,100,000

Credit Facility [Member]

Borrowings (Textual) [Abstract]

Current borrowing capacity

$ 300,000,000

Amount drew down in available borrowing capacity

280,000,000

Repayment of outstanding indebtedness

$ 300,000,000

Borrowings

0

Letters of credit or advance payment guarantees

$ 0

0

Line of credit facility covenant terms

On March 15, 2021, the Company entered into the Second Amendment to the Credit Agreement (as previously amended by the First Amendment to the Credit Agreement, dated as of June 10, 2020). On July 28, 2021, and December 13, 2021, the Company entered into the Third and Fourth Amendments to the Credit Agreement, respectively (collectively, the “Amendments”). The Amendments, among other things, (i) suspend the Senior Secured Net Leverage Ratio covenant through the first quarter of 2022, (ii) re-establish the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of EBITDA for the corresponding quarters of 2021, (iii) add a $75.0 million minimum liquidity covenant measured at the end of each calendar month, (iv) restrict the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement, (v) permit the issuance of the Convertible Notes (as discussed below) and related transactions, including the capped call transactions, or other unsecured debt, in an amount not to exceed $290.0 million, (vi) allow $30.0 million in permitted repurchases of the Company’s common shares, subject to a $300.0 million pro forma minimum liquidity covenant, (vii) increase permitted repurchases of the common shares of IMAX China from $5.0 million to $20.0 million, subject to pro forma compliance with the existing financial covenants set forth in the Credit Agreement, and (viii) facilitate a transition from a LIBOR-based interest rate to an interest rate based on the Euro Interbank Offered Rate for non-USD denominated loans. The modifications to the negative covenants, the minimum liquidity covenant, permitted share repurchases and modifications to certain other provisions in the Credit Agreement pursuant to the Amendments are effective until the earlier of the delivery of the compliance certificate for the fourth quarter of 2022 or the date on which the Company, in its sole discretion, elects to calculate its compliance with the Senior Secured Net Leverage Ratio by using either its actual EBITDA or annualized EBITDA (the “Designated Period”). As of December 31, 2021, the Company was in compliance with all of its requirements under the Credit Agreement, as amended.

Compliance with covenants

As of December 31, 2021, the Company was in compliance with all of its requirements under the Credit Agreement, as amended.

Liquidity covenant minimum

$ 75,000,000

Debt instrument, permitted repurchase amount

30,000,000

Line of credit facility pro forma minimum liquidity covenant

$ 300,000,000

Line of credit facility Increase in permitted repurchases of pro forma compliance

$ 20,000,000

$ 5,000,000

Interest rate description

Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the year ended December 31, 2021 was 2.64% (2020 — 2.38%).

Standby fees percentage

0.50%

Fees incurred with amendments

$ 1,600,000

Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

2.50%

Credit Facility [Member] | Base Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.75%

Letter of Credit | Working Capital Facility [Member]

Borrowings (Textual) [Abstract]

Remaining borrowing capacity

1,100,000

¥ 7,200,000

Wells Fargo Foreign Exchange Facility [Member]

Borrowings (Textual) [Abstract]

Unrealized gain (loss) on outstanding foreign currency forward contracts

100,000

2,000,000

Notional Amount of arrangements entered into

26,700,000

26,400,000

NBC Facility [Member]

Borrowings (Textual) [Abstract]

Current borrowing capacity

$ 5,000,000

Remaining borrowing capacity

$ 0

$ 0

Line of credit facility renewed date

Oct. 15, 2021

Minimum [Member]

Borrowings (Textual) [Abstract]

Borrowing capacity under uncommitted accordion feature

$ 440,000,000

Minimum [Member] | Convertible Notes [Member]

Borrowings (Textual) [Abstract]

Percentage of last reported sale price per common share against conversion price for specific period of time

130.00%

Minimum [Member] | Credit Facility [Member]

Borrowings (Textual) [Abstract]

Standby fees percentage

0.25%

Minimum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.00%

Minimum [Member] | Credit Facility [Member] | Base Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

0.25%

Maximum [Member] | Credit Facility [Member]

Borrowings (Textual) [Abstract]

Debt instrument net leverage ratio

3.25

Line of credit facility covenant capacity

$ 290,000,000

Standby fees percentage

0.38%

Maximum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.75%

Maximum [Member] | Credit Facility [Member] | Base Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.00%

Debt - Summary of Convertible N

Debt - Summary of Convertible Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Bank indebtedness [Line Items]
Unamortized discounts and debt issuance costs	$ (1,140)	$ (1,967)
Revolving Credit Facility Borrowings, net	223,641
Convertible Notes [Member]
Bank indebtedness [Line Items]
Borrowings	230,000
Unamortized discounts and debt issuance costs	(6,359)
Revolving Credit Facility Borrowings, net	$ 223,641

Commitments - Summary of Compan

Commitments - Summary of Company's Contractual Obligations and Commitments (Details) $ in Thousands	Dec. 31, 2021USD ($)
Purchase obligations
Purchase obligations, Total	$ 34,084	[1]
Less Than One Year, Purchase obligations	33,907	[1]
1 to 3 years, Purchase obligations	42	[1]
3 to 5 years, Purchase obligations	0	[1]
Thereafter, Purchase obligations	135	[1]
Operating lease obligations
Total lease payments	18,147
Less Than One Year, Operating Leases	3,364
Thereafter, Operating Leases	5,982
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	315,068
Less Than One Year, Total contractual obligations and commitments	42,546
1 to 3 years, Total contractual obligations and commitments	27,575
3 to 5 years, Total contractual obligations and commitments	236,114
Thereafter, Total contractual obligations and commitments	8,833
Convertible Notes [Member]
Working Capital Facility
Working Capital Facility, Total	230,000
Less Than One Year, Working Capital Facility	1,150	[2]
1 to 3 years, Working Capital Facility	2,300	[2]
3 to 5 years, Working Capital Facility	231,725	[2]
Thereafter, Working Capital Facility	0	[2]
Convertible Notes, Total	235,175	[2]
Working Capital Facility [Member]
Working Capital Facility
Working Capital Facility, Total	3,612	[3]
Less Than One Year, Working Capital Facility	3,612	[3]
1 to 3 years, Working Capital Facility	0	[3]
3 to 5 years, Working Capital Facility	0	[3]
Thereafter, Working Capital Facility	0	[3]
Operating Lease Obligations
Operating lease obligations
Total lease payments	18,833	[4]
Less Than One Year, Operating Leases	3,760	[4]
1 to 3 years, Operating Leases	4,669	[4]
3 to 5 years, Operating Leases	4,127	[4]
Thereafter, Operating Leases	6,277	[4]
Pension Obligations [Member]
Pension and Postretirement benefits obligations
Total expected future benefit payment	20,298	[5]
Less Than One Year	0	[5]
1 to 3 years	20,298	[5]
3 to 5 years	0	[5]
Thereafter	0	[5]
Postretirement Benefits Obligations [Member]
Pension and Postretirement benefits obligations
Total expected future benefit payment	3,066
Less Than One Year	117
1 to 3 years	266
3 to 5 years	262
Thereafter	$ 2,421
[1]	Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced.
[2]	The Convertible Notes bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The Convertible Notes will mature on April 1, 2026, unless earlier repurchased, redeemed or converted.
[3]	The Working Capital Facility
[4]	Represents total minimum annual rental payments due under the Company’s operating leases, which almost entirely relates to leased office space in New York. (See Note 6.)
[5]	The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. ( See Note 23.)

Commitments - Summary of Comp_2

Commitments - Summary of Company's Contractual Obligations and Commitments (Parenthetical) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Mar. 19, 2021
Borrowings (Textual) [Abstract]
Credit facility description	The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The Credit Facility provided by the Credit Agreement matures on June 28, 2023.
Working Capital Facility [Member]
Borrowings (Textual) [Abstract]
Credit facility description	On July 1, 2021, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Chinese Renminbi (“RMB”) (approximately $31.4 million), including RMB 10.0 million (approximately $1.6 million) for letters of guarantee, to fund ongoing working capital requirements (the “Working Capital Facility”).
Line of credit facility expiration period	2022-07
Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Debt instrument, annual interest rate	0.50%		0.50%
Debt instrument, principal amount	$ 230,000,000	$ 230,000,000	$ 230,000,000
Debt instrument, frequency of periodic interest payment	semi-annually
Debt instrument, payment terms	The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.
Debt instrument, date of first required payment	Oct. 1, 2021
Debt instrument, maturity date	Apr. 1, 2026

Commitments - Additional Inform

Commitments - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Accrued commission on sale or lease of the theater systems payable in future periods	$ 1.1	$ 1.6

Contingencies and Guarantees -

Contingencies and Guarantees - Additional Information (Details) - USD ($)	Dec. 03, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 27, 2008	Dec. 02, 2011	Jun. 30, 2021	Jun. 23, 2021
Contingencies And Guarantees Disclosure Textual [Abstract]
Final Award in favor of company				amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Final Award amount issued				$ 11,300,000
Final Award additional interest each day				$ 2,512
Final Award settlement cost					$ 30,000
Award inclusive of interest		$ 24,400,000
Damages awarded	$ 11,300,000
Litigation liability related to Final Judgment			$ 11,300,000
Amounts collected in respect of theater systems not delivered			7,200,000
Legal judgement and arbitration awards		(1,770,000)	4,105,000
Litigation liability paid						$ 9,500,000
Litigation settlement expense reversed							$ 1,800,000
Benefit of legal judgement and arbitration awards							$ 1,800,000
Product warranty accrual			100,000
Indemnification of its directors/officers		0	0
Other Indemnification		$ 0	$ 0

Capital Stock - Summary of Sett

Capital Stock - Summary of Settlement of Stock Option and RSU Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Plan trustee purchases	0	200,000
Cash proceeds from stock option exercises	$ 883		$ 2,404
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued from treasury	41,613		19,088
Plan trustee purchases			67,840
Total stock options exercised	41,613		86,928
Cash proceeds from stock option exercises			$ 1,752
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued from treasury	531,629	42,982
Plan trustee purchases	723	386,297	404,719
Shares withheld for tax withholdings	157,546	24,714	29,577
Total RSUs vested	689,898	453,993	434,296

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) $ / shares in Units, $ / shares in Units, ¥ in Millions, $ in Millions	12 Months Ended						55 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021CNY (¥)shares	Dec. 31, 2021HKD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020HKD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021CNY (¥)shares	Jun. 02, 2021shares	Apr. 30, 2021USD ($)	Dec. 31, 2018shares	Jul. 01, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs recorded for the period | $	$ 25,600,000			$ 21,500,000		$ 22,800,000
Stock-based compensation expense | $	$ 25,614,000			$ 21,493,000		$ 22,830,000
Common stock, shares outstanding	58,653,642			58,921,008			58,653,642	58,653,642
Common shares purchased in open market by trustee in connection with RSUs	0	0	0	200,000	200,000
Weighted average price of common shares purchased in open market by trustee in connection with RSUs | $ / shares				$ 15.43
Number of treasury shares held in trust for future settlement of share based awards				723	723
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units	6,131,792	6,131,792	6,131,792	6,999,667	6,999,667	5,809,468
Percentage of statutory net profits to statutory surplus reserve to be appropriated	10.00%						10.00%	10.00%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital, percent	50.00%						50.00%	50.00%
Statutory surplus reserve appropriated	$ 5,600,000						$ 5,600,000	¥ 36.4
Dividends declared and paid	$ 20,400,000	¥ 131.6
Statutory surplus reserve to its subsidiaries registered capital percent	50.00%						50.00%	50.00%
IMAX China
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program	In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.	In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.	In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.
Repurchase of common shares	6,664,700	6,664,700	6,664,700	906,400	906,400
Stock Acquired, Average Cost per Share | (per share)	$ 1.50		$ 11.68	$ 1.68	$ 13.07
Repurchase of common shares, value	$ 10,000,000		$ 77.8	$ 1,500,000	$ 11.9
Stock Repurchase Program, maximum percentage of shares to be repurchased	10.00%						10.00%	10.00%
Stock Repurchase Program, Authorized number of shares	34,835,824						34,835,824	34,835,824
Share repurchase limit determined date	May 6, 2021	May 6, 2021	May 6, 2021
Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program	In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.	In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.	In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount | $	$ 75,500,000						$ 75,500,000					$ 200,000,000
Stock Repurchase Program Expiration Date	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2022
Repurchase of common shares	841,331	841,331	841,331	2,484,123	2,484,123
Stock Acquired, Average Cost per Share | $ / shares	$ 16.51			$ 14.72
Repurchase of common shares, value | $	$ 13,900,000			$ 36,600,000
Statutory surplus reserve appropriated | $	3,900,000						3,900,000
Non-controlling Interests [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares, value | $	5,797,000			$ 858,000		$ 9,520,000
Statutory surplus reserve appropriated | $	$ 1,700,000						$ 1,700,000
EBITDA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding	1,073,458						1,073,458	1,073,458
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of performance stock units vesting	175.00%	175.00%	175.00%
Maximum [Member] | Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Repurchase Program, Authorized Amount | $										$ 89,400,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of performance stock units vesting	0.00%	0.00%	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved common shares for future issuance	5,807,445			15,486,807			5,807,445	5,807,445
Options outstanding	3,736,157			4,892,962		5,732,209	3,736,157	3,736,157			5,465,046
Options common shares were vested and exercisable	3,488,107			4,311,761			3,488,107	3,488,107
Income tax benefit from stock based compensation | $	$ 100,000			$ 100,000		$ 1,900,000
Options fully vested and unvested, weighted average exercise price | $ / shares	$ 26.61						$ 26.61
Aggregate intrinsic value of vested stock options | $	$ 0						$ 0
Options fully vested and unvested, weighted average remaining contractual life	4 years 1 month 6 days	4 years 1 month 6 days	4 years 1 month 6 days
Options exercisable intrinsic value | $	$ 41,613,000						$ 41,613,000
Intrinsic value of options exercised | $	100,000			0		200,000
Stock-based compensation expense | $	$ 1,064,000			$ 1,847,000		$ 8,329,000
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units	3,736,157	3,736,157	3,736,157	4,892,962	4,892,962	5,732,209
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period	4 years	4 years	4 years
Stock based awards expiration period or remaining contractual life	10 years	10 years	10 years
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding	613,405			361,844			613,405	613,405
RSU awards, granted to non-employees	309,574	309,574	309,574	370,265	370,265
Stock-based compensation expense | $	$ 5,322,000			$ 2,563,000
Unrecognized share based compensation expense | $	$ 9,300,000
Weighted average term expense expected recognized	1 year 8 months 12 days	1 year 8 months 12 days	1 year 8 months 12 days
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units	937,752	937,752	937,752	541,867	541,867	541,867
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding	1,457,883			1,564,838		1,065,347	1,457,883	1,457,883			1,033,871
Restricted Stock Unit Economic Equivalent	1	1	1
Tax benefits realized | $	$ 600,000			$ 300,000		$ 1,600,000
Accrued liabilities | $	$ 2,600,000			$ 2,100,000			$ 2,600,000
RSU that may vest on a shorter period	402,088						402,088	402,088	885,000
RSU awards, granted to non-employees	831,123	831,123	831,123	1,050,385	1,050,385	687,475
Stock-based compensation expense | $	$ 15,555,000			$ 13,761,000		$ 12,394,000
Common shares purchased in open market by trustee in connection with RSUs	723	723	723	386,297	386,297	404,719
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units	1,457,883	1,457,883	1,457,883	1,564,838	1,564,838	77,259
Restricted Share Units [Member] | Certain Advisor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU awards, granted to non-employees	0	0	0	0	0	12,580
Stock-based compensation expense | $	$ 0			$ 100,000		$ 100,000
Restricted Share Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period	3 years	3 years	3 years
Percentage of common shares authorized	5.00%	5.00%	5.00%
Restricted Share Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period							1 year
IMAX China Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $				$ 100,000
Vested stock options contractual life				1 year	1 year

Capital Stock - Share-Based Com

Capital Stock - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 25,614	$ 21,493	$ 22,830
Cost and Expenses Applicable to Revenues [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,490	691	1,709
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	23,776	20,652	20,750
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 348	$ 150	$ 371

Capital Stock - Expenses Relate

Capital Stock - Expenses Related to Stock Option Grants Issued to Employees and Directors (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 25,614	$ 21,493	$ 22,830
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,064	$ 1,847	$ 8,329

Capital Stock - Total Share-Bas

Capital Stock - Total Share-Based Compensation Expense Related to Non-Vested Employee Stock Options not yet Recognized (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to non-vested employee stock options	$ 662	$ 2,029	$ 4,073

Capital Stock - Weighted Averag

Capital Stock - Weighted Average Period over Which Awards Expected to be Recognized (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period (in years)	1 year 1 month 6 days	1 year 9 months 18 days	2 years 8 months 12 days

Capital Stock - Weighted Aver_2

Capital Stock - Weighted Average Fair Value of all Stock Options Granted to Employees and Directors and Assumptions used to Estimate Average Fair Value of Stock Option (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2019$ / shares
Stock options valuation assumptions
Weighted average fair value per share	$ 6.65
Average risk-free interest rate	2.64%
Expected volatility	31.00%
Dividend yield	0.00%
Minimum [Member]
Stock options valuation assumptions
Expected option life (in years)	6 years 8 months 23 days
Maximum [Member]
Stock options valuation assumptions
Expected option life (in years)	10 years

Capital Stock - Schedule of Sha

Capital Stock - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, beginning of year	4,892,962	5,732,209	5,465,046
Granted			1,016,882
Exercised	(41,613)		(86,928)
Forfeited	(88,934)	(34,678)	(336,493)
Expired	(903,038)	(786,086)	(299,134)
Cancelled	(123,220)	(18,483)	(27,164)
Stock options outstanding, end of year	3,736,157	4,892,962	5,732,209
Stock options exercisable, end of year	3,488,107	4,311,761	4,801,272
Stock options outstanding, weighted average exercise price per share, beginning of year	$ 26.81	$ 26.82	$ 27.63
Granted, weighted average exercise price per share			20.66
Exercised, weighted average exercise price per share	21.23		20.16
Forfeited, weighted average exercise price per share	22.49	22.49	23.63
Expired, weighted average exercise price per share	28.31	27.07	25.82
Cancelled, weighted average exercise price per share	26.68	27.97	31.13
Stock options outstanding, weighted average exercise price per share, end of year	26.61	26.81	26.82
Stock options exercisable, weighted average exercise price per share, end of year	$ 26.93	$ 27.30	$ 27.40

Capital Stock - Expenses Rela_2

Capital Stock - Expenses Related to RSU Grants Issued to Employees and Directors in Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 25,614	$ 21,493	$ 22,830
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 15,555	$ 13,761	$ 12,394

Capital Stock -Total Share-Base

Capital Stock -Total Share-Based Compensation Expense Related to Non-Vested RSUs not Yet Recognized and Weighted Average Period (Details) - Restricted Share Units [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to non-vested RSUs not yet recognized	$ 15,913	$ 17,343	$ 23,548
Weighted average period awards are expected to be recognized (in years)	1 year 7 months 6 days	1 year 10 months 24 days	2 years 8 months 12 days

Capital Stock - Restricted Stoc

Capital Stock - Restricted Stock Units Activity under the IMAX LTIP (Details) - Restricted Share Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of year	1,564,838	1,065,347	1,033,871
Granted	831,123	1,050,385	687,475
Vested and settled	(689,872)	(453,993)	(434,296)
Forfeited	(248,206)	(96,901)	(221,703)
Number of awards outstanding,end of year	1,457,883	1,564,838	1,065,347
Weighted average grant date fair value per share, beginning of year	$ 18.33	$ 23.17	$ 25.70
Granted, weighted average grant date fair value per share	21.03	15.35	22.30
Vested and settled, weighted average grant date fair value per share	19.46	22.71	27.54
Forfeited, weighted average grant date fair value per share	19.38	18.81	23.68
Weighted average grant date fair value per share, end of year	$ 19.16	$ 18.33	$ 23.17

Capital Stock - Summary of Numb

Capital Stock - Summary of Number of RSUs Issued From Carve-Out Balance (Details) - Restricted Share Units [Member] - shares	7 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU carve out, balance beginning of period	885,000
RSUs issued from carve-out	(70,867)	(412,045)
RSU carve out, balance end of period	402,088

Capital Stock - Expenses Rela_3

Capital Stock - Expenses Related to PSUs Grants Issued to Employees and Directors in Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 25,614	$ 21,493	$ 22,830
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 5,322	$ 2,563

Capital Stock - Performance Sto

Capital Stock - Performance Stock Units Activity under the IMAX LTIP (Details) - Performance Stock Units - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of year	361,844
Granted	309,574	370,265
Forfeited	(58,013)	(8,421)
Number of awards outstanding,end of year	613,405	361,844
Weighted average grant date fair value per share, beginning of year	$ 15.68
Granted, weighted average grant date fair value per share	20.77	$ 15.66
Forfeited, weighted average grant date fair value per share	16.11	4.84
Weighted average grant date fair value per share, end of year	$ 18.21	$ 15.68

Capital Stock - Summary of Expe

Capital Stock - Summary of Expense Related to Award Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 25,600	$ 21,500	$ 22,800
China Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	285	875	320
China RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	2,810	2,093
China PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	578	208	1,664
China Options, RSUs and PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 3,673	$ 3,176	$ 1,984

Capital Stock - Basic and Dilut

Capital Stock - Basic and Diluted Weighted Average Share Computations (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Issued and outstanding, beginning of period	58,921	61,176	61,434
Weighted average number of shares issued (repurchased), net	205	(1,939)	(124)
Weighted average number of shares outstanding - basic	59,126	59,237	61,310
Weighted average effect of potential common shares, if dilutive			179
Weighted average number of shares outstanding - diluted	59,126	59,237	61,489

Consolidated Statements of Op_4

Consolidated Statements of Operations Supplemental Information - Summary of Selling Expenses, Including Sales Commissions and Other Selling Expenses (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements [Line Items]
Sales Commissions		$ 2,284	$ 2,186	$ 2,414
Other Selling Expenses		11,021	5,893	26,893
Technology Sales [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[1]	1,885	1,278	2,031
Other Selling Expenses	[1]	989	1,077	1,072
Image Enhancement and Maintenance Services [Member]
Collaborative Arrangements [Line Items]
Other Selling Expenses	[2]	8,923	4,306	22,869
Technology Rentals [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[3]	399	908	383
Other Selling Expenses	[3]	$ 1,109	$ 510	$ 2,952
[1]	Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX Theater System. Direct advertising and marketing costs for each theater are expensed as incurred.
[2]	Film exploitation costs, including advertising and marketing costs are expensed as incurred.
[3]	Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the theater system is installed. Direct advertising and marketing costs for each theater are expensed as incurred.

Consolidated Statements of Op_5

Consolidated Statements of Operations Supplemental Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)exhibitorTheaterFilm	Dec. 31, 2020USD ($)exhibitorTheaterFilm	Dec. 31, 2019USD ($)Film	Dec. 31, 2017Film
Foreign Exchange
Foreign exchange translation gain (loss)	$ 1,300	$ (800)	$ (900)
Collaborative Arrangements
Total number of exhibitors under traditional and hybrid joint revenue sharing agreements | exhibitor	43	43
Total number of theater systems under traditional and hybrid joint revenue sharing agreements | Theater	1,225	1,232
Total number of operating theaters under traditional and hybrid joint revenue sharing agreement | Theater	909	890
Average percentage of the box-office receipts of the film for recovering digital re-mastering cost	12.50%
Number of films exhibited in the period | Film	69	35	72
Number of new films exhibited | Film	63	31	60
Number of carryover films exhibited | Film	6	4	12
Revenue attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 70,700	$ 28,300	$ 120,800
Number of significant co-produced film arrangement | Film	1			1
Number of other co-produced film arrangements | Film	3
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 883,247	997,750
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	452,875	532,983
Amounts attributable to transactions between the company and other parties involved in the production of films included in costs and expenses	400	2,000	600
Co-produced television collaborative arrangement revenue	200	300	400
Co-produced television collaborative arrangement costs and expenses			100
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangements
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,576	1,543
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	259	230
Retrospective adoption of ASC Topic 606, Revenue from Contracts with Customers [Member]
Collaborative Arrangements
Revenues attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	$ 51,600	$ 19,900	$ 92,000

Consolidated Statements of Ca_4

Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
(Increase) decrease in:
Financing receivables		$ (7,637)		$ (10,568)		$ (320)
Prepaid expenses		(3,230)		(979)		(290)
Variable consideration receivables		(2,905)		(2,361)		(4,056)
Other assets		1,003		(4,747)		(2,063)
(Decrease) increase in:
Accounts payable		(4,752)		414		(11,774)
Accrued and other liabilities		15,167		(6,399)		(8,505)
Changes in other non-cash operating assets and liabilities		(2,354)		(24,640)		(27,008)
Cash payments made on account of:
Income taxes	$ 8,900	18,475	[1]	4,763	[1]	17,298	[1]
Interest		$ 3,251		$ 5,773		$ 1,231
[1]	In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest.

Consolidated Statements of Ca_5

Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Parentheticals) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	[1]	Dec. 31, 2020	[1]	Dec. 31, 2019	[1]
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	$ 8,900	$ 18,475		$ 4,763		$ 17,298
Accounts Receivable Net Of Allowance For Credit Losses
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	8,900
Interest	1,600
Foreign Country [Member]
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	8,900
Interest	$ 1,600
[1]	In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $8.9 million in income taxes and $1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $1.6 million in associated interest.

Consolidated Statements of Ca_6

Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary of Depreciation and amortization
Film assets		$ 16,316	$ 8,838	$ 19,176
Property, plant and equipment:
Equipment supporting joint revenue sharing arrangements		22,320	24,930	23,153
Other property, plant and equipment		9,479	11,225	12,477
Other intangible assets	[1]	6,079	6,565	6,290
Other assets	[2]	1,888	1,146	1,882
Depreciation and amortization		$ 56,082	$ 52,704	$ 62,978
[1]	Includes
[2]	Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.

Consolidated Statements of Ca_7

Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Amortization of intangible assets net in research and development	$ 1.3	$ 1.3

Consolidated Statements of Ca_8

Consolidated Statements of Cash Flows Supplemental Information - Write-downs, Net of Recoveries (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Write-downs
Inventories	[1]	$ 890	$ 3,632	$ 446
Equipment supporting joint revenue sharing arrangements	[2]	364	1,784	2,207
Other property, plant and equipment		217	174	249
Other intangible assets		142	184	95
Film assets	[3]	151	10,804	1,379
Other assets	[4]	0	1,151	0
Write-downs		$ 1,764	$ 17,729	$ 4,376
[1]	In 2021, the Company recorded write-downs of $0.9 million (2020 — $3.6 million; 2019 — $0.4 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory.
[2]	In 2021, the Company recorded charges of $0.4 million (2020 — $1.8 million; 2019 — $2.2 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased IMAX Xenon Theater Systems which were taken out of service in connection with customer upgrades to IMAX Laser Theater Systems.
[3]	In 2021, the company recorded impairment losses of $0.2 million related to the write-down of DMR related film assets. In 2020, the Company recorded impairment losses of $10.8 million (2019 — $1.4 million) in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments.
[4]	In 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such charge was recorded in 2021 and 2019.

Consolidated Statements of Ca_9

Consolidated Statements of Cash Flows Supplemental Information - Write-downs, Net of Recoveries (Parenthetical) (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Theater system components written off in Costs and expenses		$ 400,000	$ 1,800,000	$ 2,200,000
Write-downs for excess and obsolete inventory	[1]	890,000	3,632,000	446,000
Film assets write downs on impairment loss		0.2	10,800,000	1,400,000
Other assets write down on impairment		$ 0	$ 1,200,000	$ 0
[1]	In 2021, the Company recorded write-downs of $0.9 million (2020 — $3.6 million; 2019 — $0.4 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory.

Consolidated Statements of C_10

Consolidated Statements of Cash Flows Supplemental Information - Significant Non-cash Investing Activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net (decrease) increase in accruals related to:
Investment in equipment supporting joint revenue sharing arrangements	$ 1,009	$ (1,888)	$ (2,013)
Acquisition of other intangible assets	(891)	792	(51)
Purchases of property, plant and equipment	(188)	158	496
Net accruals	$ (70)	$ (938)	$ (1,568)

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Revenue from Contracts with Customers [Line Items]
Revenues	[1]	$ 254,883	$ 137,003		$ 395,664
Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		101,919	66,369		148,200
Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		78,584	36,350		138,498
Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		63,588	24,168		98,055
Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		10,792	10,116		10,911
Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		66,153	49,728		118,245
Technology Sales [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		43,738	37,492		87,657
Technology Sales [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		5,617	5,909		10,469
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		5,406	2,056		11,014
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,363	1,666		8,390
Technology Sales [Member] | Other Theater Business [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,363	1,666		8,390
Technology Sales [Member] | Other Theater Business [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	3,516	2,067		2,431
Technology Sales [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	3,475	1,957		2,209
Technology Sales [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	41	110		222
Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[3]	54,868	43,939	[4]	96,410	[4]
Technology Sales [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[3]	37,900	33,869	[4]	77,058	[4]
Technology Sales [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[3]	5,576	5,799	[4]	10,247	[4]
Technology Sales [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		16,798	6,327		20,119
Technology Sales [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		5,406	2,056		11,014
Technology Sales [Member] | Lease Arrangements [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	0	0		0
Technology Sales [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[3]	11,392	4,271	[4]	9,105	[4]
Technology Sales [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Finance Income [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Sales [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	0	0		0
Technology Sales [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[3]	0	0	[4]	0	[4]
Image Enhancement and Maintenance Services [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		131,148	59,318		188,547
Image Enhancement and Maintenance Services [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		58,181	28,877		60,543
Image Enhancement and Maintenance Services [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		72,967	30,441		128,004
Image Enhancement and Maintenance Services [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,426	335		2,421
Image Enhancement and Maintenance Services [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		377	0		0
Image Enhancement and Maintenance Services [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,049	335		2,421
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		70,659	28,265		120,765
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		70,659	28,265		120,765
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		4,260	3,878		7,392
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		4,260	3,878		7,392
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,464	4,841		4,818
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		205	3,000		0
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,259	1,841		4,818
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		53,339	21,999		53,151
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		53,339	21,999		53,151
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Rentals [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		46,790	17,841		77,961
Technology Rentals [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Rentals [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		25
Technology Rentals [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		606			1,288
Technology Rentals [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			0
Technology Rentals [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			25
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		46,184	17,841		76,673
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Rentals [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		46,790	17,841		77,936
Technology Rentals [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		606			1,263
Technology Rentals [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		46,184	17,841		76,673
Technology Rentals [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Technology Rentals [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			0
Technology Rentals [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		10,792	10,116		10,911
Finance Income [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Finance Income [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Finance Income [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Finance Income [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		$ 10,792	$ 10,116		$ 10,911
[1]	The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020.
[2]	Other sales include revenues associated with New Business Initiatives.
[3]	Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements.
[4]	Prior period comparatives have been revised to appropriately classify $4.3 million and $9.1 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the years ended December 31, 2020 and 2019.

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Parenthetical) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Revenue from Contracts with Customers [Line Items]
Revenues	[1]	$ 254,883	$ 137,003		$ 395,664
Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		66,153	49,728		118,245
Technology Sales [Member] | IMAX Systems Reporting Unit [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	54,868	43,939	[3]	96,410	[3]
Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		63,588	24,168		98,055
Lease Arrangements [Member] | Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		16,798	6,327		20,119
Lease Arrangements [Member] | Technology Sales [Member] | IMAX Systems Reporting Unit [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	$ 11,392	4,271	[3]	9,105	[3]
Lease Arrangements [Member] | Maximum [Member] | Technology Sales [Member] | IMAX Systems Reporting Unit [Member]
Revenue from Contracts with Customers [Line Items]
Revenues			$ 4,300		$ 9,100
[1]	The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020.
[2]	Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements.
[3]	Prior period comparatives have been revised to appropriately classify $4.3 million and $9.1 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the years ended December 31, 2020 and 2019.

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Maintenance Services [Member]
Revenue from Contracts with Customers [Line Items]
Revenue Remaining Performance Obligation	$ 20.2	$ 21.6	$ 17.7

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021
Segment Reporting (Textual) [Abstract]
Description of products and services from which each reportable segment derives its revenues	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; (vii) Film Post-Production; and (viii) New Business Initiatives.
Disclosure on geographic areas, description of revenue from external customers	No single country in the Rest of the World, Western Europe, Latin America, and Asia (excluding Greater China) classifications comprise more than 10% of total revenue.

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenue	[1]	$ 254,883	$ 137,003	$ 395,664
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		134,406	21,540	214,172
Assets
Assets		883,247	997,750
Amortization
Amortization		56,082	52,704	62,978
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		(2,187)	36,337	6,806
Purchase of property, plant and equipment
Purchase of property, plant and equipment		13,684	7,351	47,910
IMAX DMR [Member]
Revenues
Revenue	[1]	70,659	28,265	120,765
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		44,782	13,731	78,592
Assets
Assets		48,299	29,672
Amortization
Amortization		15,917	10,269	16,117
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		151	1,057
Purchase of property, plant and equipment
Purchase of property, plant and equipment				99
IMAX Technology Network [Member]
Revenues
Revenue	[1]	116,843	46,106	197,438
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		66,543	4,231	127,038
IMAX Systems [Member]
Revenues
Revenue	[1],[2]	65,660	54,055	107,321
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	34,981	24,816	58,168
Assets
Assets		249,672	240,972
Amortization
Amortization		2,076	3,548	3,878
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		837	2,872	276
Purchase of property, plant and equipment
Purchase of property, plant and equipment		621	50	452
IMAX Maintenance Reporting Unit [Member]
Revenues
Revenue	[1]	53,339	21,999	53,151
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		27,572	3,068	23,010
Assets
Assets		38,530	36,949
Amortization
Amortization			213	299
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		53	510	170
Purchase of property, plant and equipment
Purchase of property, plant and equipment		25		311
Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenues
Revenue	[1]	5,406	2,056	11,014
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		1,343	529	2,613
Assets
Assets		27,930	27,778
Other Theater Business [Member]
Revenues
Revenue	[1],[3]	2,363	1,666	8,390
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[3]	398	(438)	2,624
Assets
Assets		82	106
New Business Initiatives [Member]
Revenues
Revenue	[1]	3,704	2,226	2,754
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		3,399	1,878	2,106
Assets
Assets		1,420	1,196
Amortization
Amortization			11	58
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense			52	96
IMAX Technology Sales and Maintenance [Member]
Revenues
Revenue	[1]	126,768	79,776	179,876
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		64,294	27,975	86,415
Post-Production [Member]
Revenues
Revenue	[1]	4,260	3,878	7,392
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		1,969	(358)	1,680
Assets
Assets		31,575	35,526
Amortization
Amortization		924	1,281	1,301
Purchase of property, plant and equipment
Purchase of property, plant and equipment		609	456	1,210
Film Distribution [Member]
Revenues
Revenue	[1],[4]	1,464	4,841	4,818
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[4]	(1,121)	(9,840)	(2,942)
Assets
Assets		7,185	5,984
Amortization
Amortization		600	1,213	3,894
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense			9,997	1,379
Purchase of property, plant and equipment
Purchase of property, plant and equipment		1,599
Sub-total for Reportable Segments
Revenues
Revenue	[1]	253,039	136,827	392,278
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		135,084	23,886	214,297
Assets
Assets		601,482	574,005
Amortization
Amortization		43,725	42,611	50,583
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		1,405	16,272	4,128
Purchase of property, plant and equipment
Purchase of property, plant and equipment		12,948	7,160	42,561
Reportable Segments [Member]
Revenues
Revenue	[1]	5,724	8,719	12,210
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		848	(10,198)	(1,262)
Other [Member]
Revenues
Revenue	[1]	1,844	176	3,386
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		(678)	(2,346)	(125)
Joint Revenue Sharing Arrangements Reporting Unit [Member]
Revenues
Revenue	[1]	46,184	17,841	76,673
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		21,761	(9,500)	48,446
Assets
Assets		196,789	195,822
Amortization
Amortization		24,208	26,076	25,036
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		364	1,784	2,207
Purchase of property, plant and equipment
Purchase of property, plant and equipment		10,094	6,654	40,489
Corporate and other non-segment specific assets [Member]
Assets
Assets		281,765	423,745
Amortization
Amortization		12,357	10,093	12,395
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense	[5]	(3,592)	20,065	2,678
Purchase of property, plant and equipment
Purchase of property, plant and equipment		$ 736	$ 191	$ 5,349
[1]	The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020.
[2]	The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams.
[3]	The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses.
[4]	During the year ended December 31, 2020, Film Distribution segment results were significantly influenced by impairment losses of $10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments (2019 ― $1.4 million). No such impairment losses were incurred in 2021.
[5]	During the year ended December 31, 2021, includes the net reversal of current expected credit losses of $4.0 million, which is excluded from the measurement of the Company’s segment performance (2020 ― provision of $18.6 million; 2019 ― provision of $2.4 million).

Segment Reporting - Segment R_2

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Percentage of total revenues represented by largest customer		10.00%	16.00%	17.00%
Recognition of maintenance revenue earlier deferred due to covid	$ 6,300
Recognition of maintenance revenue prior year deferred			$ 2,500
Segment Reporting (Textual) [Abstract]
Amortization of deferred financing costs		$ 2,513	902	$ 509
Distribution [Member]
Segment Reporting (Textual) [Abstract]
Impairment loss		0	10,000	$ 1,400
Corporate and other non-segment specific assets [Member]
Segment Reporting (Textual) [Abstract]
Write-downs, included in current expected credit loss expense		$ 4,000	$ 18,600

Segment Reporting - Geographic

Segment Reporting - Geographic Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total	[1]	$ 254,883	$ 137,003	$ 395,664
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		73,499	30,157	121,264
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		112,801	52,331	124,294
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		3,266	1,365	9,220
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		20,942	13,683	46,911
Asia (excluding Greater China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		23,682	20,090	48,386
Russia & the CIS [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		7,308	2,927	16,124
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		3,601	6,114	9,438
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		$ 9,784	$ 10,336	$ 20,027
[1]	The Company’s largest customer represents 10% of total Revenues as of December 31, 2021 (2020 ― 16%; 2019 ― 17%). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2021 and 2020.

Segment Reporting - Schedule of

Segment Reporting - Schedule of Property Plant and Equipment By Geographic Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 260,353	$ 277,397
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	91,856	100,495
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	100,182	104,731
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	32,643	31,624
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	21,684	25,487
Asia (excluding Greater China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	9,463	9,930
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 4,525	$ 5,130

Financial Instruments - Additio

Financial Instruments - Additional Information (Details)	1 Months Ended	12 Months Ended
	Feb. 28, 2021USD ($)shares	Dec. 31, 2021USD ($)Country	Dec. 31, 2020USD ($)
Financial Instruments (Textual) [Abstract]
Cash and cash equivalents		$ 189,711,000	$ 317,379,000
Cash held outside of Canada		102,100,000	89,900,000
Transfers into/out of Level 3		$ 0	0
Number of countries that generate box office | Country		87
Foreign Exchange contract settlement date range		settlement dates throughout 2022
Estimated gains to be reclassified to earnings within the next twelve months		$ 100,000
Investment in equity securities		1,087,000	13,633,000
Investment in equity securities - cost		$ 15,200,000
Equity securities restrictions		lock-up period of six months
Fixed Income Securities [Member]
Financial Instruments (Textual) [Abstract]
Equity Investment, Debt Securities		$ 1,100,000	1,100,000
Preferred Stock [Member] | Other Assets [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities		$ 1,000,000	1,000,000
Maoyan [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities			12,600,000
Number of shares sold | shares	7,949,000
Gross proceeds from sale of investment	$ 17,800,000
Gain relating to acquisition cost	2,600,000
Realized gain on fair value of investment	$ 5,200,000
Gain (loss) in fair value of equity securities			2,100,000
Maximum [Member]
Financial Instruments (Textual) [Abstract]
Equity securities percentage ownership		1.00%
China [Member]
Financial Instruments (Textual) [Abstract]
Cash held/undistributed earnings		$ 76,300,000	$ 77,200,000

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
Other Financial Instrument
Cash and cash equivalents		$ 189,711	$ 317,379
Net investment in sales-type leases		28,392	19,414
Credit Facility borrowings		(2,472)	(305,676)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	189,711	317,379
Equity securities	[2]	1,087	13,633
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Net financed sales receivables	[3]	112,657	112,396
Net investment in sales-type leases	[3]	28,392	19,414
Equity securities	[1]	1,000	1,000
COLI	[4]	3,275	3,155
Working Capital Facility borrowings	[1]	(3,612)	(7,643)
Credit Facility borrowings	[1]		(300,000)
Convertible Notes	[5]	(230,000)
Carrying Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[3]	79	1,635
Carrying Amount, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[3]		344
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	189,711	317,379
Equity securities	[2]	1,087	13,633
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Net financed sales receivables	[3]	112,662	112,603
Net investment in sales-type leases	[3]	28,407	19,373
Equity securities	[1]	1,000	1,000
COLI	[4]	3,275	3,155
Working Capital Facility borrowings	[1]	(3,612)	(7,643)
Credit Facility borrowings	[1]		(300,000)
Convertible Notes	[5]	(223,100)
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[3]	$ 79	1,635
Estimate of Fair Value, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[3]		$ 344
[1]	Recorded at cost, which approximates fair value.
[2]	Fair value is determined using quoted prices in active markets.
[3]	Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.
[4]	Measured at cash surrender value, which approximates fair value.
[5]	Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data

Financial Instruments - Notiona

Financial Instruments - Notional Amount of Derivative (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 26,702	$ 31,910
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 26,702	26,358
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards		$ 5,552

Financial Instruments - Fair _2

Financial Instruments - Fair Value of Foreign Exchange Contracts (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Foreign currency derivatives	$ 184	$ 1,979
Other Assets [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign currency derivatives	184	1,635
Other Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign currency derivatives	0	344
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	(105)	0
Accrued and other liabilities [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	$ 79	$ 1,979

Financial Instruments - Derivat

Financial Instruments - Derivatives in Foreign Currency Hedging Relationships (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Derivative Gain Recognized in OCI (Effective Portion)	$ 468	$ 500	$ 552
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	1,707	(604)	(1,183)
Derivative Gain (Loss) Recognized In and Out of OCI (Effective Portion)		17	(22)
Fair Value Hedging [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative Gain Recognized in OCI (Effective Portion)	468	550	552
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	1,707	(578)	(1,109)
Inventories [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	(26)	(42)
Property, Plant and Equipment [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 0	$ 0	$ (32)

Financial Instruments - Non Des

Financial Instruments - Non Designated Derivatives in Foreign Currency Relationships (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments Gain Loss [Line Items]
Derivative Gain Reclassified From AOCI (Ineffective portion)	$ (318)
Foreign Exchange Contracts - Forwards [Member] | Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain	$ 398	$ 344

Employee's Pension and Postreti

Employee's Pension and Postretirement Benefits - Additional Information (Details) - USD ($) $ in Thousands	Nov. 01, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Deferred compensation plan description		The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein).
Deferred Compensation Plan [Member] | Accrued and Other Liabilities [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit obligation recorded		$ 3,800		$ 3,700
Deferred Compensation Plan [Member] | Prepaid Expenses [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Company-owned life insurance		$ 3,300		3,200
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined benefit pension plan		The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L. Gelfond.
Companies contribution and expenses		$ 0
Expected interest costs in the remainder of the year		200
Expected interest costs		$ 72	$ 379	564
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined contribution pension plans for employees		The Company also maintains defined contribution pension plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company		5.00%
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Companies contribution and expenses		$ 1,100		1,100	$ 1,200
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Companies contribution and expenses		500		600	$ 600
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Expected interest costs		42	$ 47	$ 49
Postretirement Benefits Canadian Employees [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Expected interest costs		$ 100
Richard L. Gelfond [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit payable	$ 20,300

Employee's Pension and Postre_2

Employee's Pension and Postretirement Benefits - Summary of Amounts Accrued for the SERP (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amounts Accrued
Obligation, beginning of period	$ 20,116	$ 18,840
Interest cost	72	379	$ 564
Actuarial (gain) loss	(132)	897
Obligation, end of period and unfunded status	$ 20,056	$ 20,116	$ 18,840

Employee's Pension and Postre_3

Employee's Pension and Postretirement Benefits - Summary of Accumulated Other Comprehensive Income and Components of Net Periodic Benefit Cost in Future Periods (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ (679)	$ (547)	$ (1,444)
Unamortized prior service cost	184	369	456
Net periodic benefit costs to be recognized in future periods	$ (495)	$ (178)	$ (988)

Employee's Pension and Postre_4

Employee's Pension and Postretirement Benefits - Summary of Disclosure of Pension Expense (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net periodic benefit cost
Interest cost	$ 72	$ 379	$ 564
Amortization of prior service cost	185	87
Pension expense	$ 257	$ 466	$ 564

Employee's Pension and Postre_5

Employee's Pension and Postretirement Benefits - Summary of Assumptions to Determine SERP Obligation and Any Related Costs (Details) - SERP Benefits [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020
Assumptions used to determine obligation and cost status
Discount rate	2.00%	0.80%	0.36%
First 25 years	2.12%
Lump sum interest rate - thereafter	2.26%
Cost of living adjustment on benefits	1.20%

Employee's Pension and Postre_6

Employee's Pension and Postretirement Benefits - Summary of Amounts Include within Accrued and Other Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Obligation, beginning of period	$ 710	$ 665
Interest cost	16	20	$ 26
Benefits paid	(16)	(29)
Actuarial (gain) loss	(48)	54
Obligation, end of period and unfunded status	662	710	665
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Obligation, beginning of period	1,862	1,581
Interest cost	42	47	49
Benefits paid	(118)	(110)
Actuarial (gain) loss	(92)	280
Unrealized foreign exchange (gain) loss	8	64
Obligation, end of period and unfunded status	$ 1,702	$ 1,862	$ 1,581

Employee's Pension and Postre_7

Employee's Pension and Postretirement Benefits - Summary of Components of Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost	$ 16	$ 20	$ 26
Amortization of actuarial gain		(17)
Pension expense	16	3	26
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost	42	47	49
Pension expense	$ 42	$ 47	$ 49

Employee's Pension and Postre_8

Employee's Pension and Postretirement Benefits - Summary of Accumulated Other Comprehensive Income and Components of Net Pension Cost in Future Periods (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Postretirement Benefits Executives [Member]
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ (27)	$ 21	$ (50)
Postretirement Benefits Canadian Employees [Member]
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ 185	$ 277	$ (3)

Employee's Pension and Postre_9

Employee's Pension and Postretirement Benefits - Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation (Details)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Postretirement Benefits Executives [Member]
Assumptions used to determine obligation and cost status
Discount rate	2.71%	2.36%	3.13%
Postretirement Benefits Canadian Employees [Member]
Assumptions used to determine obligation and cost status
Discount rate	2.80%	2.30%	3.05%

Employee's Pension and Postr_10

Employee's Pension and Postretirement Benefits - Summary of Weighted Average Assumptions Used to Determine the Net Postretirement Benefit Expense (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Postretirement Benefits Executives [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate used in calculating net periodic benefit cost	2.36%	3.13%	4.15%
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate used in calculating net periodic benefit cost	2.30%	3.05%	3.80%

Employee's Pension and Postr_11

Employee's Pension and Postretirement Benefits - Summary of Benefit Payment are Expected in Next Five Year (Details) $ in Thousands	Dec. 31, 2021USD ($)
Postretirement Benefits Executives [Member]
Pension and Postretirement benefits obligations
2022	$ 9
2023	19
2024	20
2025	21
2026	23
Thereafter	938
Total expected future benefit payment	1,030
Postretirement Benefits Canadian Employees [Member]
Pension and Postretirement benefits obligations
2022	108
2023	115
2024	112
2025	113
2026	105
Thereafter	1,483
Total expected future benefit payment	$ 2,036

Non-Controlling Interests - Add

Non-Controlling Interests - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2014USD ($)Film
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 73,531	$ 70,004
Net income (loss) attributable to non-controlling interests	12,752	(13,711)	$ 11,705
Investment in film assets	$ 14,810	$ 7,665	23,437
IMAX China Noncontrolling Interest
Redeemable Noncontrolling Interest [Line Items]
Minority Interest Ownership Percentage By Company	71.11%	69.89%
IMAX China
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 73,500	$ 70,000
Net income (loss) attributable to non-controlling interests	12,800	(8,600)	13,300
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Net income (loss) attributable to non-controlling interests	$ (1)	$ (5,139)	$ (1,638)
Non-controlling interest description	The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014, and has reached its maximum contribution.
Number Of Expected Original Films | Film				10
Investment in film assets	$ 22,300
Other Noncontrolling Interest [Member] | Third Party [Member]
Redeemable Noncontrolling Interest [Line Items]
Film Fund Expected Capital Contribution				$ 25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Redeemable Noncontrolling Interest [Line Items]
Film fund contributions paid	$ 9,000

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary of Movement of the Non-controlling Interest in Temporary Equity in Original Film Fund (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Non-controlling Interests
Issuance of subsidiary shares to non-controlling interests			$ 1,106
Net loss	$ 12,752	$ (13,711)	11,705
Other Noncontrolling Interest [Member]
Non-controlling Interests
Beginning Balance	759	5,908	6,439
Return of capital to non-controlling interests		(10)	(243)
Share issuance costs from the issuance of subsidiary shares to a non-controlling interest			1,350
Net loss	(1)	(5,139)	(1,638)
Ending Balance	$ 758	$ 759	$ 5,908